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ABSTRACT  
 
 The insulin-like growth factor (IGF) system is composed of IGF, IGF binding 
proteins (IGFBP-1 to -10) and the acid labile subunit (ALS). IGF exists as two isoforms, 
IGF-I and IGF-II. IGF-I is the major circulatory form and is primarily secreted by the 
liver. It functions to regulate proliferation and differentiation in a number of different cell 
types and elicits an insulin-like metabolic effect. As well as being regulated at levels of 
transcription and translation, IGF-I activities are also regulated through formation of 
complexes in circulation. IGF complexes form as binary complexes, such as the IGFBP-1 
complex, and ternary complexes containing IGF-I, IGFBP-3 and ALS. Binary and ternary 
IGF complexes function to maintain stable pools of bioactive IGF-I. They also function 
to increase IGF half-life and sequester IGF in the bloodstream.  
 ALS and IGFBP-1 are well characterized and exist as 85 kDa and 32 kDa 
proteins, respectively. They are expressed primarily in liver hepatocytes. Circulating ALS 
binds the IGF-I-IGFBP-3 complex and increases IGF half-life from 10 min in the IGFBP-
3 binary complex to 10-15 hr in the ternary complex. IGFBP-1 binds IGF-I and increases 
the half-life from 10 min to 30 min. The ternary complex is the predominant IGF-I 
binding protein complex found in circulation. The IGFBP-1 complex represents only a 
small fraction of circulating IGF complexes.     
In this thesis ALS and IGFBP-1 regulation were investigated in terms of 
expression related to metabolic modulators and streptozotocin (STZ)-induced diabetes. 
Results from rat studies showed a decreased liver ALS gene expression in STZ-induced 
diabetic rats. STZ-treatment in rats mimics type-I diabetes with no change in secreted 
insulin with increase of circulatory glucose. The administration of insulin into the STZ-
induced diabetic rats brought ALS levels to that of the untreated controls. ALS 
expression was positively regulated by insulin in H4IIE hepatoma cells. Growth hormone 
(GH), glucose, dexamethasone also positively regulated ALS gene expression while 
cAMP (2-b-cAMP) acted as a negative regulator in H4IIE cells. HepG2 cells expressing 
constitutively active protein kinase B (PKB) (HepG2-PKB-CA) increased ALS gene 
expression to levels 20% higher then parental HepG2. Insulin treatment of these cells 
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unexpectedly increased ALS levels in both parental and PKB-CA HepG2. This may have 
indicated a partial regulatory role of the mitogen activated protein (MAP) kinase pathway 
as PKB was thought to be over-expressed therefore rendering the insulin signal 
redundant. Inhibition of the phosphoinositol-3 (PI-3) kinase and MAP kinase pathways 
through wortmannin and PD98059 incubation, respectively, suggested a possible 
interplay or crosstalk between the two pathways in insulin signaling. PKB is known to be 
activated through the PI-3 kinase pathway. Results suggested possibility that PKB may 
interact through the MAP kinase pathway in regulation of ALS gene expression. The 
activity of cAMP on ALS gene expression may occur through interaction with the PI-3 
kinase pathway as inhibition enhanced the negative effect of cAMP on ALS expression.  
The secretion of IGFBP-1 was positively regulated by glucose and GH and 
negatively regulated by insulin in H4IIE cells. HepG2-PKB-CA cells showed 
significantly lower IGFBP-1 secretion as compared to parental HepG2 cells. The 
involvement of the PI-3 and MAP kinase pathways in the modulator-mediated effect on 
IGFBP-1 secretion were. As observed for ALS expression, the effect of insulin on 
IGFBP-1 secretion may also be affected through interplay or crosstalk between the PI-3 
kinase and MAP kinase pathways. Glucose and GH effected IGFBP-1 expression and 
secretion independent of these pathways although glucose expression may interact in 
some way through the PI-3 kinase pathway. Our investigation of hepatic regulation of 
IGFBP-1 secretion and ALS gene expression has shown regulatory roles for the 
metabolic hormones tested, especially insulin. Mechanisms of cell signaling have also 
been approached with the use of pathway inhibiters and HepG2-PKB-CA cells. Much 
work is yet to be done to fully understand the effects of insulin and other hormones on 
the secretion and expression of IGFBP-1 and ALS.  
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1.0 INTRODUCTION 
 
Cell regulation occurs at transcriptional and post-transcriptional levels through 
covalent and non-covalent modifications. Therefore, the regulation of protein activity 
involves many factors and many levels of function. The complexity of protein function 
increases when one looks from the cell to the whole animal. The regulation of secreted 
proteins occurs either through direct modification of the protein, itself, or it can be 
modulated through binding to specific binding proteins in circulation. The latter effect 
may be to sequester the protein in the bloodstream, making it unavailable for binding to 
target tissues, or it may be to increase the stability of the protein in circulation allowing a 
larger pool of bioactive protein. 
 The insulin-like growth factors (IGF-I and IGF-II) are synthesized by most tissues 
in the body and are abundant in circulation. They function to regulate proliferation and 
differentiation in a number of different cell types and elicit an insulin-like metabolic 
effect. IGFs exert their effects at the cellular level through their binding to IGF receptors 
(IGF-IR). IGF also binds the insulin receptor as well as IGF/insulin hybrid receptors but 
binds these alternative receptors with a much lower affinity than for the IGF-IR (Werner, 
1999). In circulation, IGF-I is primarily in a complex consisting of IGF-I, IGF-I binding 
proteins (IGFBPs) and the acid labile subunit (ALS). Ten IGFBPs and ALS combine to 
comprise the IGFBP complexes. IGFBPs, with the exception of IGFBP-3 and -5, form 
binary complexes that account for small percentages of the total complexes formed in 
circulation. The most abundant complex found is the ternary complex formed by IGF-I, 
IGFBP-3 and ALS. 
 Both, IGFBP-1 and ALS have been highly characterized. IGFBP-1 is a 32 kDa 
protein synthesized primarily in the liver and kidney and ALS is an 85 kDa glycoprotein 
primarily secreted by liver. IGFBP-1 both inhibits and potentiates the metabolic and 
mitogenic effects of IGF-I. Addition of purified IGFBP-1 inhibits binding of IGFs to cell 
surfaces but pre-incubation with IGFBP-1 results in a potentiation of IGF-1 activity 
(Elgin et al., 1987; Lewitt et al., 1991). IGFBP-1 has a 5-fold greater affinity for IGF-I 
than the IGF-IR and may be important in the transport of IGF-I across the endothelial 
barrier. IGF-1 in the IGFBP-1 complex extends the IGF-I half-life from 10 min to 30 min 
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(Jones et al., 1990). ALS, like IGFBP-1, also extends the IGF-I half-life, but in the 
ternary complex IGF-I half-life is extended to 10-15 hr (Baxter et al., 1989). The ternary 
complex disables any transport of IGF-1 across endothelial barriers and therefore 
sequesters the IGF-I in circulation. If ALS is not bound to the IGFBP-3, the IGFBP-3-
IGF-I complex acts much like the IGFBP-1 complex. 
 Hepatocyte cells are sensitive to hormone levels in respect to changes in 
metabolic gene expression due to downstream cell signaling. IGFBP-1 and ALS act to 
regulate the IGF bioactivity including the IGF mediated effects on metabolism. Metabolic 
modulator hormones such as insulin, dexamethasone and glucagon therefore should  have 
effects on ALS and IGFBP-1 expression. Glucose has also been shown to possibly 
regulate cell expression and may also regulate ALS and IGFBP-1 expression (Snyder et 
al., 1990). GH promotes IGF expression and thus IGF activity (Norstedt et al., 1987). It 
is hypothesized that GH will also promote ALS and IGFBP-1 expression in order to 
stabilize IGF in circulation and thus promote IGF effects on responsive tissues. 
Somewhat aside, it is hypothesized that H4IIE cell ALS expression will be regulated as 
has been shown in primary hepatocytes. ALS gene regulation has not been investigated in 
H4IIE or HepG2 cells due to instability of the ALS mRNA transcript. Newly available 
rALS probes may allow the possibility of successful visualization and measurement of 
H4IIE and HepG2 ALS gene expression through Northern analysis. 
As IGF ternary complex formation with IGFBPs and ALS may regulate IGF-I 
activity, it is of interest to investigate the regulation of ALS expression in the liver. 
Investigation of liver cell ALS gene expression will give a clearer picture of the role of 
hormonal regulation of IGF and may allow conclusions to be made as to how the IGF 
system changes as result of changes in hormone levels such as in the case of altered 
insulin levels during diabetes. Primary hepatocytes have shown insulin to positively 
regulate ALS expression (Dai et al., 1994a). Streptozotocin-treated rats have decreased 
insulin levels and therefore should show a decrease in ALS levels. In addition, it has been 
suggested that IGF-I may have a role in tumour development related to diabetes. The 
altered nutritional and hormonal states of diabetes results in changes in the expression of 
ALS altering the availability of IGF-I. Although this idea is not supported through the 
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results of this thesis it is nonetheless a strong relationship which should be investigated in 
the near future.  
The regulation of IGFBP-1 secretion and ALS gene expression by hormones is 
primarily through cell signaling mechanisms which alter expression. IGFBP-1 secretion 
may also be controlled by posttranslational modifications such as phosphorylation which 
has been shown in literature and may involve similar signaling. Regulation of expression 
through insulin is mediated through two primary signaling pathways, the MAP kinase 
and the PI-3 kinase pathways. IGFBP-1 has been shown to be regulated through the PI-3 
kinase pathway through activation of PKB and downstream effectors such as mTOR and 
FKHR proteins (Durham et al., 1999; Patel et al., 2002). Other studies have shown 
involvement of the MAP kinase pathway (Band et al., 1997). I hypothesize that although 
PKB may be involved the regulation of IGFBP-1 this may occur through crosstalk 
between PKB, the PI-3 kinase pathway and the MAP kinase pathway. It was also of 
interest to investigate whether glucose and GH may interact with the PI-3 kinase and 
MAP kinase pathways in IGFBP-1 regulation due to the potential involvement of many 
of the same effecter molecules. In the case of ALS regulation by insulin it is hypothesized 
that this regulation is through the PI-3 kinase pathway and PKB activation. As no data 
exists for this to date this idea is only supported by the fact that insulin has been shown to 
positively regulate ALS gene expression (Dai et al., 1994a). As cAMP has been shown to 
be a negative regulator of ALS expression I hypothesize that this altered regulation may 
be through the involvement of effecter molecules downstream of the cAMP signal 
altering an activity of the PI-3 kinase pathway on ALS expression.      
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2.0 REVIEW OF LITERATURE 
 
2.1 Overview on Metabolic Role of IGF in Regulation  
 
2.1.1 Animal Tissue Growth and Regulation 
 
 IGF regulation of animal tissue growth and differentiation occurs throughout 
animal development. During embryonic and post-embryonic development IGF-I and 
IGF-II are required for normal growth and differentiation. IGFBPs, ALS and IGFBP 
proteases also function in growth and differentiation through the regulation of IGF 
activity and in some cases may act independent of IGF. IGF-I and IGF-II are small 
peptides of approximately 7 kDa and are highly similar in sequence and conformation. 
The small differences in sequence may reflect in their receptor specificities. IGF-I binds 
to the IGF-I receptor (IGF-IR) whereas IGF-II binds to the mannose 6-phosphate receptor 
(M-6-P receptor or IGF-IIR). IGF-II may also bind IGF-IR and signal through this 
receptor (Nakae et al., 2001). The downstream effects of the M-6-P receptor activation by 
IGF-II are unclear but have been reported to have roles in fetal organogenesis, lysosomal 
enzyme trafficking, cytotoxic T cell-induced apoptosis and tumour suppression. IGF-II is 
the major IGF expressed during early embryonic development (Bhaumick et al., 1987). 
The IGF-II gene is subject to genomic imprinting, a process whereby the gene is 
expressed primarily by one parental allele. Imprinted genes have been shown to be 
important in fetal development (Reik et al., 1996, Claire et al., 1996). Experiments 
utilizing homologous recombination have resulted in IGF-II null mice 60% smaller in 
size than normal mice, but otherwise normal and fertile (Allan et al., 2001). The resulting 
phenotype suggests that IGF-II, although important for normal development, may not be 
essential for survival. 
The IGF-IR is highly similar to the insulin receptor (IR) in sequence and function. 
Both have similar downstream signaling events which include many of the same 
signaling molecules as seen with the IR such as insulin substrate-1 (IRS-1) (Figure 2.1). 
Ligand binding analysis in chicken embryos shows IGF-IR/IGF-I association in stages as  
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                                                             IGF-I 
 
                                     IGF-IR                     α           α 
           MAP kinase pathway                                                    PI-3 kinase pathway 
  
 
                                                                             P              PI-4,5-P2        PI-3,4,5-P3       PI-3,4-P2           
            Ras              Ras                                  β        β                                                                            PDK-1 
                GTP        GDP      Sos                            P                                                                               P 
                                                  Grb2     Shc         P     IRS-1    p85    p110                              PKB      PDK-2 
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                                                                                                                                                             P 
                                                                                                                GSK-3 
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                                                                                                          Pi                       
                                                                                                                             
           
                                                                      glycogen                                   
                                       Stat5, Id2 ?             synthase                                         P     
                                                                       (active)                              GSK-3 
 
               Erk1         Erk2 
 
                                                                                                     Glucose transport      Protein Synthesis 
                                                                                                              (GLUT4)                 (p70s6k) 
                                                
                                                                                                                    Cellular Proliferation      Apoptosis     
                                                                    Cell Differentiation ?                                                          (Bad)  
 
                 Cellular proliferation 
                       and apoptosis  
 
 
 
 
 
 
Figure 2.1.  Signal transduction mechanism of insulin-like growth factor-I receptor. Once 
ligand (IGF-I) is bound, IGF-IR is activated leading to phosphorylation events and 
downstream activities involving multiple proteins. Depicted to the left of the IGF-IR is 
the mitogen activated protein (MAP) kinase pathway which signals for cell proliferative 
and apoptotic activities. Depicted to the right of the IGF-IR is the PI-3 kinase pathway. 
Briefly, IRS-1 is phosphorylated and activated leading to the phosphorylation of 
phosphoinositols. PKB is activated downstream of PI-3,4-P2 effecting glucose transport, 
glycogen synthesis, cellular proliferation, protein synthesis and apoptosis. Also depicted 
is the activation of molecules such as Stat5 and Id2 which may be involved in cell 
differentiation.  
 
Abbreviations: P , Phosphorylation; Remaining abbreviations given in the List of 
Abbreviations on page xii                                                                                                                                  
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early as gastrulation and neurulation. In addition, IGF-I dependent tyrosine kinase 
activity has been detected in day 2 embryos (Claire et al., 1996). IGF-IR mRNA has also 
been detected in chicken blastoderm by PCR analysis (Bassas et al., 1985). Analysis of 
growth kinetics in mouse embryos carrying IGF-I null mutations indicate growth 
deficiencies if heterologous in mutation. If homologous in mutation, a 60% mortality rate 
occurs along with growth retardation (Baker et al., 1993). In contrast, null mutations in 
the gene encoding IGF-II do not cause mortality in mice but do result in growth 
retardation similar to that seen in heterologous IGF-I null mutations. Double knockouts 
of IGF-I and IGF-IR in mice have resulted in malformation of limbs, muscle dystrophy 
and a 95% mortality rate at the time of birth (Liu et al., 1993). The growth promoting 
activity of both IGF-I and IGF-II and their receptors appear to be required for proper 
growth of tissues and act as cell survival factors. However, IGF-I may also be required 
for specialized developmental activities required for survival.  
 The involvement of IGF-I system activity in mammalian and avian limb bud 
formation has also been reported. Limb bud formation has been shown to involve the cell 
survival promoting activity of IGF within the rapidly dividing mesoderm tissue proximal 
to the apical endodermal ridge (AER) region of the developing limb bud. Expression of 
IGF-I and IGF-IR mRNA has been detected in this region. In IGF-I and IGF-IR 
knockouts, limb formation is attenuated leading to deformation (Allan et al., 2001). Other 
components of the IGF axis such as IGFBP-2 and IGFBP-5 have been detected and 
implicated in the apoptotic activity which is necessary for limb development at later 
stages (Allan et al., 2001). IGF-I/IGFBP association sequesters IGF and disables the 
mitogenic response. IGF-I/IGFBP association in developing limb tissue may therefore 
allow decreased tissue growth and act as an alternative to apoptotic activity in the control 
of tissue growth. In the developing limb, possible IGF-I independent IGFBP action may 
also be responsible as recent studies show IGFBP binding to specific receptors and 
changing expression within certain cell types (Allan et al., 2001). 
 Cell differentiation is a cellular event where a cell may become terminally 
programmed for a certain function. The activity of the IGF-IR has been implicated in the 
induction of terminal differentiation. Under certain conditions, myoblasts, osteocytes, 
adipocytes, neurons and haemopoietic cells can be induced to differentiate by IGF-I 
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(Baserga et al., 2001). IGF-IR is known to use IRS-1 as a substrate and cause 
downstream mitogenic effects. Recent evidence suggests that in the absence of IRS-1 
(IRS-1 gene knockout) the activated IGF-IR may signal for cell differentiation. For 
example, in 32D cells, murine haemopoeitic cells of the myeloid lineage, there is no IRS-
1 and IRS-2 expression and a very low IGF-IR expression. In culture, these cells undergo 
apoptosis within 24 hours following the removal of interleukin-3 (IL-3) from the media. 
When 32D cells express human IGF-IR cDNA they survive with the absence of IL-3. 
With the addition of IGF-I they grow for 48 hours and then differentiate along the 
granulocytic pathway. In 32D cells expressing IRS-1 cDNA this differentiation is 
inhibited (Valentis et al., 1999). The absence of the IRS-1 substrate leads to a 
contradictory receptor signaling pathway leading to differentiation. Separate studies 
investigating mutation of the IGF-IR domains in H19-7 rat neuronal cells have been done 
to determine the region of the receptor required for differentiation. Tyrosine 950 and 
serine 1280-1283 residues in the C-terminus of the receptor are required for IGF-I-
induced differentiation although they are dispensable for IGF-I-mediated growth (Claire 
et al., 1996). The involvement of downstream proteins in the IGF-IR differentiation 
pathway has not yet been clearly determined but possible roles for Id2 and STAT5 
proteins have been suggested (Figure 2.1) (Baserga et al., 1999; Valentinis et al., 1999; 
Navarro et al., 2001,).   
 Discussion of IGF activity must be accompanied with a discussion on the role of 
IGF binding proteins, ALS and IGFBP proteases. The role of IGF in cell survival and 
developmental biology is well documented, but the study of IGFBP, ALS and IGFBP 
proteases in relation to IGF activities is in its infancy. The IGFBPs and ALS have a 
counter regulatory effect. Association with IGF-I in the bloodstream sequesters the 
protein and disables the effects of IGF. The aforementioned 10 IGFBPs have been 
characterized and will be discussed in some detail later in this section. All IGFBP genes 
are tightly structurally associated with and are thought to have co-evolved with the HoxA 
to HoxD genes. The Hox family of proteins are DNA binding proteins which have an 
important role in embryonic development. The co-evolution may follow in function as it 
is known that many IGFBPs are expressed in early developmental stages (Allander et al., 
1995). IGFBP-2 expression has been shown in rat embryo amongst rapidly dividing or 
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differentiating tissues. The function of IGFBP-2 in the embryo may be in the modulation 
of IGF activity or in activities independent of IGF. IGFBP-5 expression in early rat 
embryo has also been shown. It has been shown that IGFBP-2 and IGFBP-5 have highly 
complimentary expression patterns that often overlap in adjacent cell populations 
indicating a complimentary function. Expression of all IGFBPs has been shown by day 
14 in the rat embryo (Allan et al., 2001).  
Genetic modification has shown the involvement of the IGFBPs during 
developmental processes. In transgenic mice, the over expression of IGFBP-1 causes 
mild growth retardation (Rajkumar et al., 1995) while targeted gene disruption of IGFBP-
2 showed surprisingly little effect on development probably due to the complementary 
activity of IGFBP-5. IGFBP-3 over expression showed an increased size of mouse liver, 
heart and spleen (Murphy et al., 1995). Gene deletion of ALS caused a 40% decrease in 
IGF-I in circulation and a 10% reduction in body mass due to the assumed destabilization 
of the IGF binding protein complex and the resulting decrease in IGF-I half-life (Yakar et 
al., 2002).  
Some IGFBPs may have receptor binding activity independent of IGF-I which 
may affect growth and development. Receptors have been found for IGFBP-1 (Jones et 
al., 1993), IGFBP-2 (Rauschnabel et al., 1999), IGFBP-3 (Oh et al., 1993) and IGFBP-5 
(Andress et al., 1995) but none of these receptors has yet been cloned. IGF independent 
effects have been found to include modulation of bone cell proliferation (Mohan et al., 
1995) as well as growth arrest of breast and prostate cancer cells (Oh et al., 1993; 1995). 
The recognition of IGFBP protease activity is a recent development and may have a 
profound effect on the understanding of the regulation of IGF activities including 
developmental processes. Categories of IGFBP proteases, to date, include kallikriens 
(Cohen et al., 1992), cathespins (Canover et al., 1994) and matrix metalloproteinase 
proteins (MMPs or matrixins) (Fowlkes et al., 1994). Proteolysis of IGFBP-2 to 6 has 
been shown in many clinical states and cellular systems. It has also been shown that 
IGFBP proteases are important regulators of autocrine and paracrine growth seen in 
processes such as ovarian follicular growth and atresia (Watterau et al., 1999).  
 
 
 9
2.1.2 Metabolic Function in Animal Tissue 
 
 IGF-I has important effects on carbohydrate, lipid and protein metabolism. The 
insulin-like effects of IGF-I in cells expressing IGF-IR on the cell surface is likely due to 
a high similarity between IGF-IR and IR. IGF-IR is expressed in adult animal tissues, 
excluding the liver, and does not show significant tissue specific expression. It is known 
that, like the IR, IGF-IR has kinase domains which phosphorylate IRS-1 and lead to 
downstream signaling pathway activation. Through the Phosphoinositol-3 (PI-3) kinase 
pathway, protein kinase B (PKB) and Protein phosphatase-1G (PP-1G) are activated and 
Glycogen synthase kinase-3 (GSK-3) is inactivated which in turn activates glycogen 
synthase (Syed et al., 2000). Active PKB also leads to the stimulation of p70s6k that also 
have downstream effects on protein synthesis (Kadowaki et al., 1996). These activated 
pathways give rise to anti-apoptotic effects, glycogen storage and decreased glucose in 
circulation (Figure 2.1). The effects of infusions of human recombinant IGF-I (hrIGF-I) 
in patients have been determined on glucose metabolism. There was a ten-fold increase in 
glucose consumption with a 30 µg / kg * hr IGF-I dose (Turkalj et al., 1992; Zenobi et al., 
1992). Also shown were increased glucagon concentrations with decreasing glucose 
levels in circulation. Separate studies using subcutaneous injection of IGF-I over a five 
day period showed no change in glucose turnover, but showed increased insulin 
sensitivity during a euglycemic/hyperinsulinemic clamp treatment (Hussain et al., 1993). 
 The effect of hrIGF-I (80% in free form – not bound to IGFBPs) on the 
production of hypoglycemia in healthy adults is 6% as potent as insulin on a molar basis 
(Guler et al., 1987). Comparative analysis of the effects of insulin and IGF-I has been 
well documented. With the use of a euglycemic clamp and IGF-I infusion it was shown 
that glucose disposal mediated by IGF-I had a slower onset than insulin as well as a 
slower return to normal glucose levels after IGF-I infusion had ceased (Russel-Jones et 
al., 1995). Boulware et al. (1994) also observed increases in glucose uptake and 
inhibition of hepatic glucose production in studies with acute IGF-I infusions. Muscle 
tissue is especially responsive to the IGF-I signal while hepatic tissue response is 
negligible due to absence of IGF-IR in this tissue. The IGF-I induced response in muscle 
is likely due to the presence of a higher number of IGF-IR. In the case of hepatic tissue 
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where IGF-IRs is almost non-existent, its inhibitory effects on hepatic glucose production 
may occur through alternate receptors. IGF-I may interact with alternative receptors such 
as the IR or hybrid IGF-I/IR or may affect substrate delivery for hepatic gluconeogenesis. 
It is of importance to note that in the above studies showing the hypoglycemic effect of 
IGF-I (Boulware et al., 1994; Russel-Jones et al., 1995) the dosage used was ten-fold 
higher than insulin and could have also been influenced by dietary states, routes of 
administration, time and dose. 
 A consequence of increased IGF-I levels in circulation is a decrease in growth 
hormone (GH) and insulin release. IGF-I, which is positively regulated by GH and 
insulin, acts to regulate GH concentrations through a feedback mechanism involving GH 
releasing pituitary and the growth hormone releasing hormone (GHRH) secreting 
hypothalmus. Decreased IGF-I, through mice igf1 gene deletion and low dose euglycemic 
hrIGF-I infusion, leads to GH hypersecretion (Hartman et al., 1993). GH is known to 
have an antagonistic effect on insulin action (Dominici et al., 2002) through reducing IR 
levels (Venkatesan et al., 1995) and IR/IRS-1 phosphorylation (Balbis et al., 1996). 
Increased GH concentrations, therefore, have an effect on glucose metabolism by limiting 
insulin mediated glucose removal. GH has been found to be a cause of insulin resistance 
in rodent models exhibiting chronic GH excess (Yakar et al., 2001). Studies with liver 
specific IGF-I gene inactivation in mice (LI-IGF-I - /- mice) show increased insulin 
secretion compared to controls over a nine month period. Measurements of plasma 
insulin before and after intravenous injections of glucose (1 g/kg) showed insulin levels 
in LI-IGF-I - /- mice were more than 2-fold higher than control mice. With increased 
insulin concentrations, there was no difference in glucose clearance between the LI-IGF-I 
- /- mice and the control mice even though insulin levels in the transgenic mice were 
higher (Isaksson et al., 2001). Decreased liver derived IGF-I, therefore, may lead to 
changes in metabolism due to increased insulin secretion, but the inability to bring down 
glucose concentration irrespective of increased insulin secretion may indicate a state of 
insulin resistance. Separate studies looking at the effects of hrIGF-I administration on 
insulin levels and insulin secretion showed direct suppression of insulin secretion in 
human subjects (Zenobi et al., 1992) through a reciprocal mechanism in agreement with 
the above data. IGF-I has also been shown to interact or interfere with the metabolic 
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effects of thyroid hormone (TH) in liver cells through the modulation of thyroid hormone 
receptor (THR) expression and the activity of thyroid responsive enzymes such as α-
glycerophosphate dehydrogenase (α−GPD) and malic enzyme (ME) (Pellizas et al., 
1998).  
 The role of IGF-I in the regulation of lipid metabolism is similar to that of insulin. 
hrIGF-I infusion shows decreased plasma triglyceride,  β-hydroxybutyrate and free fatty 
acid (FFA) levels with increasing IGF-I presence in circulation. Decreased β-
hydroxybutyrate may indicate inhibition of ketogenesis by IGF-I, but it is likely due to 
decreases in plasma FFA (Turkalj et al., 1992). Similar results were obtained with insulin 
infusion (Kazumi et al., 1986). The involvement of IGF-I in lipolysis and subsequent 
release of FFA is still debatable. Russel-Jones et al. (1995) and Boulware et al. (1994) 
have both shown decreases in non-esterified fatty acids (NEFA) with IGF-I infusion, but 
Hussain et al. (1993) have shown an increase in NEFA with IGF-I subcutaneous injection 
in healthy patients. Other work has been done using liver specific igf-I gene inactivation 
in mice (LI-IGF-I - /- mice). There was a 26.5% decrease in fat mass in thirteen month old 
transgenic mice compared to control (Isaksson et al., 2001). Leptin levels have been 
associated with the amount of body fat in mice (Ahren et al., 1997). Leptin (from the 
Greek leptos, meaning thin) is a protein hormone which effects the regulation of body 
weight, metabolism and reproductive function. The protein is encoded by the obese (ob) 
gene and is mainly expressed in adipocytes. Leptin levels have been positively correlated 
with obesity due to an increased number of adipocytes in obesity. The injection of 
recombinant mouse or human leptin into ob-/ob - mice results in a 50% decrease in body 
weight and a large decrease in food intake. In LI-IGF-I - /- mice, increases in leptin levels 
were also reported. Increased leptin levels may also lead to a 26.5% decrease in fat 
storage as seen in transgenic mice lacking liver derived IGF-I (Isakkson et al., 2001). The 
fat levels became similar after thirteen months, but the control animals had a higher fat 
percentage than transgenic mice. Although it has been shown that IGF-I binds to 
adipocytes its metabolic effects are through the IR (Bolinder et al 1987). It has not been 
yet determined whether insulin has a similar effect on leptin levels. The decrease in liver 
derived IGF-I expression also caused an increase in cholesterol levels mainly in the high 
density (HDLP) and low density lipoprotein fractions (LDLP) (Isaksson et al., 2001).   
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 Protein metabolism involves the synthesis and breakdown of protein, the energy 
consumed and/or released in these processes and the byproducts produced. The in vivo 
metabolic effects of IGF-I are difficult to determine due to the consequential 
modifications in the levels of other hormones known to affect protein metabolism such as 
insulin and GH. However, data exists that shows IGF-I to have a similar effect as insulin, 
but with 14 times less potency (Giordano et al., 1995). The overall effect of IGF-I on 
protein metabolism has been in reduction of proteolysis and little or no effect on protein 
synthesis. In human subjects, increased IGF-I dose exhibited a dose-dependent decrease 
in plasma leucine and α-ketoisocaproate, the ketoacid metabolite of leucine. The decrease 
in whole body leucine flux and leucine oxidation has also been observed with increase in 
IGF-I (Turkalj et al., 1992). This indicates a decrease in overall protein breakdown and 
an inhibition or irreversible loss of leucine due to oxidation catalyzed by the rate limiting 
branched-chain alpha-keto acid dehydrogenase (BCKD) complex. Similar to insulin, 
IGF-I may signal cells to limit the usage and breakdown of protein by gluconeogenesis 
and instead follow metabolic pathways that favor carbohydrate breakdown and usage 
which is far less expensive in terms of energy costs. Most of the above data was 
performed on fasted subjects where amino acid availability is non-physiologically low for 
protein synthesis to occur. To address this issue, Russel-Jones et al. (1995) used an amino 
acid clamp protocol to maintain amino acids in circulation while evaluating the effect of 
an IGF-I infusion. IGF-I produced an increase in the non-oxidative leucine disposal rate 
(protein synthesis) with no effect on protein degradation. It was postulated that the 
actions of IGF-I on protein metabolism may depend on the availability of amino acids. 
IGF-I may reduce proteolysis during low amino acid availability but causes an increase in 
protein synthesis with increased amino acid availability. From this, it may be concluded 
that IGF-I may serve as a link between short term metabolic control (insulin) and longer 
term regulation of growth and body composition (GH) (Simpson et al., 1998). 
The involvement of IGF binding proteins and ALS in metabolic processes involve 
the sequestering of IGF-I activity a well as, perhaps, functions independent of IGF-I. As 
mentioned earlier, IGFBPs bind IGF-I. IGFBP-3, ALS and IGF-I form the main ternary  
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Table 2.1 Summary of in vivo effects of IGF levels on carbohydrate, protein  
                 and fat metabolism 
 
 
 in vivo Treatment                                        Effects 
 
 
 increased IGF-I                                            -     decreased GH secretion 
 (injection or infusion)                                     -    decreased insulin response 
- increased glucose metabolism 
- increased glucose consumption 
- increased glucagon secretion 
- increased sensitivity to insulin 
- decreased insulin release 
- decreased thyroid hormone response 
- decreased plasma triglyceride,  β-
hydroxybutyrate and free fatty acids 
- decreased proteolysis 
- decrease in plasma leucine and α-
ketoisocaproate 
- decrease in overall protein breakdown 
- increased protein synthesis 
 
 
 
 decreased IGF-I                                           -     increased GH secretion 
 (gene deletion or transgenics)                        -     reduced IR levels and IR/IRS     
      phosphorylation  
- decreased glucose removal 
- increased insulin secretion 
- decreased fat mass 
- increased leptin levels 
- increased cholesterol 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations:  abbreviations given in the List of Abbreviations on page xii                                                                
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complex found in circulation comprising 80-90% of all bound IGF-I. The other binding 
proteins make up the remaining 10-20% forming binary complexes without ALS. IGF- I 
complexes inhibit the hypoglycemic potential of free IGF-I as well as the effects on lipid 
and protein metabolism. Therefore, in formation of IGF-I complexes, IGFBPs and ALS 
contribute to the metabolic status of the individual. IGFBP-1 was the first binding protein 
discovered and has been the subject of most studies. Recently, much attention has been 
paid to IGFBP-1 because of its potential physiological role in metabolism, diabetes and 
its regulation by insulin. IGFBP-1 levels are inversely related to insulin levels (Cotterill 
et al., 1989). In normal healthy adults, IGFBP-1 expression follows a diurnal variation 
with highest levels overnight when insulin secretion is the lowest (Holly et al., 1988). 
Experiments with rhIGFBP-1 injection have shown that IGFBP-1 induces 
hyperglycemia; this condition was abolished with co-injection of IGF-I and amniotic 
IGFBP-1 (Lewitt et al., 1991). IGFBP-1 infusion reduces plasma free IGF-I (Lang et al., 
2003) and its hypoglycemic effect due to its association with IGF-I. The administration of 
rhIGFBP-1 in rats showed a stimulation of insulin release without any effect on glucose 
levels. In this case, IGFBP-1 was bound to free endogenous IGF-I thus lowering its active 
concentration (Mortensen et al., 1997). The decrease of IGF-I levels through IGF-I gene 
deletion in mice has also been shown to increase insulin levels (Isaksson et al., 2001). 
Absence of changes in glucose levels may be partially due to the absence of 
phosphorylation of rhIGFBP-1 (Frystyc, 2000). This will be discussed further in a later 
section. Recently, IGFBP-7, a low affinity IGF binding protein, was found to be a high 
affinity insulin binding protein (Yamanaka et al., 1997).   
 
2.2 Structure and Regulation of Expression of Components of the IGF-I System  
 
2.2.1 IGF-I 
 
 The igf-I gene is located on human chromosome 12 (Barreca et al., 1989). The 
gene sequence contains six exons and 5 introns spanning 80 kb of chromosomal DNA 
(Rotwein et al., 1986). Exons 3 and 4 encode a portion of the N-terminal leader peptide, 
the complete sequence of the mature protein and a portion of the C terminus (E domain). 
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Exons 1, 2, 5 or 6 can be alternatively spliced leading to four splice variants or mRNA 
subtypes containing differences in the 5’ and 3’ untranslated regions (UTR). Exon 1 or 
exon 2 can form the N-terminal sequence giving rise to subtype distinction type 1 or type 
2, respectively. The C-terminus sequence can be formed by either exon 5 or 6 giving rise 
to the distinction Ea or Eb, respectively. Therefore, the 4 subtypes are referred to as 1/Ea, 
1/Eb, 2/Ea and 2/Eb. IGF-I mRNA expression of all four subtypes is seen in all tissues in 
early development but the primary subtype is 1/Ea. At postnatal stages of development, 
the 1/Ea becomes more prominent in expression especially in the GH responsive liver 
tissue. The IGF-I gene sequence has been highly conserved amongst species and the 
existence of different mRNA subtypes within the same species may indicate a functional 
significance (Yakar et al., 2002). Two promoter regions in the IGF-I gene sequence have 
been identified to date and are termed P1 and P2 (Nolten et al., 1994). 
 IGF-I is a single chain polypeptide composed of 70 amino acid residues having a 
MW of 7.6 kDa. The IGF-I sequence is known for a number of different species and is 
shown to be highly conserved with few exceptions. It has a 70% sequence homology with 
IGF-II and a 50% sequence homology with pro-insulin. The protein has 4 domains with 
domain A and B having the most homology with insulin (60 to 70% similarity). There are 
three intrachain disulfide bridges and the C and D domains have no homology with pro-
insulin and form the carboxy terminus of the protein (Figure 2.2) (Daughaday et al., 
1989). The ternary structure of the mature IGF-I has not been determined by X-ray 
crystallography but is thought to have a similar structure to insulin due to the high 
sequence similarity.  
 The biological effects of IGF-I can be modulated through a number of regulatory 
principles: Firstly, the number of IGF-IRs expressed on the cell surfaces of target cells; 
secondly, interaction with IGFBPs and ALS which extend IGF half-life, protect from IGF 
degradation, facilitate IGF transport into distinct body compartments and interfere 
positively or negatively with IGF-IR interaction; and finally the availability of IGF due to 
the regulation of its own expression. It has been known for some time that during prenatal 
and postnatal growth and development, serum IGF-I concentration varies from 20 ng/mL  
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   IGF-I protein                                                    
                         
 
 
Figure 2.2 Schematic illustration of the IGF-1 mRNA transcript and protein structure. 
The IGF-I mRNA subtype is not shown for simplification. The mRNA transcript 
possesses a 5’UTR and leader sequence derived primarily from exons 1 or 2 depending 
on the mRNA subtype. A 3’UTR is derived from exons 5 or 6 also dependant on the 
mRNA subtype. Exons 3 and 4 encode B, C, A, D and E domains which are translated 
into pre-protein. Proteolytic cleavage of the C-terminal E domain results in the formation 
of a mature protein. The protein contains three disulfide bridges. X-ray crystallography 
has not been done to determine 3-D structure, but due to sequence similarities structure is 
thought to resemble that of insulin.     
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in fetal stages to 200 ng/mL after birth (Bennet et al., 1983, Rotwein 1999). This large 
increase reflects a strong IGF-I regulation pattern and has lead to extensive research in 
this area. Several studies have elucidated promoter sequences, transcription factors and a 
number of hormones and signaling molecules involved in regulation of IGF-I (Table 2.2). 
Although IGF-I is expressed in many tissues, this section will primarily review regulation 
of IGF-I expression in hepatic tissue. 
 Production of IGF-I in liver is relatively insignificant in early development. 
Postnatal hepatic expression of IGF-I increases to a maximum at birth and then decreases 
with age. A second and less prominent peak occurs during puberty. There are a number 
of factors which have been found to regulate the bioactive levels of hepatic derived IGF-
I.  Insulin has been found to increase liver IGF-I transcription in vivo (Pao et al., 1992) 
and in primary hepatocyte cultures (Pollak et al., 1989). GH also has been found to 
increase IGF-I mRNA in primary hepatocytes (Norstedt et al., 1987) and in the liver (in 
vivo) (Bichell et al., 1992). Glucagon increases IGF-I mRNA in primary hepatocytes 
(Kachra et al., 1991) whereas estrogen increases transcription of IGF-I in HepG2 
hepatoma cells (Umayahara et al., 1994). The thyroid derived hormone, triiodo-L-
thyronine (T3), increases IGF-I mRNA levels in both primary hepatocyte cultures (Tollet 
et al., 1990) and in liver (in vivo) (Wolf et al., 1989). Hormones can regulate protein 
levels through regulation of transcription, post-transcriptional processes that govern 
formation, stability and translation, and post-translational processes such as proteolytic 
cleavage and glycosylation. It is not yet clear the methods the above mentioned hormones 
utilize in IGF-I regulation. However, a number of the mentioned hormones will be 
discussed in detail later in this thesis. 
 The IGF-I gene contains two promoter sequences, P1 and P2, which are located 
upstream of exon 1 and exon 2, respectively and do not contain TATA and CAAT 
elements (Sussenbach et al., 1989). To date, three liver specific transcription factors (TF) 
have been identified. These three TFs bind to six binding sites located in the P1 promoter 
and after birth are expressed at much higher levels in the liver than any other tissue. The 
roles of liver specific TFs, as well as other more ubiquitous TFs, have been studied using 
transient transfection assays. The first TF, the CAAT- box / enhancer binding protein  
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Table 2.2 Modulators of IGF-I expression 
 
Molecule Class Effect on IGF-I 
Expression 
Reference 
Insulin 
 
 
GH 
 
 
Glucagon 
 
 
Estrogen 
 
 
T3 
 
 
C/EBP (α,Β) 
 
 
HNF-1α 
 
 
HNF-3β 
 
 
cAMP 
 
 
AP-1 
 
 
ETF 
 
 
glucocorticoid 
Hormone 
 
 
Hormone 
 
 
Hormone 
 
 
Hormone 
 
 
Hormone 
 
 
Transcription factor 
 
 
Transcription factor 
 
 
Transcription factor 
 
 
Signaling molecule 
 
 
Transcription factor 
 
 
Transcription factor 
 
 
Hormone 
 
Increases IGF-I 
mRNA 
 
Increases IGF-I 
mRNA 
 
Increases IGF-I 
mRNA 
 
Increases IGF-I 
mRNA 
 
Increases IGF-I 
mRNA 
 
increase promoter 
activity (liver) 
 
increase promoter 
activity (liver) 
 
increase promoter 
activity (liver) 
 
increase promoter 
activity (liver) 
 
increase promoter 
activity (liver 
 
increase promoter 
activity  
 
Increases IGF-I 
mRNA 
Pao et al., 1992 
Pollak et al., 1989 
 
Norstedt et al., 1987 
Bichell et al., 1992 
 
Kachra et al., 1991 
 
 
Umayahara et al., 
1994 
 
Tollet et al., 1990 
Wolf et al., 1989 
 
Nolten et al., 1994 
 
 
Nolten et al., 1995 
 
 
Nolten et al., 1996 
 
 
De Simone et al., 
1992  
 
De Simone et al., 
1992  
 
De Simone et al., 
1992 
 
De Simone et al., 
1992 
 
 
 
 
Abbreviations: abbreviations are given in the List of Abbreviations on page xii                                                         
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(C/EBP), has two binding sites on P1. Two subtypes exist, C/EBPα and C/EBPβ, which 
bind to either of the two P1 binding sites and increase promoter activity (Nolten et al., 
1994). The other two TFs belong to the hepatocyte nuclear factor (HNF) family. HNF-1, 
and more specifically the HNF-1α isotype, bind to two sites on the P1 promoter (Nolten 
et al., 1995). The other liver specific HNF is HNF-3 with the isoform HNF-3β being the 
strongest activator. This TF binds to two binding sites on P1 (Nolten et al., 1996). 
Presence of these liver-specific TFs may help in explaining why the liver has developed 
as the source of endocrine IGF-I. Other more ubiquitous TFs exist which may also be 
active in hepatocytes. One example is those TFs which act downstream of the cAMP 
signal which interact with the cAMP response element (CRE) within the untranslated 
region of exon 1 of the IGF-I gene. Others TFs include adaptor protein (AP)-1, E2F and 
glucocorticoid (De Simone et al., 1992).   
 
2.2.2 IGF-I Receptor 
 
The IGF-IR gene consists of 21 exons arranged in a 100 kb span at the distal end 
of human chromosome 15 (Abbott et al., 1992). Exons 1-10 contain a 5’ UTR, a signal 
peptide sequence, a cysteine rich domain (CRD) and the remaining sequence of the α 
subunit. A proteolytic cleavage site exists within exon 11 and exons 12-21 code for the β 
subunit. In the β subunit portion of the gene exon 14 codes for a transmembrane domain 
and exons 16-20 code for the tyrosine kinase domain (Cohick et al., 1993) (Figure 2.3). 
Comparison of the IGF-IR and IR genes show that 12 out of the 21 exons are identical in 
size. In the other existing exons the differences do not exceed 15 nucleotides. The highest 
similarity in sequence (84%) is found in the tyrosine kinase domain. Significant 
homology also exists between the non-cysteine rich portion of the α subunit (64%) and 
the cysteine rich regions (45%) (Werner 1999). The mRNA transcript of the IGF-IR gene 
is seen as an 11 kb band on a Northern blot (Lowe et al., 1990). The transcript includes a 
1 kb 5’ UTR, a 5.1 kb coding region and a 5 kb 3’ UTR. The IGF-IR has been identified 
in virtually every tissue, except the liver, and regulation depends on developmental stage. 
During early embryonic growth stages transcription levels are high and decrease  
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Figure 2.3 IGF-1R mRNA structure, processing and protein structure. IGF-1R functional 
domains are indicated above corresponding to numbered exons. Upon translation the pre-
peptide is processed through glycosylation, proteolytic cleavage and addition of disulfide 
linkages ( _____ ).  The α and β subunits are assembled and expressed on the cell 
membrane with the α subunit exclusively extracellular and the β subunit primarily 
intracellular but also contains a transmembrane region and a small extracellular region.  
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postnatally with lowest expression observed in adults (Werner et al., 1989). The liver 
produces the highest amount of IGF-I but produces the least IGF-IR. IGF-I may 
downregulate expression of its own receptor. High levels of IGF-IR mRNA have also 
been seen in de-differentiated states. For example, rat granulosa cells transfected with 
simian virus-40 (SV-40) show marked increases in IGF-IR expression (Werner et al., 
1989).    
 The IGF-IR is translated and processed to synthesize a 180 kDa glycoprotein 
(Figure 2.3). Precursor processing involves the removal of a polar residue rich signal 
peptide and core glycosylation. The proreceptor partial processing involves terminal 
glycosylation, disulfide linkages as well as proteolytic cleavage at a basic tetrapeptide 
sequence (Arg-Lys-Arg-Arg). This gives rise to the α and β subunits which are 
synthesized co-linearly from a single precursor molecule composed of 1367 amino acids 
(Ullrich et al., 1986). Structurally, the α subunit is entirely extracellular. The sequence 
contains 11 N-linked glycosylation sites as well as a cysteine rich region (24 cysteine 
residues) which is important for binding to IGF-I. The β subunit spans the membrane 
with a large cytosolic portion. The extracellular portion contains 5 N-linked glycosylation 
sites and is 194 residues in length. The transmembrane region consists of 24 hydrophobic 
residues. The cytoplasmic portion of the β subunit contains a 256 amino acid tyrosine 
kinase domain with a conserved glycine rich region important for phosphate transfer to 
specific substrates (Werner 1999).             
The regulation of IGF-IR expression occurs mainly at the transcriptional level. 
The IGF-IR gene contains control elements found in both constitutive and regulated 
genes.  IGF-IR, therefore, is expressed in every cell type but is regulated. The promoter 
region, like the IGF-I promoter, does not contain the CAAT and TATA motifs and is 
similar to other promoter sequences which have been termed as ‘housekeeping genes’ 
(Werner et al., 1990). In comparison to the IR, the IGF-IR is unique. The IGF-IR 
promoter contains a single ‘initiator’ motif that can direct transcription in the absence of 
the TATA and CAAT cis-elements normally required for proper transcription. The IR 
also lacks the TATA and CAAT elements but contains multiple initiator sites (Araki et 
al., 1987). The existence of the initiator motif has been found in promoters of genes 
which are highly regulated during differentiation and development. The promoter 
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sequence is G and C rich (Cooke et al., 1991) and contains multiple G-C boxes which are 
potential binding sites for the SP1 and the early growth response (EGR) (including WT-
1) families of TFs (Courey et al., 1992, Sukatme et al., 1992). SP-1 binds G-C boxes in 
the IGF-IR gene promoter through three zinc-finger domains and stimulates IGF-IR 
expression (Courey et al., 1988). In addition, the 5’ flanking region of the IGF-IR gene 
contains potential binding sites for GC factor (GCF), AP-2 and ETF (Werner et al., 1990, 
Cooke et al., 1991). 
 Local and circulating levels of a number of hormones and growth factors exhibit a 
control on IGF-IR expression. IGF-I itself regulates IGF-IR expression. Increased IGF-I 
concentrations result in decreased IGF-IR levels. The mechanism by which IGF-I 
regulates IGF-IR is likely through a translocation or downregulation of the cell surface 
IGF-IR to an intracellular pool. This downregulation is reversed with decreased IGF-I 
levels (De Souza et al., 1995). Increased IGF-IR has been associated with growth 
disorders such as Laron-type dwarfism and caloric deprivation both due to decreased 
IGF-I levels. The presence of free IGF-I is therefore significantly controlled through the 
level of IGF-IR expression. Control elements which cause this effect on IGF-IR 
expression have not been determined. Other growth factors and hormones also have an 
effect on IGF-IR expression. Stimulatory factors are PDGF and FGF whereas insulin and 
estrogen are inhibitory factors (Werner 1999) (Table 2.3).     
Higher levels of IGF-IR expression have been found in most tumours and cancer 
cells and have been implicated in malignant transformation. This was demonstrated in 
NIH3T3 fibroblasts overexpressing functional IGF-IR. Results indicated a ligand 
dependent, highly transformed phenotype that resulted in tumour formation in nude mice 
(Kaleco et al., 1990). Truncation or mutation of the IGF-IR gene results in its inability to 
transform transfectants suggesting that the IGF-IR is a target for multiple oncogenic 
agents such as the c-myb protooncogene (Travali et al., 1991) and the src oncogene which 
encodes pp60src. The effect of transformation of human cells by pp60src results in 
constitutive tyrosine phosphorylation of the IGF-IR β-subunit. Of the expressed IGF-IR 
unstimulated tyrosine kinase domains, 10% to 50% are phosphorylated leading to 
activation of downstream mitogenic pathways (Kozma et al., 1990). Regulation of the 
IGF-IR gene also occurs through tumour suppressors. Tumour suppressors are mutated in 
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a large number of human cancers where IGF-IR is overexpressed. The absence of 
functional tumour suppressor therefore transcriptionally derepresses IGF-IR expression 
leading to its over-expression and downstream mitogenic responses in these cells. 
Examples of tumour suppressors which exhibit this activity are WT1 (Werner et al., 1993 
Werner et al., 1994) and mutant p53 (Oren 1992) (Table 2.3).     
 
 
 
Table 2.3 Modulators of IGF-IR expression 
 
Molecule Class Effect on IGF-IR 
Expression 
Reference 
SP-1 
 
 
 
WT-1 
 
 
 
GCF, AP-2, ETF 
 
 
IGF-I 
 
 
PDGF, FGF and 
estrogens 
 
Insulin, estrogen 
 
c-myb proto-oncogene 
 
src oncogene 
 
 
 
 
p53 
Transcription factor 
 
 
 
Transcription factor 
 
 
 
Transcription factors 
 
 
Hormone 
 
 
Hormones 
 
 
Hormones 
 
oncogene 
 
pp60src protein   
 
 
 
 
tumour suppressor 
transcription factor 
 
G-C box binding 
increases expression 
 
 
tumour suppressor G-
C box binding 
decrease expression 
 
Not yet determined 
 
 
Negatively regulates 
unknown mech. 
 
Increase expression 
 
 
Increase expression 
 
Increase expression 
 
IGF-IR 
phosphorylation 
mitogenic pathway 
activation 
 
Decreased 
transcription 
Courey et al., 1988 
Beitner-Johnson et al., 
1995 
 
Sukatme et al., 1992 
Werner et al., 1993 
 
 
Werner et al., 1990 
Cooke et al., 1991 
 
De Souza et al., 1995 
 
 
Werner 1999 
 
 
Werner 1999 
 
Travali et al., 1991 
 
Kozma et al., 1990 
 
 
 
 
Oren 1992 
 
 
Abbreviations: abbreviations are given in the List of Abbreviations on page xii 
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2.2.3 IGF Binding Proteins 
 
2.2.3.1 IGFBP-1 
 
 IGFBP-1 is encoded by a single copy gene on human chromosome 7p14-p12 
(Figure 2.4) (Ekstrand et al., 1990). The gene spans 5.2 kb and contains 4 exons. The 
larger size of exon 1 is a characteristic of all IGFBPs. The IGFBP-1 gene sequence is 
found contiguous with IGFBP-3 in a tail to tail conformation. A 24 bp direct repeat exists 
between intron 3 and exon 4 and a 3’ acceptor splice site has been identified in the same 
region, 93 bp upstream of exon 4 (Allander et al., 1993). The promoter region of the 
IGFBP-1 gene extends -1205 bp upstream of the transcription initiation site which exists 
nt -28 bp upstream of the translation initiation site or the ATG codon. The transcribed 
IGFBP-1 mRNA product consists of a 56-164 bp 5’UTR, 564-612 bp 3’UTR, a coding 
region of 798 bp and a consensus poly A signal (AATAAA) followed by a poly (A) tail 
(Figure 2.4). A single mRNA transcript for IGFBP-1 with a size of 1.5 kb has been 
determined by Northern analysis (Cubbage et al., 1989). IGFBP-1 cDNA has been 
isolated from human deciduas, liver, placenta and HepG2 hepatocarcinoma cells (Guck et 
al., 1999).  
 The isolated IGFBP-1 cDNA encodes a 259 amino acid precursor, with a 25 
residue signal peptide and a 234 residue mature polypeptide. The apparent molecular 
mass of IGFBP-1 is 32-34 kDa as determined by sodium dodecyl sulphate 
polyacrylamide gel electrophoresis (SDS-PAGE) (Rechler 1993). The amino acid 
sequence contains 18 cysteine residues mainly localized in clusters within the C and N-
terminus which form disulfide linkages in the protein ternary structure (Brinkman et al., 
1991a and b). There are no sites for N-glycosylation, but the protein sequence does 
contain a RGD (Arg-Gly-Asp) motif at the C-terminus; a consensus sequence for the 
binding of proteins to cell surface integrin molecules. Similar RGD sequences have been 
identified and studied in fibronectin and matrix adhesion molecules (Ruoslahti et al., 
1987, 1991, Jones et al., 1993). Also within the C-terminal sequence are PEST (Pro-Glu-
Ser-Thr) motifs which have been found to be common in rapidly degraded proteins  
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 1.2 kb                                   5.2 kb
   Promoter               exon 1               intron    exon 2     intron           exon 3        intron              exon 4                       exon  4 
     region                                                                                                                                                                        IGFBP-3 
       1.5 kb
5’UTR                                     Coding Region                                                              3’UTR                     poly A 
56-164 bp                                798 bp                                                                         564-612 bp 
IGFBP-1 mRNA transcript 
IGFBP-1 primary protein structure 
 C C    C    C    C CCC    C CC                 P (Serine 101)                                                      C C  C    C    C C   C 
259 aa 
  Signal peptide                                           234 residue mature polypeptide                                                               RGD 
 C/EBP
      GRE       HNF binding site      IRE             AP-2 binding site   CGTCA motif    CCAAT   TATA box 
cAMP 
responsive 
elements 
HNF-1 AP-2
 
 
Figure 2.4 Schematic of IGFBP-1 promoter, gene, mRNA and primary protein structure. The 
promoter region is shown with TF binding sites indicated as well as important regulatory 
elements mentioned in the text. The gene consists of 1.2 kb promoter and 5.2 kb region 
containing 4 exons and 3 introns. 1.5 kb mRNA transcript consists of a 5’UTR, coding 
region, 3’UTR and Poly A tail. The 259 amino acid (aa) primary protein structure as shown 
above has cysteine rich domains in the C- and N- terminal regions. Also shown are the 
relative locations of Ser 101, the signal peptide and the RGD domain.  
Abbreviations: C, cysteine; P, Phosphorylation; aa, amino acids; for remaining abbreviations 
see List of Abbreviations pg. xii 
    IGFBP-1 promoter and gene
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(Julkunen et al., 1988). Binding of IGF-I to IGFBP-1 in circulation is somewhat 
dependent on the degree of IGFBP-1 phosphorylation. Non-phosphorylated IGFBP-1 has 
a lower affinity for IGF-I as compared to phosphorylated IGFBP-1 (Jones et al., 1991). 
The non-phosphorylated IGFBP-1 might have a stimulatory role rather than an IGF 
inhibitory role (Wetterau et al., 1999). In humans, residue Ser 101 is phosphorylated and 
is an important site for the IGFBP-1 affinity to IGF-I. This residue does not have any role 
in rat and mouse (Lee et al., 1994).      
 In human serum, IGFBP-1 shows dynamic regulation. In vivo studies have 
indicated that developmental and metabolic statuses regulate IGFBP-1 levels in humans 
and rats. During development, IGFBP-1 levels are elevated in fetal serum but decrease by 
a factor of ten at term and then gradually decrease following birth to a steady state level 
at puberty (Drop et al., 1984). The regulatory effect of metabolic status on IGFBP-1 
expression is mediated through insulin levels. IGFBP-1 expression is suppressed by 
increased insulin levels (Suikkari et al., 1989a). Metabolic conditions which cause 
decreased insulin levels such as diabetes, fasting and prolonged exercise cause opposite 
effects on IGFBP-1 levels (Hilding et al., 1991, Brismar et al., 1988, Busby et al., 1988, 
Suikkari et al., 1989b). Glucose intake may have a positive effect on IGFBP-1 
expression, but the effect is probably independent of insulin (Snyder et al., 1990). In 
adults with GH deficiency, IGFBP-1 levels are higher suggesting that GH may have a 
suppressive effect (Busby et al., 1988). Along with metabolic and developmental 
regulation of IGFBP-1 levels, it has also been shown that IGFBP-1 expression occurs in 
the uterine decidua where IGFBP-1 levels can increase five-fold during pregnancy 
(Rutanen et al., 1985). IGFBP-1 levels in human amniotic fluid can increase to 1000-fold 
than that of serum concentration at midterm pregnancy (Guck et al., 1999). 
 Along with in vivo studies, in vitro regulation of IGFBP-1 expression has also 
been shown with the use of a number of cells. IGFBP-1 expression has been shown in 
liver-derived hepatoma cell lines (H4IIE, HepG2) as well as in breast cancer and 
endometrial adenocarcinoma cells. The H4IIE rat hepatoma cells have been utilized for a 
number of studies with different potential effector molecules. It has been found that 
physiological amounts of dexamethasone increase H4IIE IGFBP-1 mRNA abundance 10-
fold (Orlowski et al., 1990). Insulin and cAMP inhibit H4IIE cell IGFBP-1 protein 
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expression (Unterman et al., 1991). GH has no effect in H4IIE cells (Orlowski et al., 
1991) although some studies have shown a transcriptional repression of IGFBP-1 
expression by GH in rat liver (Seneviratne et al., 1990). Similar patterns of IGFBP-1 
regulation by the above mentioned metabolic modulators have been shown in liver tissue 
explants, rat hepatocyte culture and HepG2 cells (Guck 1999).  
 Many IGFBP-1 gene promoter cis regulatory regions have been identified for 
transcription factors in hepatocytes (Table 2.4, Figure 2.4). The IGFBP-1 promoter 
region is located within -1205 bps upstream of the transcription initiation site. The 
promoter contains a TATA box at nt -28 and a CCAAT sequence at nt -72 to which the 
C/EBP TF may bind and affect expression. Analysis of the promoter region through a 
progressive 5’ deletion indicated a basal promoter activity dependent on a cis-element 
which binds HNF-1. This element is highly conserved in several species and when 
abolished or mutated basal activity is decreased (Suwanichkul et al., 1990). 
 There have also been studies indicating the involvement of a number of TFs 
which mediate hormonal regulation of the human IGFBP-1 promoter. It has been 
proposed that IGFBP-1 has a glucoregulatory role (Lewitt et al., 1991). The similarity of 
IGFBP-1 hormonal regulation to that of phosphoenolpyruvate carboxykinase (PEPCK), a 
key enzyme in gluconeogenesis, strengthens this proposition (O’Brien et al., 1990a and 
b). Within the human IGFBP-1 promoter, between nt -263 and 254, a CGTCA motif 
exists which is known to mediate the effect of cAMP on a number of different promoters 
(Montminy et al., 1990). Mutation of this motif results in a 51% decrease in cAMP 
stimulated promoter activity (Suwanichkul et al., 1993a). An AP-2 binding site has been 
identified in the rat IGFBP-1 gene promoter. It has been indicated that cAMP may effect 
expression through the AP-2 binding cis-element and TF (Roesler et al., 1988, Suh et al., 
1994). The positive regulation of the IGFBP-1 gene to dexamethasone is attributed to the 
presence of two glucocorticoid response elements (GREs) located in the first 200 bp of 
human IGFBP-1 promoter sequence. The GRE sequences have week affinity for the 
glucocorticoid receptor and the loss of either of the two elements results in complete loss 
of activation (Suwanichkul et al., 1994). The IGFBP-1 promoter contains an insulin 
response element (IRE) located as a palindromic sequence in both rat and human (Suh et  
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Table 2.4 Modulators of IGFBP-1 expression  
 
Molecule Class Effect on IGFBP-1 
Expression 
Reference 
Insulin 
 
 
Glucose 
 
GH 
 
Dexamethasone 
 
cAMP 
 
C/EBP 
 
HNF-1 
 
 
AP-2 
Hormone 
 
 
Carbohydrate 
 
Hormone 
 
Hormone 
 
Signaling molecule 
 
Transcription factor 
 
Transcription factor 
 
 
Transcription factor 
Decrease expression 
 
 
Undecided 
 
Decrease expression 
 
Increase mRNA 
 
Inhibits expression 
 
Undecided 
 
Maintains level of 
basal transcription 
 
cAMP mediated 
regulation ? 
Suikkari et al., 1989 
 
 
Snyder et al., 1990 
 
Busby et al., 1988 
 
Orlowski et al., 
1990 
 
Unterman et al., 
1991 
 
Suwanichkul et al., 
1990 
 
 
 
Suwanichkul et al., 
1994 
 
 
Abbreviations: abbreviations given in the List of Abbreviations on page xii     
  
 
 
                                                                                                            
al., 1994). The IRE sequence was first discovered in the PEPCK gene promoter region 
and was comprised of a 10 bp sequence located between nt -416 and -407 (O’Brien et al., 
1990a). Mutation of one of the IGFBP-1 IRE palindromic sequences slightly decreases 
insulin mediated effects on transcription, but abolishing the sequence entirely leads to 
loss of all inhibition of promoter activity by insulin (Suwanichkul et al., 1993b). The 
commonality of the IRE between IGFBP-1 and PEPCK may explain the dynamic 
regulation by insulin seen for both of these proteins. 
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2.2.3.2 IGFBP-3 
 
 The human IGFBP-3 gene exists on chromosome 7 separated 20 kb from the 
IGFBP-1 gene in a tail-to-tail conformation (Ehrenborg et al., 1992). The gene spans 8.9 
kb and contains four exons. Unlike the other IGFBPs, IGFBP-3 contains most of the 3’ 
untranslated region and polyadenylation signal on an additional fifth exon. The IGFBP-3 
promoter has been identified and characterized (Cubbage et al., 1990). The promoter 
contains proximal GC boxes as well as a TATA box. Northern analysis has identified a 
single mRNA sequence of 2.5 kb (Shimasaki et al., 1989) which is conserved in a 
number of species.  
 The IGFBP-3 cDNA predicts a 291 amino acid precursor, with a 27 residue signal 
peptide and a 264 residue mature polypeptide (Wood et al., 1988). The peptide sequence 
contains 18 cysteine residues and three potential N-glycosylation sites. On non-reducing 
SDS-PAGE gels IGFBP-3 has shown migration in doublets of 40-50 kDa which reflect 
different levels of N-glycosylation (Rechler et al., 1993). It has also been found in 
Chinese hamster ovary (CHO) cells that the mature IGFBP-3 protein contains 
phosphorylation on serine 111 and 113 (Hoeck et al., 1994). IGFBP-3 cDNAs have been 
studied in rat, bovine, porcine and human models with similar characteristics.  
 During embryonic development IGFBP-3 expression is detectable as early as day 
18 in the developing mouse liver and vertebrae (Schuller et al., 1993). In the rat embryo, 
expression is identified as early as day 14 in the urogenital system and in muscle tissue. 
By day 21, IGFBP-3 mRNA is detectable in liver, kidney, muscle and the developing 
cerebral cortex. Endothelial cells, such as those found in rat liver, placenta, white adipose 
tissue (WAT) and human testis, are particularly abundant in IGFBP-3 expression (Chin et 
al., 1994). Human in vivo study of IGFBP-3 indicates birth levels to be one third of the 
levels seen in the adult (Bang et al., 1994). In rodents, birth levels are nearly undetectable 
(Donovan et al., 1989). Post-natally, IGFBP-3 is the most abundant IGFBP in circulation 
comprising 75-85% of all circulating IGFBPs (Baxter et al., 1986, Baxter et al., 1989). 
The levels of IGFBP-3 in serum increase to a maximum level during puberty. Marked 
decreases in IGFBP-1 levels occur during birth, GH insufficiency (Baxter et al., 1986), 
diabetes (Zapf et al., 1990) and undernutrition (Thissen et al., 1994). IGFBP-3 mRNA 
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abundance after birth or hypophysectomy show little change in the liver and kidney while 
exhibiting significant changes in serum IGFBP-3 levels. Regulation of IGFBP-3 
synthesis, therefore, appears to occur mainly through translational and/or postranslational 
mechanisms (Chin et al., 1994, Albiston et al., 1992). In vitro studies indicate that 
Kuppfer and sinusoidal endothelial cells express IGFBP-3 exclusively. In these cells, 
dexamethasone treatment decreases IGFBP-3 mRNA while insulin increases it 
(Villafuerte et al., 1995).  In vivo study suggests IGF-I to be a direct regulator of IGFBP-
3 mRNA expression due to its ability to increase serum IGFBP-3 levels in GH deficient 
rodent models (Zapf et al., 1989). This activity of IGF-I is not seen in humans. However, 
in vitro, within human Kuppfer and sinusoidal cells, IGF-I increases IGFBP-3 half life. 
This probably explains the in vivo effect mentioned above (Villafuerte et al., 1996). 
 The IGFBP-3 promoter contains a TATA box and a GC box within its sequence. 
The GC box contains binding sites for Sp1 and AP-2 (Albiston et al., 1995). An IRE has 
also been identified, but the sequence of this IRE is non-homologous to the IRE found in 
IGFBP-1. The sequence recognizes a 90 kDa nuclear protein which is upregulated with 
insulin signal in parenchymal cells and diabetic liver (Villafuerte et al., 1997). The 
tumour suppressor, p53, was also identified as an IGFBP-3 inducer in EB1 colon 
carcinoma cells. Two elements in intron 1 and 2 are capable of binding p53 and cause 
induction through a heterologous promoter (Buckbinder et al., 1995). 
 
2.2.4 Acid Labile Subunit 
 
 The ALS gene exists as a single copy gene which maps to the short arm of 
chromosome 16 p13-3 (Suwanichkul et al., 2000). In mice, the ALS gene spans 3.3 kb on 
chromosome 17 and is composed of two exons. Exon 1 encodes 5 amino acids of the 
signal peptide and exon 2 encodes the entire precursor protein and the remaining 27 
amino acids of the signal peptide. There is no TATA box or other initiation elements in 
the ALS gene, but transcription begins in a region 140 bp upstream from the ATG codon. 
ALS promoter activity has been identified between nt -2001 and -49 (Boisclair et al., 
1996). This chromosomal structure is conserved across species (Boisclair et al., 2001). 
Transcription of the ALS gene results in a 2.2 kb mRNA transcript. Sequence identity of 
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mature ALS is 93% between mouse and rat, 79% between rat and human and 73% 
between mouse and human. 
 Human cDNA for ALS encodes an ORF of 605 amino acids containing a 27 
amino acid signal peptide and a 578 amino acid mature protein (Leong et al., 1992). The 
primary protein structure contains 18-20 leucine rich domains (LRD) each comprised of 
24 amino acids of which 6 are typically leucine residues (Figure 2.5). The leucine rich 
repeat (LRR) region accounts for 75% of the mature ALS protein. These repeated 
domains are thought to be important in protein-protein interactions and characterize the 
LRR superfamily of proteins, of which ALS is a part. Although the crystal structure of 
ALS has not yet been determined, comparative analysis based on molecular modeling of 
LRR structures in other LRD containing proteins has been done to determine the ALS 
tertiary structure. The repeated LRDs give a curvature to the protein conformation. This 
has been shown for the structure of another leucine-rich repeat family member, the 
porcine ribonuclease inhibitor (RI). RI is the only LRR superfamily member of which a 
crystal structure has been solved and it contains only 15 LRR compared to the 18 LRRs 
found within ALS structure. The RI protein conformation resembles a horseshoe with 
each repeat containing a β-sheet and a α-helix alternating when a number of repeats are 
linked. This characteristic secondary structure gives the RI and other LRR proteins a 
facedness. The internal face is lined with a parallel β-sheet lying perpendicular to the 
plane of the molecule and the external face is made up of α-helices and loops. The extra 
LRRs allow ALS to complete a circular/donut shaped structure, akin to the joining of the 
two ends of the RI horseshoe structure with 3 LRDs (Figure 2.5). This structure is 
strongly supported through visualization of ALS molecules by electron microscopy 
(Janosi et al., 1999b). The primary structure also contains 13 cysteine residues and 7 
potential N-linked glycosylation sites (Leong et al., 1992). One site for N-linked 
glycosylation is located in the middle of the ALS sequence and three are located at each 
terminal end. On SDS- PAGE, ALS migrates as a 84-86 kDa glycoprotein. After 
enzymatic removal of N-linked sugars, ALS migrates as a 63-66 kDa protein indicating 
approximately 20 kDa of N-linked sugar content (Baxter et al., 1994). Studies done on 
ALS N-linked glycosylation have shown that in the proposed donut conformation the six 
terminal N-linked sugars are  
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Figure 2.5 Schematic illustration of ALS domain structure and tertiary structure. The 
domain structure as shown exhibits the central LRR region flanked by cysteine rich 
regions and N-terminal and C-terminal regions. Also indicated are Asn residues 
important for the formation of N-linked glycosylations. These glycosylations are 
indicated on the diagram of ternary structure (see numbered circles). The determined 
ternary structure resembles a donut which is due to the conformation of LRRs. Structure 
is inferred from similar structures in other LRR containing proteins. Tertiary structure 
adapted from Janosi et al., 1999. 
  
Abbreviations are defined in List of Abbreviations pg. xii  
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clustered and may provide a strong negative charge due to the presence of negatively 
charged sialic acids (Janosi et al., 1999a). The importance of this charged group will be 
discussed in section 2.3.    
 ALS is almost exclusively found in serum. It is first detectable in humans during 
the late stages of fetal life and then increases 5-fold during puberty and remains constant 
in adulthood (Baxter 1990a). Subsequently, IGF exists only in the 50 kDa binary 
complex before birth and is found in the ternary complexes, with ALS, after birth. 
Postnatally, ALS mRNA is only detectable by Northern analysis in liver parenchymal 
cells, the principle site of ALS synthesis. The proximal tubule of the kidney, the lung, the 
thymus and the mammary gland also express ALS but the amounts are negligible (Chin et 
al., 1994, Dai et al., 1994b). Immunoreactive ALS is present in cerebrospinal fluid, 
amniotic fluid, milk and lymph, and at low concentrations in peritoneal, synovial, ovarian 
and blister fluid (Baxter 1990, Xu et al., 1995, Cwyfan-Hughes et al., 1997, Khosravi et 
al., 1997, Labarta et al., 1997). Typical concentrations of ALS in human and rat serum, 
respectively, are 230 and 570 nM (Baxter 1990a, Khosravi et al., 1997). Serum is the 
main source of extravascular ALS but local production may also occur. Reduction of 
serum ALS levels has been shown due to a variety of conditions in rats and humans. 
Conditions include: fasting, under nutrition and catabolic diseases such as diabetes, burn 
injury and cirrhosis (Boisclaire et al., 2001). 
 GH is the most potent in vivo hormonal inducer of ALS expression in circulation. 
The increased ALS expression seen after birth is concomitant with the increases in GH 
levels detected during the same developmental period (Boisclaire et al., 2001). The 
pituitary gland is the principle source of GH in animals. With removal of the pituitary 
gland (i.e. hypophysectomy) liver ALS mRNA levels decrease dramatically (Dai et al., 
1997). Circulating levels of ALS decrease in adult humans with GH deficiency, GH 
receptor defects and chronic IGF-I infusion. High IGF-I levels cause a feedback 
inhibition on GH secretion from the pituitary gland therefore decreasing ALS expression 
(Labarta et al., 1997). Decreases in ALS expression have also been linked to GH 
resistance in the liver. Studies have shown that the development of GH resistance is 
accompanied by an increase in the negative actions of cAMP and inflammatory cytokine 
interleukin (IL)-1β on ALS expression (Delhanty 1998a and b). In primary hepatocytes, 
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insulin induces ALS secretion without any change in ALS mRNA levels indicating a 
post-translational mechanism of regulation (Dai et al., 1994a). Decreased ALS levels in  
diabetes, undernutrition and fasting may be due to decreased levels of insulin in these 
metabolic conditions. Decreased ALS expression also occurs through direct regulation at 
the transcriptional level by dexamethasone, cAMP, and epidermal growth factor (EGF) 
(Werner 1999) (Table 2.5). This has been shown in primary hepatocyte culture and may 
explain the decreased levels of ALS expression in conditions such as thermal damage and 
liver damage which are associated with increased internal glucocorticoid and cAMP.  In 
vitro mRNA and protein expression of ALS are unsuccessful in a number of liver cells  
such as H4IIE, H35, HTC, 5123TC, FAO, BRL3A and human HepG2 cells (Guck et al., 
1999). The reason for lack of ALS gene expression is thought to be due to chromatin 
modifications such as methylation of CpG islands (Antequera et al., 1990). 
 
 
Table 2.5 Modulators of ALS expression 
 
Molecule Class Effect on ALS 
Expression 
Reference 
GH 
 
cAMP 
 
IL-1β 
 
Insulin 
 
Dexamethasone 
 
EGF 
Hormone 
 
Signaling molecule 
 
Hormone 
 
Hormone 
 
Hormone 
 
Hormone 
Increase expression 
 
Decrease expression 
 
Decrease expression 
 
Increase expression 
 
Decrease expression 
 
Decrease expression 
 
Boisclaire et al., 
2001 
Delhanty 1998 
 
Delhanty 1998 
 
Dai et al., 1994a 
 
Werner 1999 
 
 
Abbreviations: abbreviations are given in the List of Abbreviations on page xii 
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2.3 IGF Binding Protein Complex Formation and the Regulation of IGF-I  
      Biological Activity 
 
2.3.1. Introduction 
 
 Although IGF regulation is directly related to the transcriptional and translational 
regulation of IGF system components, the regulation of IGF activity is ultimately due to 
the ability of the IGFBPs and ALS to bind IGF and form binary and ternary complexes. 
The formation of IGF binding protein complexes stabilizes IGF in circulation and 
potentiates or inhibits its ability to act on target tissues. Conserved structural 
characteristics of IGFBPs indicate the importance of these conserved domains in IGF 
binding. Other factors related to IGF binding by the IGFBPs are ionic strength, pH 
glycosylation, phosphorylation and IGFBP proteolysis. Knowledge of the chemistry of 
IGF and IGFBP association and the subsequent effects on IGF bioactivity is limited, but 
the available information will be reviewed with emphasis on the IGFBP-1 binary 
complex and the IGFBP-3 and ALS containing ternary complex. The view that ALS and 
IGFBPs simply bind and inhibit IGF-I and II activity is very simplistic. Consideration 
must be taken for the nature or degree of the modulation depending on the IGFBP 
present, upstream modifications to the IGFBPs themselves, IGFBP proteolysis and IGF 
independent activities which alter the IGF bioactivity.   
 Along with IGFBPs, which will be reviewed later in this section, IGF-I has also 
been studied in relation to IGFBP complex formation. Mutational analysis of IGFBP and 
IGF interaction has been done with specific mutations in the N-terminal regions of IGF. 
Substitution of Glu3 with Arg greatly reduces IGF-I binding to IGFBPs and appears to be 
particularly important for IGFBP-3 association (Baxter et al., 1992). Insulin binds 
IGFBP-3 as well, but with 1000-fold less affinity when compared to IGFs (Helding et al., 
1994). This characteristic of insulin resulted in the “B chain” mutant IGF-I derivative 
which substitutes the first 16 insulin residues for the first 16 residues of IGF-I and 
resulted in highly decreased IGFBP binding affinity (Clemmons et al., 1992). Other IGFs 
with decreased affinities for IGFBPs include [Gln3Ala4Tyr15Leu16] IGF-I, also known as 
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QAYL IGF-I, N-terminally extended forms such as “long” [Arg3] IGF-I and Des(1-3) 
IGF-I (Francis et al., 1994, Forbes et al., 1988).    
 
2.3.2 The IGFBP-1 Binary IGF Binding Protein Complex 
 
 The estimated combined molecular weight of the IGFBP-1:IGF-I complex is 
approximately 35 kDa and this complex comprises a small percentage (< 5 %) of all 
bound IGF in serum. IGFBP-1 expression is highly regulated by insulin and as such, 
changes in nutrition, fasting-feeding, and diabetes strongly modulate IGFBP-1 levels and 
the role it plays in IGF regulation. For example, the IGFBP-1 level varies from 10 ng/mL 
when fed to 100 ng/mL while fasting (Katz et al., 1995). The affinity of IGFBP-1 for 
IGF-I is slightly higher than for IGF-II and it is partially dependent on phosphorylation. 
These characteristics are unique to IGFBP-1 as the other high affinity IGFBPs (-2 to -6) 
have higher affinities for IGF-II than IGF-I and phosphorylation does not have any 
functional significance. Human plasma derived IGFBP-1 has an affinity for IGF-I and 
IGF-II of Ka = 2.3 x 1010 L/mol and 3.6 x 109 L/mol, respectively.  These values are 
derived for the phosphorylated form of IGFBP-1. When dephosphorylated The Ka for 
IGF-I decreases 10-fold to 2.5 x 109 L/mol (Westwood et al., 1997).  
 There have been no X-ray crystallographic or nuclear magnetic resonance (NMR) 
structures determined for any IGFBP complex. Any inferences to IGFBP structural 
domains have been done based on natural variants (i.e. proteolyzed forms), mutagenesis 
and expression studies (Martin et al., 1999). A naturally occurring N-terminal 21 kDa 
IGFBP-1 fragment has been isolated from human placenta and was found to have IGF-I 
binding activity (Huhtala et al., 1986). Separate studies indicated a similar activity with 
12 kDa C-terminal IGFBP fragments isolated from human milk which showed IGF-II 
binding activity (Ho et al., 1997). Confirmation of the importance of these domains in 
IGFBP-1:IGF-I binding activity was assessed in mutagenesis studies on IGFBP-1. 
Deletion of 60 N-terminal residues or of 20 C-terminal residues of IGFBP-1 sequence 
both abolished IGF binding indicating the requirement for both the N- and C-terminal, 
cysteine-rich domains for IGF binding activity (Figure 2.4) (Brinkman et al., 1991a, 
1991b).  
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IGFBP-1 phosphorylation plays an important role in IGFBP-1 affinity for IGF-I. 
The human phosphorylated forms of IGFBP-1 have a 10-fold higher affinity for IGF-I 
than the non-phosphorylated forms (Jones et al., 1991). Also in humans, residue Ser 101 
of IGFBP-1 has been shown to be an important phosphorylation site required to maintain 
affinity for IGF-I. These properties vary amongst IGFBP-1 from different species. For 
example, the phospho and non-phosphoforms of IGFBP-1 on Ser 101 residues from rat 
hepatoma cells show no differences in IGF binding activity (Peterkofsky et al., 1998). 
Similarly, Ser 101 of IGFBP-1 from mice does not have a role (Lee et al., 1994). The 
phosphorylated IGFBP-1 protein does, however, predominate in circulation. It may be 
possible that different forms may have different biological activities. In endometrial 
stromal cells, phosphorylated and non-phosphorylated forms of IGFBP-1 showed equal 
inhibition of IGF stimulated DNA synthesis through the sequestering of free IGF-I, but 
progestin-stimulated DNA synthesis was significantly more sensitive to inhibition by the 
phophorylated form of IGFBP-1 (Frost et al., 1993).  
Interestingly, IGFBP-1 has also been shown to potentiate the effect of IGF  
through enhancement of cellular DNA synthesis in humans, mice and chick embryo 
fibroblasts (Elgin et al., 1987, Koistinin et al., 1990). Changes in IGF-I affinity for 
IGFBP-1 are associated with potentiation of IGF effects. This change in affinity may 
occur through the dephosphorylation of IGFBP-1 (Jones et al., 1991). Thus cellular or 
extracellular derived dephosphorylated IGFBP-1 may lead to a potentiation of IGF-I 
activity while the phosphorylated form may lead to an inhibition of IGF-I activity. 
 Much research has been done regarding the acute modulation of endocrine IGF 
action by IGFBP-1. In a serum sample, “free IGF-I” comprises approximately 0.5% of 
total IGF (Frystyk et al., 1994). “Free IGF-I” has a significant hypoglycemic activity. 
This was first assessed following a bolus injection of human IGFBP-1 into rats and a 
subsequent transient hyperglycemia (Lewitt et al., 1991). Transgenic rats expressing 
IGFBP-1 show development of hyperglycemia during fasting (Rajkumar et al., 1995). 
Injection of human recombinant IGFBP-1 into human subjects causes pulses of insulin 
secretion, indicative of transient hyperglycemia (Mortensen et al., 1997). Therefore 
IGFBP-1:IGF-I complex formation appears to block the hypoglycemic activity of free 
IGF-I. Endogenous IGFBP-1 expression decreases after glucose ingestion and rises in 
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response to hypoglycemia. Thus, IGFBP-1 counter-regulates the unbound, free IGF-I 
acutely and inhibits further hypoglycemic activity. It has been shown that serum IGFBP-
1 and free IGF-I have an inverse relationship as shown in normal healthy subjects with a 
bolus of oral glucose (Frystyk et al., 1997).  Uptake of glucose in extrahepatic tissues is 
also affected by IGFBP-1. In vivo rat studies have shown that the bolus co-administration 
of IGF-I and IGFBP-1 slows the disappearance of IGF-I 5-fold but blocks the normal 
IGF-I induced uptake of glucose by heart and muscle tissues (Lewitt et al., 1993).  
 The mitogenic effect of IGF-I is also inhibited by IGFBP-1 association. This was 
first shown in fibroblasts, in vitro, with the use of a pure IGFBP-1 preparation from 
amniotic fluid (Chochinov et al., 1997). Since that time many cell type models have 
shown similar results in IGFBP-1 inhibition of the IGF-I induced mitogenic effects 
(Martin et al., 1999). Of interest is that the cell proliferative effects of estradiol are also 
inhibited by IGFBP-1 in MCF-7 cells that do not secrete IGF-I or II (Figueroa et al., 
1993). This may indicate a possible intrinsic bioactivity of IGFBP-1 independent of IGF 
activities.  
 IGF-independent activity of IGFBP-1 has been partially explained through 
IGFBP-1 cDNA analysis revealing the presence of a C-terminal RGD domain. RGD 
domains have been identified as integrin recognition sequences (Shimasaki et al., 1991). 
It has been shown that the addition of a synthetic RGD containing peptide blocks binding 
of IGFBP-1 to cell surfaces (Clemmons 1989). Experiments in Chinese hamster ovary 
(CHO) cells investigating the binding effects of IGFBP-1 to the α5β1 integrin 
(fibronectin receptor) have shown a functional significance of IGFBP-1 binding. CHO 
cell transfection or addition of exogenous human IGFBP-1 both resulted in stimulation of 
cell migration in monolayer binding assays. Affinity chromatography of 125I- labeled 
CHO cell surface receptor proteins identified the α5β1 integrin as the only surface 
receptor protein to bind IGFBP-1 in an RGD dependent manner. Mutation of the RGD 
sequence to Trp-Gly-Asp (WGD) in IGFBP-1 prevented α5β1 integrin binding and the 
cell migration effect seen with normal IGFBP-1 (Jones et al., 1993). 
 IGFBP-1 may also be involved in the transport of IGF-I through the capillary 
barrier. Evidence suggests that this process may involve an insulin dependent mechanism 
as insulin differentially alters transcapillary movement of intravascular IGFBP-1 in rat 
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heart. In rat heart perfusion studies, IGFBP-1 showed an insulin dose dependent increase 
in movement from the vascular space to heart tissues (Bar et al., 1990). Such insulin-
facilitated changes may potentiate nutrient-dependent transport of IGF-I to peripheral 
tissues.  
 The regulation of IGFBP-1:IGF-I complex formation is also regulated by the 
proteolytic activity of proteases specific for the cleavage of IGFBP-1. Although rare in 
comparison to other IGFBPs, IGFBP-1 fragments have been found in human placenta, 
milk, human decidua and amniotic fluid. In vitro analysis has indicated Cathespin D, 
Stromelysin-3 and MMP-2, -3, -7 and -11 as proteases able to cleave IGFBP-1 (Binoux et 
al., 1999). Most IGFBP fragments have reduced affinities for IGF-I when compared to 
intact protein, with the exception of a 21 kDa carboxy terminal IGFBP-1 fragment which 
shows similar affinity to IGF-I (Huhtala et al., 1986). Interest has been shown for this 
protein fragment due to the ability of IGFBP-1 to potentiate IGF-I activity and the 
possibility that the C-terminal RGD sequence may have a role. Although little is known, 
the implication for IGFBP-1 protease activity will further increase the complexity of IGF-
I regulation. 
 
2.3.3 The Ternary IGF Binding Protein Complex 
 
 The combined molecular weight of the ternary IGF-I: IGFBP-3: ALS complex is 
approximately 150 kDa and consumes 80-90% of all free IGF-I in serum. Glycosylated 
IGFBP-3 has an affinity for IGF-I of 2.0 x 1010 L/mol (Martin et al., 1986). The complex 
stability is affected by pH and ionic strength. Optimal binding occurs at a pH of 5.0 and 
decreases with increases in pH to physiological pH. High ionic strength enhances the 
interaction between IGFBP-3 and IGF-I (Holman et al., 1996). ALS is not able to bind 
IGF alone, but forms high affinity IGF containing complexes only in the presence of 
IGFBP-3. ALS has an immeasurably low binding affinity for IGFBP-3 alone (Martin et 
al., 1999). Therefore, it has been postulated that the IGFBP-3: IGF-I complex forms a 
binding site for ALS. This view has been challenged with the use of patially proteolyzed 
and unglycosylated IGFBP-3 which show weak interactions with ALS (Lee et al., 1995, 
Barreca et al., 1995). These conditions have not been demonstrated in vivo. With ALS 
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bound, the half-life of IGF is extended from 10 min in free form and 60-90 min in the 
binary complex to more than 12 hrs in the ternary complex (Boisclaire et al., 2001). Like 
the binary complex, the ALS association is dependent upon pH and ionic strength. The 
affinity constant for ternary complex formation under RT conditions of low ionic strength 
and slightly acidic pH was approximately 1 x 109 L/mol (Baxter et al., 1989). A decrease 
in affinity to 2.5 x 108 L/mol was observed at near physiological conditions of salt, pH 
and temperature (Holman et al., 1996). 
The interactions between IGF-I, IGFBP-3 and ALS in formation of the ternary 
complex depend on many factors. In formation of the IGFBP-3 binary complex, 
glycosylation seems to play a minimal role. Comparison between the IGF-I binding 
affinities of IGFBP-3 produced in E.coli (no glycosylation) with that of IGFBP-3 from 
mammalian origins (glycosylation) result in little or no change in affinity (Conover 
1991). Chinese hamster Ovary (CHO) cells expressing an IGFBP-3 N-terminal fragment, 
IGFBP-3 [1-88], show a large reduction in IGF-I binding activity compared to the intact 
IGFBP-3 protein. In separate studies, removal of negatively charged amino acid residues 
within the C-terminus (Lys254Glu254 to ArgGly) decreases IGF binding 75-80% (Firth et 
al., 1998). Domain swapping experiments with IGFBP-1-6 have shown that the carboxy 
terminal domains of IGFBP-3 are also important for ALS binding to the ternary complex. 
This has been further mapped to a group of 18 amino acids which are basic and positively 
charged (Twigg et al., 1998) (Figure 2.6).  
ALS contains seven N-glycosylation sites in its primary structure. Structural 
analysis of ALS has indicated that in the proposed donut conformation of Janosi et al., 
(1999), the seven N-terminal N-linked sugars are clustered providing a strong pocket of 
negative charge due to the presence of negatively charged sialic acids. Removal of the 
sialic acid residues from the glycan chain of ALS results in reduction of affinity for 
IGFBP-3 binary complexes but do not eliminate complex formation. Independent 
mutation of the seven N-linked glycosylation sites results in partial reduction in affinity 
for IGF-I complexes. Complete deglycosylation eliminates all interaction with the IGF-
I/IGFBP-3 complex (Janosi et al., 1999a). Thus, the model that exists identifies a 
positively charged, conserved domain of 18 amino acids present in IGFBP-3 as 
interacting with two dense pockets of negative charge on ALS. The negatively charged  
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pockets on ALS are due to N-terminal clusters of N-linked sugars as well as basic and 
negatively charged amino acids located on the internal face of the donut shaped structure 
of ALS (Janosi et al., 1999b) (Figure 2.6).         
 IGFBP-3 is susceptible to proteolysis and, as such, exists as a mechanism to 
modulate IGFBP-3 activity. A variety of metabolic conditions that lead to IGFBP-3 
proteolysis include catabolic states such as type-1 and type-2 diabetes and pregnancy. 
During human pregnancy, a 30 kDa form of IGFBP-3 is found exclusively in serum and 
is found to have an 8-fold decrease in IGF-I affinity (Binoux et al., 1994). However, 
levels of circulating IGF ternary complex during pregnancy are normal or elevated, 
indicating binding affinity may not be lost by the proteolized IGFBP-3. The explanation 
for this conflicting data is that ALS is acting to increase the affinity of proteolyzed 
IGFBP-3 for IGF-I by 7-fold to stabilize the formed ternary complex (Gargosky et al., 
1991). This idea has been highly debatable and many investigators have shown that 
complex formation with the 30 kDa IGFBP-3 fragments result in a decreased affinity for 
IGF-I and therefore an increased release of bioactive IGF-I. Other proteolized forms of 
IGFBP-3 have also been identified with decreased IGF-I affinity. For example, a 22 kDa 
plasmin fragment of non-glycosylated IGFBP-3 has a 50-fold reduction in IGF-I affinity 
(Lalou et al., 1996). A 30 kDa form of rat IGFBP-3 has a 50 fold preferential increase in 
IGF-II affinity (Lee et al., 1995). At the tissue level, it is postulated that proteolysis may 
allow release of IGFBP bound to IGF leading to local IGF bioactivity. IGF-I exists in 
circulation at a concentration of 100 nM (700-800 ng/mL) and in normal conditions 
exhibits 5-10% of the hypoglycemic potential of insulin. Circulating IGF-I, therefore, if 
not bound in IGFBP complexes, has the potential to vastly exceed insulin in its 
hypoglycemic potential. IGFBP-3 and ALS, together in the ternary complex, function to 
sequester IGF and inhibit its potential activity. Administering potentially lethal 
hypoglycemic doses of IGF-I together with IGFBP-3 ablates any hypoglycemic effect 
(Sommer et al., 1991). IGF-I administration, with or without IGFBP-3, form ternary 
complexes within the first three minutes of treatment (Lewitt et al., 1994) showing that 
ternary complexes form readily in serum. An illustration of the inhibitory effect of 
ternary complexes comes from patients with a clinical condition called non-islet-cell 
tumour hypoglycemia (NICTH). These patients have IGF-II secreting tumours and 
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experience severe hypoglycemia. In these cases there are large increases in free IGFs and 
a feedback induced decrease in GH secretion. As a result, ALS expression decreases and 
IGFBP-3 exists mainly in binary complexes which are able to, presumably, cross 
capillary barriers. GH or glucocorticoid administration alleviates the hypoglycemic 
effects through increasing ALS and IGFBP-3 levels and thus clearly indicating the 
inhibition of IGF activity (Frystyk et al., 1998). 
 The generation of ALS-null mice has allowed investigators to clarify the 
involvement of ALS in a manner delineated from other IGF system components. In ALS-
null mice, the ternary complex is absent in circulation (Ueki et al., 2000). The ALS-null 
mice have dramatically reduced concentrations of IGF-I and IGFBP-3 in circulation (62 
and 88% decrease, respectively) as compared to wild type mice. Hepatic expression of 
IGF-I and IGFBP-3 in the ALS-null mice is normal indicating the importance of ALS in 
maintaining a large accumulation of IGF-I and IGFBP-3 in circulation. In single allele 
ALS-null mice, ALS secretion is decreased. IGF-I and IGFBP-3 levels were again lower 
(17% and 40% decrease, respectively) as compared to wild-type. The ALS-null mice 
showed only a 13% growth deficit when compared to wild type.  A significant effect was 
expected due to the central role of IGF in growth regulation and the decreases in IGF-I 
and IGFBP-3 levels. In ALS-null mice it was also surprising to see normal levels of 
insulin and glucose since IGF is known to have a strong hypoglycemic potential. A 
proposed explanation was in the noted absence of IGF-II. Mammals have high levels of 
IGF-II. IGF-II has been shown to be a more potent insulin-like effector and it may be 
plausible that lowered concentrations lead to decreased hypoglycemic effects (Ueki et al., 
2000, Boisclaire et al., 2001). 
 In the ternary complex, IGF is believed to be restricted to the vascular system due 
to the inability of the ternary complex to traverse the capillary barrier. It may be possible 
that some crossover may occur since ternary IGF complexes have been identified in a 
number of extrahepatic fluids such as skin interstitial fluids, mammary lymph and wound 
fluid (Martin et al., 1999). ALS has a relatively weak affinity for IGFBP-3 and may allow 
for easy disassociation and subsequent release of IGF-I. However, ALS circulatory 
concentrations far exceed the required amount for ternary complex formation. It has thus 
been excluded from discussion relating to mechanisms of escape into extravascular 
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tissues even though complex dissociation may occur in order for passage out of the 
circulatory system. Dissociation of ALS from the ternary complex has been shown in 
vitro. Proteoglycan and more specifically, Heparin, mediates the reduction in the affinity 
of ALS for IGFBP-3, but this has not been shown in vivo (Baxter 1990b).  Limited 
IGFBP-3 proteolysis may be expected to also decrease ALS affinity for the IGFBP-3 
binary complex. In pregnant women, association constants may not change between 
proteolized and non-proteolyzed complexes. It remains to be found whether IGFBP-3 
proteolysis may induce escape from circulation.       
 Complexation of IGF-I in ternary complexes also has effects on IGF-I mitogenic 
potential. This has been shown in a number of studies at the cellular level with much of 
the work derived from human skin fibroblasts. Co-incubation or pre-incubation of 
IGFBP-3 and the ratio of IGFBP-3 to IGF-I are very important factors in determining 
whether the IGFBP-3 effect is inhibitory or stimulatory on IGF mediated mitogenic 
activities. Co-incubation of equimolar ratios of IGFBP-3 and IGF reversed the mitogenic 
effects of IGF in human fibroblasts in a dose dependent manner. In contrast, pre-
incubation of cells with IGFBP-3 for 8-48 h before adding IGF-I resulted in a 
potentiation of the subsequent IGF-I effect (De Mellow et al., 1988). IGFBP-3 
transfected BALB/c 3T3 fibroblasts, in the presence of serum (IGF-I), also exhibited 
inhibited cell proliferation. Insulin was not able to override this effect of endogenous 
IGFBP-3. Insulin, however, was able to override the effect of exogenous IGFBP-3 
inhibition (Cohen et al., 1993). A dual mechanism for both IGF-dependent and 
independent activity was postulated for IGFBP-3 and its effect on cell proliferation. 
Reports of IGFBP-3 expression being induced by the tumour suppressor, p53, have also 
implicated IGFBP-3 in the mechanism of programmed cell death. This has been 
strengthened by results indicating that mutant p53 fails to induce expression of IGFBP-3 
in cells exhibiting a loss of apoptotic activity (Buckbinder et al., 1995). 
 In some cases the concentration of ternary complex positively correlates with 
growth. In clinical conditions with GH excess or through GH administration, which 
causes an increase in ternary complex component (ALS and IGFBP-3) concentrations, a 
concomitant increase in growth response occurs. From these studies there is support for 
the idea that the ternary complex forms a reservoir from which IGF activity can be made 
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available. However, this conflicts with the idea that IGF-I must be in free form to elicit its 
effects on cells. Studies show that it is not necessary to form tight IGF complexes. 
Ternary complexes containing des(1-3) IGF-I, which binds with seven fold less affinity, 
are at least as effective as IGF-I (Martin et al., 1999). Studies have furthered the 
argument of complex activity in wound healing where it was found that IGF:IGFBP-3 
applied topically was more effective than IGF-I alone in stimulating wound recovery 
(Sommer et al., 1991). 
 The potentiating effects of IGFBP-3 correlate with an increased level of IGF-1R 
interaction at the cell surface. This may be due to the presence of serine proteases 
(Canover et al., 1996). The resulting IGFBP-3 fragments, as with other IGFBP 
fragments, may have decreased binding affinity for IGF-I and result in an increase in free 
IGF bioactivity at the cell surface. Studies have found that the 30 kDa fragment (lacking 
the C-terminal third of the protein) purified from rat serum enhances IGF-I stimulated 
DNA synthesis whereas intact IGFBP-3 blocks stimulation in osteoblasts (Schmid et al., 
1991) This induced mitogenic activity is inhibited with the addition of serine protease 
inhibitors (Angelloz-Nicaud et al., 1995). Similarly the IGFBP-3 plasmin fragment of 
22kDa also stimulates PC-3 cell proliferation but it does so in the absence of IGF-I 
(Angelloz-Nicaud et al., 1998). IGFBP-3 has been indicated to act independent of IGF-I 
and has unique features to strengthen this supposition including a heparin binding motif 
and nuclear localization sequence. It has also been shown that IGFBP-3 has its own 
receptor on cell surfaces which appear to be TGF-β receptors (Leal et al., 1997). 
Addition of IGF inhibits the binding of IGFBP-3 to these cell surfaces. This further 
enhances the evidence for IGFBP-3s anti-proliferative effect and indicates this effect 
independent of IGF-I.   
 
2.4 Metabolic and Mitogenic Modulators of IGF System Component Expression    
 
2.4.1 Insulin 
 
 The insulin receptor (IR) is a member of the receptor tyrosine kinase (RTK) 
superfamily and more specifically, the insulin receptor family, which also includes IGF-
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IR. Unlike the EGF and PDGF receptors, where dimerization occurs upon ligand binding, 
the IR is dimeric even in the absence of ligand. The receptor is a heterotetramer 
composed of two α and two β chains. The α chains contain most of the extracellular 
portion of the receptor, a cysteine rich domain and 2 fibronectin type III domains. The β 
chain contains the transmembrane domain and the cytoplasmic portion of the receptor 
containing the tyrosine kinase domain. IR ligand binding induces conformational changes 
leading to autophosphorylation of three tyrosine residues located in the tyrosine kinase 
domain (White et al., 1994). Phosphorylation of the tyrosine residues in the so-called 
“activation loop” of RTKs allows a conformational change which gives unrestricted 
access to ATP and substrates. Without ligand binding the kinase activity is inhibited by 
the α subunit’s influence on receptor conformation and ATP is blocked from entering the 
kinase active site (Hubbard 1999).  
 The IR requires interaction with receptor-specific substrates for signal 
transduction. Phosphotyrosines (pYs) and src homology -2 (SH2) domains of 
downstream signaling molecules associate through a three amino acid motif on the C-
terminal side of the pY residue (Nystrom et al., 1999). The two major IR substrates are: 
IRS-1 and IRS-2. Other IR substrates critical for insulin signaling are IRS-3, -4, GAB-1 
and Shc. Common to IR substrates are N-terminal pleckstrin homology (ph) domains. In 
IRS (1 to 4) pY binding domains (PBD) mediate interaction with the IR. IR substrates 
often have a number of pY motifs which act as docking sites for SH2 containing proteins.    
 Signaling proteins containing SH2 domains have a number of different functions. 
Some may act as affector molecules with an intrinsic catalytic function while others may 
act as adaptor proteins. For example, Grb2 is normally pre-bound to the SOS guanidine 
exchange factor, but when bound, via the SH2 domain, to an IRS-1 pY residue SOS 
catalyzes the Ras exchange of GTP for GDP and activates Ras (Figure 2.7). Another 
example is the PI-3K p85 subunit, which after interacting with IRS-1, activates the PI-3K 
p110 catalytic subunit (Nystrom et al., 1999).  
 Activation of Ras and PI-3K give rise to phosphorylation cascades. Ras directly 
activates Raf, a serine/threonine kinase, which in turn phosphorylates and activates MEK. 
Active MEK then phosphorylates MAP kinase, Erk1, Erk2 and c-Jun NH2-terminal 
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Figure 2.7 Insulin receptor signal transduction and repression of IGFBP-1 gene 
expression. See text for full details on signaling pathways and relation to IGFBP-1 
expression.   
 
Abbreviations: P , Phosphorylation; abbreviations are given in the List of Abbreviations 
on page xii                                                                                                                             
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Kinase (JNK) which has roles in cellular proliferation and apoptosis (Figure 2.8) 
(Nystrom et al., 1999). PI-3K phosphorylates inositides on the inner cell membrane and  
3-phosphoinositide products. Phosphoinositol-3, 4, 5-triphosphates (PI-3,4,5-P3) activate 
phosphoinositide-dependent kinase-1 (PDK-1) and PDK-2. PDK-1 phosphorylates 
protein kinase B (PKB) on residue Thr308 whereas PDK-2 phosphorylates PKB on 
residue Ser473 within the PKB regulatory region. Active PKB phosphorylates and 
inactivates glycogen synthase kinase-3 (GSK-3) which in turn leads to activation of 
glycogen synthase (Patel et al., 2002). Accumulation of PI-3,4,5-P3 also gives rise to the 
activation of S6 protein kinase (S6K or p70s6k ) through a mechanism dependent on PDK-
1 and a kinase termed the mammalian target of rampamycin (mTOR). Activity of mTOR 
may be dependent on PKB for its activation (Raught et al., 2001). S6K phosphorylates 
ribosomal S6 protein and may be involved in the insulin regulation of protein translation 
(Price et al., 1992, Jefferies et al., 1994). 
Insulin has been shown to suppress IGFBP-1 expression while stimulating ALS 
expression. Over expression studies using inhibitors of the PI-3K pathway have shown a 
possible role for PI-3K, PKB and fork head related protein (FKHR) in the regulation of 
IGFBP-1 expression by insulin (Figure 2.7) (Cichy et al., 1998, Rena et al., 1999, Guo et 
al., 1999). FKHR is a member of the FOX(o) transcription factor family and may be 
activated through phosphorylation by PKB (Rena et al., 1999, Patel et al., 2002). The 
IGFBP-1 gene contains a thymine rich IRE (TIRE) required for insulin induced 
repressive IGFBP-1 regulation (Suwanichkul et al., 1994). FHKR-related binding to the 
TIRE sequence has been shown in vitro (Durham et al., 1999). Inhibition of mTOR with 
rapamycin strongly antagonizes basal insulin repression and glucocorticoid-induced 
IGFBP-1 expression. Transfection studies utilizing a TIRE-luciferase reporter construct 
in H4IIE cells show complete abolishment of insulin repression in the presence of 
rapamycin (Patel et al., 2002). 
Although mTOR activity has been shown to be important in the insulin mediated 
repression of IGFBP-1 expression, a second rapamycin-resistant element is present 
within the TIRE sequence. The insulin-mimetic agent, peroxovanadium (bpV(phen)), 
showed IGFBP-1 gene repression independent of PI-3K and S6K. An alternative 
pathway, independent of PI-3K, may be responsible for repression of IGFBP-1. The 
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wortmannin inhibition of insulin signaling caused a decrease in ERK activity indicative 
of PI-3K pathway involvement. However, wortmannin did not abolish the increases in 
ERK1 activity with bpV(phen)-stimulated cells. Using the MEK inhibitor, PD98059, 
ERK1 activity did not change. Another protein may be responsible for ERK activation 
and ERK repression of IGFBP-1 expression (Band et al., 1997). 
Insulin does not affect ALS expression at the transcriptional level, but rather 
affects at the posttranslational level. Insulin increases ALS secretion in the absence of 
any change in mRNA within primary rat hepatocytes (Dai et al., 1994a, Boisclair et al., 
2001). Little is known as to the cell signaling responsible for the insulin effect on ALS 
expression and secretion. 
 
2.4.2 cAMP 
 
 The cAMP biosynthetic pathway is initiated in metabolic conditions having low 
circulating glucose levels (i.e. exercise or starvation) and released glucagon into 
circulation. Hepatic cells and adipocytes express β-adrenergic receptors which bind 
glucagon with high affinity (Figure 2.8). Upon ligand association, a conformational 
change occurs in the receptor. This change allows the association of a GDP bound G 
protein composed of two subunits, the α subunit with GDP bound and the β,γ subunit. 
Once the G protein has associated to the ligand bound receptor the association induces 
the exchange of a GDP for GTP on the α subunit. The α subunit dissociates and binds a 
membrane bound adenylate cyclase enzyme. Upon binding to the G protein subunit, 
adenylate cyclase is activated leading to the conversion of ATP to cAMP, PPi and loss of 
the Pi from the α subunit bound GTP. The G protein subunits re-associate and are ready 
for activation once more.  
In the liver, the cAMP-responsive signaling pathways play important roles in gene 
regulation. Correlations in liver gene expression have been made to increases in cAMP 
levels, modulations in G proteins, adenylate cyclase and protein kinase A (PKA) 
expression (Diehl et al., 1996, Diehl et al., 1992, Ekanger et al., 1989). Upon stimulation 
of the adenylate cyclase pathway and biosynthesis of cAMP, transcriptional regulation is                                
mediated by a group of cAMP-responsive nuclear factors through distinct promoter  
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responsive sites. These factors are either activators or repressors and contain basic 
domain/leucine zipper motifs which bind as dimers to cAMP-reponsive elements (CRE). 
Increased cAMP levels activate the tetrameric PKA which is composed of two regulatory  
subunits and two catalytic subunits. Once cAMP association to PKA occurs the catalytic 
subunits are released. Activated PKA regulates glycogen metabolism through 
phosphorylation of phosphorylase kinase and subsequent phosphorylation of glycogen 
phosphorylase. Catalytic subunits of PKA also enter the nucleus and phosphorylate 
nuclear target proteins such as CRE-binding protein (CREB). Another member of the 
cAMP-responsive nuclear protein family is the inducible cAMP early repressor (ICER) 
protein which is the product of the CREM gene and strongly represses cAMP activity. 
cAMP treatment of hepatoma cells results in strong CREB phosphorylation and increases 
in ICER levels (Figure 2.8) (Servillo et al., 1997). Both CREB and CREM have major 
functions in cAMP mediated responses within hepatocytes affecting metabolic responses 
such as inhibition of glycogenesis, stimulation of gluconeogenesis through activation of 
PEPCK as well as effects on differentiation and cell proliferation.  
Very little is known as to how IGFBP-1 and ALS are regulated by cAMP. 
Delhanty et al., (1998b) indicated that cAMP decreases ALS expression, in vitro, through 
the reduction of ALS mRNA in primary hepatocytes. In cAMP promoting states such as 
acute starvation or nutritional deprivation, serum ALS levels are also decreased (Dai et 
al., 1994b). Dose-dependent cAMP effects on ALS mRNA levels are only seen in the 
rhGH stimulated cells indicative of a pre-translational cAMP mediated effect. Basal ALS 
gene expression exhibited no decrease in expression with increasing cAMP dosage. 
These results indicate that transcriptional regulation of ALS may depend on the status of 
GH in the system and cAMP may regulate primarily at a translational or posttranslational 
level (Delhanty 1998b).  
IGFBP-1 expression is stimulated by cAMP at transcriptional and post-
transcriptional levels (Unterman et al., 1991). Glucagon has been shown to increase 
circulatory concentrations of IGFBP-1 in HepG2 cells. Glucagon increased IGFBP-1 
protein levels without having any effect on IGFBP-1 mRNA levels. The effect of 
glucagon on IGFBP-1 expression does not involve a transcriptional level of regulation 
(Hilding et al., 1993). However, IL-1β, which has also been shown to stimulate IGFBP-1, 
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appears to effect expression of IGFBP-1 through a PKA/CREB/CRE dependent pathway 
just as seen for cAMP responsive genes (Frost et al., 2000, Suwanichkul et al., 1993a). 
These in vitro results are conflicting as many in vivo studies have shown a glucagon 
effect on IGFBP-1 mRNA levels (Kachra et al., 1991) (Figure 2.9).             
 
2.4.3 Dexamethasone 
 
 Glucocorticoids (GC) function to maintain homeostasis in mammalian organisms 
through regulation of glucose, fat and protein metabolism. Due to the importance of GCs 
in the co-ordination of gene expression in many cell types, there is a tight control on its 
release through the hypothalmo-pituitary-adrenal axis. GC is a adrenocorticoid and 
occurs naturally but is also produced synthetically as in the case of dexamethasone. As 
steroid hormones, GCs readily cross cell membranes due to their intrinsic hydrophobic 
nature. Once in cells, GC binds glucocorticoid receptors (GR). The GR has a modular 
structure consisting of a DNA binding domain, a ligand binding domain and two 
activation domains (Beato et al., 1995). The GR exists in its cytosolic unbound form 
associated in a complex with heat shock protein (HSP) 56 and 90. Upon ligand binding 
HSP56 and HSP90 dissociate from the GR and the activated GR is translocated to the 
nucleus where it controls transcription of specific target genes (Figure 2.9) (Tronche et 
al., 1998). 
 GR can both activate and repress the transcription of target genes through binding 
to GC responsive elements (GRE) present in promoters or enhancers. GC affects 
transcription through direct interaction with basal transcriptional machinery or through 
crosstalk with other co-factors and transcriptional factors. GC induces expression of 
several anti-inflammatory proteins such as interleukin (IL)-1 receptor antagonist and 
IκBα (Clark et al., 2003). GC also activates the transcription of many liver 
gluconeogenic metabolic enzymes such as PEPCK, glucose-6-phosphatase, tyrosine 
amino transferase (TAT) and serine dehydratase following dimerization of GR and 
binding to palindromic GREs. Binding of the active GR to the PEPCK and TAT 
promoter regions has been shown to involve a N-terminal ligand independent domain and 
a C-terminal ligand dependent domain which both flank a central domain containing two 
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zinc finger motifs utilized for DNA binding and GR dimerization (Groner et al., 2002, 
Clark et al., 2003). In H4IIE hepatoma cells dexamethasone was found to induce the 
expression of α2,6(N)-sialyltransferase which catalyze the transfer of activated sialic 
acids to terminal positions on carbohydrate chains of glycoproteins and glycolipids 
(Coughlan et al., 1997). 
 Activated GRs can also repress gene expression through direct repression or 
through interaction and crosstalk with other proteins. GR can repress transcription when 
bound to a specific DNA sequence called the negative GRE (nGRE) (Drouin et al., 
1993). GR crosstalk with TFs such as NFκβ and AP-1 also leads to direct repression of  
transcription. This protein-protein interaction has been termed transactivation as 
association inhibits transcriptional activation while not affecting the binding capacity of 
the TFs. A similar antagonism exists with other TFs such as CREB, GATA-1 and Spi-1 
(Tronche et al., 1998). 
Recent evidence suggests that GC induction of glucocorticoid-induced leucine 
zipper (GILZ) and MAPK phosphatase-1 (MKP-1) protein expression provides crosstalk 
between the GR and the MAP kinase pathway. In mammalian cells, there are three main 
MAPK families: ERKs, JNK and p38s. MAP kinase pathways are organized into parallel 
signaling cascades mediated by sequential phosphorylations. GC induction of GILZ leads 
to inhibitory actions on MAPK pathway activity through formation of cytoplasmic 
complexes with Raf and inhibits Raf activity by an unknown mechanism. Association of 
AP-1 and NFκΒ directly to responsive genes inhibits induction of gene expression by 
cJun and p38/ERK. So far, genes inhibited or blocked by GILZ include Fas ligand and 
IL-2 to date. Little is known about the mechanism of MAPK pathway regulation by 
MKP-1 but it has been shown that it inhibits p35 and JNK  (Clark  et al., 2003).  
 The ability of GCs, such as dexamethasone, to modulate levels of ALS and 
IGFBP-1 has been shown in rat primary hepatocytes. Physiological amounts of 
dexamethasone increase H4IIE IGFBP-1 mRNA by 10-fold (Orlowski et al., 1990) and 
decreases ALS levels through regulation at the transcriptional level. Little is known as to 
how IGFBP-1 and ALS are regulated and through what mechanism. The relationships 
between hepatic regulated GH and GR and growth promotion indicates GR physically 
interacts as a co-activator. GR and STAT5 act in synergy to induce IGFBP-1 expression. 
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This synergy results in increased transcription rates and growth affects in vivo (Tronche 
et al., 2004). GR is synergistic with other TFs as well such as jun homodimers and 
C/EBPβ (Tronche et al., 1998).   
 
2.4.4 Glucose 
 
 The regulation of gene expression via intracellular glucose concentrations has 
been seen for a number of genes and gene products. These include the stimulation of 
glucose transportors, glycolytic and lipogenic enzymes (e.g. L-type pyruvate kinase (L-
PK), acetyl CoA carboxylase (ACC) and fatty acid synthase) and repression of 
gluconeogenic pathway enzymes such as PEPCK (Vaulont et al., 2000). In glucose-
sensitive tissues, glucose enters cells through specific glucose transporters. In adipocytes 
and muscle cells the insulin sensitive transporter, GLUT4, is utilized whereas in liver and 
pancreatic β cells the GLUT2 transporter is utilized. The GLUT2 transporter allows for 
rapid equilibrium between extracellular and intracellular glucose levels. Further, it has 
been suggested that the large intracytoplasmic loop of GLUT2 may play a role in 
signaling due to the hyperexpression of this loop disrupting glucose responsiveness 
(Guillemain et al., 2000). Once glucose enters liver cells, muscle cells, adipocytes and 
β cells it is phosphorylated to glucose-6-phosphate (G-6-P) by hexokinase which is the 
first step in glycolysis (Figure 2.10). G-6-P is utilized in glycolysis, the pentose 
phosphate pathway and glycogen synthesis in the liver. In muscle cells and adipocytes G-
6-P is also used in hexosamine synthesis. Although G-6-P has been implicated as a 
required molecule for glucose mediated changes in gene expression other downstream 
intermediates may also be involved. 
Utilization of G-6-P in the metabolic pathways has been investigated for possible 
intermediates involved in glucose mediated changes in gene expression. An intermediate 
in the non-oxidative branch of the pentose phosphate pathway, xylitol, has been shown to 
mimic the effects of hyperglycemia on glucose-regulated gene expression (Massilon et 
al., 1998). In fat and muscle tissue, the hexosamine pathway may be responsible for some 
of the transcriptional effects of glucose (Sayeski et al., 1996). However, it is widely  
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thought that G-6-P is independently responsible because regulation has been shown to be 
primarily dependent on the synthesis of G-6-P (Mourrieras et al., 1997).  
 Much research has implicated phosphorylation/dephosphorylation cycles in the 
cell signaling and regulation of glucose mediated transcription. Protein phosphatase 
inhibitors inhibit the glucose induction of L-PK expression (Datta et al., 1999). cAMP  
dependent protein kinase has also been implicated in regulating glucose dependent 
signaling (Gourdon et al., 1999). Recently it has been shown that the activation of AMP-
activated protein kinase (AMPK) by 5-amino-4-imidazolecarboxamide riboside inhibits 
the activation of many glucose-regulated genes in primary hepatocytes (Leclerc et al., 
1998). In response to cellular changes such as stress, which depletes ATP, AMPK is  
activated leading to the phosphorylation of many cellular target proteins involved in 
carbohydrate and fat metabolism. In pancreatic β cells, high glucose leads to the 
inactivation of AMPK and a subsequent increase in L-PK transcription and vice-versa  
(da Silva Xavier et al., 2000). 
 The glucose response element (G1RE) has been defined and is involved in the 
glucose mediated positive effect on gene transcription (Cuif et al., 1993). The L-PK 
G1RE consists of two palindromic boxes separated by 5 base pairs, which bind to 
upstream stimulatory factors (USFs), and an auxiliary site which act synergistically for 
gene activity (Vaulont et al., 2000). Many G1RE DNA-binding proteins have been 
reported in addition to USF. An orphan nuclear receptor of the steroid/thyroid hormone 
class, the chicken ovalbumin upstream promoter transcription factor II (COUP-TFII), 
binds the G1RE in vitro and is found in liver extracts. Through G1RE binding COUP-
TFII interferes with USF transactivation of the L-PK gene and represses the glucose 
effect on L-PK transcription (Lou et al., 1999). Other TFs involved are the sterol 
response element-binding protein 1c (SREBP-1c) (Foretz et al., 1999, Osborne et al., 
2000), Sp1 (Daniel et al., 1996a) and pancreatic duodenum homeobox protein (PDX-1) 
(Macfarlane et al., 1999).  
 Glucose may have effects on gene expression and a number of possible 
intermediates may be involved. However, the effects of glucose on components of the 
IGF system are not yet known. Glucose uptake may have an insulin-independent effect 
on IGFBP-1 levels (Snyder et al., 1990)  but its effect on ALS expression has not been 
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thoroughly investigated. However, it is well known that nutritional status has an effect on 
expression of components of the IGF system including IGFBP-1 and ALS. Both hyper- 
and hypo-glycemia lead to changes in expression of IGF system components. 
 
2.4.5 Growth Hormone 
 
 The interactions between GH and the IGF system have been well documented and 
have been collectively termed the IGF:GH axis. GH has a positive regulatory role on the 
expression of IGF-I, ALS, IGFBP-3 and IGFBP-1. Therefore, GH levels normally 
correlate with levels of IGF system components in circulation. Functionally, IGF-I 
mediates much of the growth promoting activity of GH and controls GH expression 
through an indirect feedback mechanism through interaction with the pituitary and 
hypothalmus, the origin of GH and GHRH secretion, respectively. When levels of GH are 
high, IGF-I functions to inhibit further GH release.     
 The GH receptor is a member of the cytokine receptor superfamily. The GH 
receptor contains a single putative membrane spanning domain, a 210 amino acid 
extracellular region (fibronectin III domain) with conserved pairs of cysteine residues, C-
terminal YXXFS–like motifs and two short homologous domains in the intracellular 
domain entitled box 1 and 2. Box 1 contains a consensus sequence for association with 
Janus kinase 2 (Jak2) and is required for most GH-stimulated cell functions. Box 2 is less 
defined but deletion or mutation of these boxes abrogates Jak activation and subsequent 
proliferative effects on cells (Zhu et al., 2001) (Figure 2.11). 
 Receptor activation follows the binding of GH to two dimerized GH receptors. 
With the use of X-ray crystallography technique, it has been suggested that hGH has two 
receptor binding sites, a high affinity site and a low affinity site. These sites sequentially 
bind the dimerized GH receptor homodimer and provide the signal required for biological 
activity (DeVos et al., 1992). The GH receptor lacks an intrinsic tyrosine kinase activity. 
Activation of signaling relies on the recruitment and/or activation of cytoplasmic tyrosine 
kinases. Many non-receptor tyrosine kinases have been identified which show an ability 
to interact with the intracellular motifs of different receptors. These kinases contain SH-1, 
SH-2 or SH-3 domains (Avraham et al., 2000, Zhu et al., 2001). 
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 Upon ligand binding and receptor dimerization the Janus kinase, Jak2, binds to 
the Box 1 sequence which is sufficient for kinase activation. Jak2 phosphorylates sites on 
the cytoplasmic domain of the GH receptor (Sotiropoulos et al., 1994). Jak2 and the 
phosphorylated receptor provide docking sites for a number of signaling molecules 
containing SH-2 or PTB domains. Some signaling molecules which associate to Jak2 are 
SHC (src homology 2/α collagen-related), IRS, SHP-1 (SH2-containing protein tyrosine 
kinase phosphatase), p85 subunit of the PI-3 kinase and STAT-1, -3, -5. Other signaling 
molecules undergo tyrosine phosphorylation and therefore have a role downstream of GH 
receptor activation such as Raf-1 and IRS-1 which can activate both the MAP kinase and 
PI-3 kinase pathways (Dominici et al., 2002) (Figure 2.11). 
Although it has been shown that a number of signaling pathways are affected by 
GH mediated receptor signaling, the STAT family has been the most extensively studied 
and relates to the expression of components of the IGF system.  ALS, for example, has 
been shown to contain a growth hormone-responsive promoter element in the mouse, 
sheep and human ALS gene (Suwanichkul et al., 2000, Rhoads et al., 2000). A GH 
responsive promoter between nt -2001 and nt -49 has been shown in rat liver cells. 
Deletion and mutational analysis of the mouse ALS promoter sequence identified a single 
γ - interferon activated sequence (GAS) corresponding to nt -633 to -625 which was 
entitled ALSGAS1 (Figure 2.12). Stimulation of expression is through the binding of 
Stat5a and Stat5b protein factors to the ALSGAS1 fragment (Ooi et al., 1997, 1998). The 
ALSGAS1 sequence is highly conserved amongst mouse, rat, sheep and human genes 
and has been shown to be required for ALS activation by GH (Rhoads et al., 2000, 
Suwanichkul et al., 2000). GH activation is through the Jak-Stat pathway and its 
responsiveness is blocked by IL-1β. IL-1β affects responsiveness through the down 
regulation of the GH receptor or through interference with Stat5 activity. Interference 
with Stat5 may be mediated by a intracellular suppressor of cytokine signaling (SOCS)-3 
which is an inhibitor of the Jak-Stat pathway (Wolf et al., 1996, Boisclair et al., 2000). 
Interestingly, IL-1β is seen to increase IGFBP-1 expression (Frost et al., 2000). The 
regulation of IGFBP-1 expression through GH signaling has not been shown and it is 
possible that IGFBP-1 is regulated independent of GH secretory status (Baxter et al., 
1987).  
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2.5 Experimental Models 
  
2.5.1 Streptozotocin-Induced Diabetic Rats 
 
In 1963, murine tumour studies led to the discovery that streptozotocin (STZ) 
produced hyperglycemia (Rakieten et al., 1963), and further toxicology studies in dogs  
and rhesus monkeys demonstrated that STZ had a potent diabetogenic effect (Carter et 
al., 1971). Since this time streptozotocin has been used in research as a diabetogenic 
agent in animals. The first rat studies conducted were in 1965 (Evans et al., 1965).  The 
mechanisms of STZ-induced hyperglycemia are considered as follows: STZ causes DNA 
strand breaks in pancreatic islets and stimulates nuclear poly (ADP- ribose) synthetase, 
and thus depletes the intracellular NAD+ and NADP+ levels, which inhibits proinsulin 
synthesis and induces diabetes (Wilson et al., 1988). This is Type I diabetes with no 
pancreatic insulin production. The study of liver cell expression in STZ-induced diabetic 
rats has been done by a number of groups. In fact, a group recently has investigated 
IGFBP and IGF-I liver cell mRNA expression in streptozotocin- induced diabetic rats 
(Goya et al., 1999). 
 
2.5.2 HepG2 Cell Lines as a Model of Hepatocyte Function and Metabolism 
 
 Human hepatoma HepG2 cells (ATTC HB-8065,  Javitt et al., 1990) have been 
used by researchers for over 25 yrs. The cell line was initially established in 1980 as a 
human hepatocellular carcinoma cell line (Knowles et al.,1980). Since that time it has 
been extensively used in studies investigating hepatocyte function related to metabolism. 
The study of HepG2 cell line gene regulation by metabolic hormones such as insulin and 
glucagon has been investigated by numerous researchers (Khamzina et al., 2005, Roesler 
et al., 1996). Investigation of IGF system component regulation has also been performed 
in HepG2 cell lines (Frost et al., 2000).    
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2.5.3 H4IIE Cell Lines as a Model of Hepatocyte Function and Metabolism 
 
Rat hepatoma H4IIE cells (ATTC CRL-1548, Reuber 1961; Pitot et al., 1964) 
have been used by researchers for over 45 yrs. The cell line was initially established in 
1964 as a rat hepatocellular carcinoma cell line (Pitot et al. 1964). Since that time it has 
been extensively used in studies investigating hepatocyte function related to metabolism. 
The study of H4IIE cell line gene regulation by metabolic hormones such as insulin and 
glucagon has been investigated by numerous researchers (Patel et al., 2002, Crossen et al 
1997). Investigation of IGF system component regulation has also been performed in 
H4IIE cell lines (Patel et al., 2002).    
 
      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 63
 
3.0 OBJECTIVES 
 
 The general objective of this thesis was to investigate the regulation of ALS and 
IGFBP-1 expression in the liver and in hepatoma cell lines in respect to the hypotheses 
made in the introduction (section 1.0). To satisfy this objective studies would assess the 
protein secretion and gene expression of IGFBP-1 and ALS, respectively. The specific 
objectives are as follows:  
 
1) To identify modulation of IGFBP-1 and ALS expression in rat hepatoma H4IIE cells, 
time course and dose dependency experiments were performed using a number of 
candidate modulators of expression including insulin, cAMP, dexamethasone, glucose 
and GH.  
 
2)  To characterize the in vivo regulation of liver ALS expression in streptozotocin-
treated diabetic rats and streptozotocin-treated diabetic rats with insulin replacement.  
 
3) To investigate the combined effects of cAMP and insulin using methods with the 
measurement of ALS gene expression as a function of modulator incubation time and 
order of incubation. 
 
4) To investigate hepatocyte signaling pathways which operate in the regulation of 
IGFBP-1 secretion and ALS gene expression through the use of modulator co-incubation 
with MAPK and PI-3K pathway inhibitors. 
 
5) To investigate the function of PKB in the regulation of IGFBP-1 and ALS expression 
using HepG2 PKB-CA cell lines and comparing expression in these cells to the 
expression in normal HepG2 cell lines. 
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4.0 MATERIALS AND METHODS 
 
4.1 Materials 
  
4.1.1 Cell lines 
 
 Human hepatoma HepG2 cells (ATTC HB-8065, Knowles et al.,1980, Javitt et 
al., 1990) and rat hepatoma H4IIE cells (ATTC CRL-1548, Reuber 1961; Pitot et al., 
1964) were a generous gift from Dr. W. Roesler, Department of Biochemistry, University 
of Saskatchewan. The HepG2-PKB-CA cell line expresses a constitutively active PKB 
construct and was a gift from Dr. D. Gupta, Department of Biochemistry, University of 
Saskatchewan. All cells were grown in Dulbecco’s Modified Eagle Medium (DMEM): 
Nutrient mixture F12 (Ham) (1:1) – with glutamine supplemented with 10% fetal bovine 
serum and 1% antibiotic/antimycotic agent (10,000 units of penicillin (base), 10,000 µg 
of streptomycin (base), and 25 µg of amphotericin B/ml utilizing penicillin G (sodium 
salt), streptomycin sulfate, and amphotericin B as Fungizone® Antimycotic in 0.85% 
saline). Cells were grown on 100 mm tissue culture dishes at 37o C and 5% CO2 in a 
humid incubator.  Cells were grown 3 to 4 days until approximately 80% confluent. Cell 
cultures were maintained through passaging using trypsinization with Trypsin-EDTA 
(1%) (10x solution contains 0.5% Trypsin (2.5% (10X), liquid) and 5.3 mM EDTA * 
4Na) in 1x phosphate buffered saline (1xPBS) (Table 4.1) to lift cells off plate. Cells 
were passaged 1:4 for H4IIE and 1:3 for HepG2 cells. Cells were visualized for 
confluency (concentration of cells on plate), contamination and cell morphology using a 
Nikon Phase Contrast-2 microscope. Before cell treatments, confluent cell cultures (80 – 
90% coverage of plate) were incubated overnight in the presence of serum-free media 
(DMEM, 0.2% BSA, 1% antibiotic/antimycotic).    
 
4.1.2 Animals 
 
 Male Wistar rats (3 month old, 120-150 g body weight) were purchased from 
Charles River Laboratories (St. Constant, Quebec, Canada) and were used as a source for 
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mRNA analysis. These animals were kept in an air conditioned environment with a 12 hr 
light-dark cycle. Animals were fed with liberty a pellet rodent stock which consists of 
77% carbohydrate, 16% protein and 7% fat. The research protocols were as approved by 
the University of Saskatchewan Animal Care Protocol Review Committee as per 
guidelines of the Canadian Council on Animal Care.   
 
 
Table 4.1 List of buffers and solutions   
Buffer or solution Components 
1 x PBS 7.2 g/L NaCl, 1.48 g/L Na2HPO4,  0.43 g/L KH2PO4, pH 7.4 
10 x MOPS 
Electrophoresis 
buffer 
0.4 M MOPS, 100 mM sodium acetate, 10 mM EDTA 
5 x Run buffer 9 g tris base, 43.2 g glycine, 3 g SDS made to 600 mL with DDH2O  
20 x SSC buffer 3 M NaCl, 0.3 M sodium citrate 
50 x Denhardts 1 g ficoll, 1 g polyvinyl pyrrolidine reagent (50x), 5 g BSA (fraction V)  
dissolved in 100 mL DDH2O  
LB 
 
2.5 g bacto-tryptone, 1.25 g bacto- yeast extract, 2.5 g NaCl in 250 mL DDH2O  
LBA  
 
2.5 g bacto-tryptone, 1.25 g bacto- yeast extract, 2.5 g NaCl, 3.75 g agar in 250 
mL DDH2O  
pH 12.5 buffer   1 µL H2O, 10 µL 5 M NaCl, 8.5 µL 5 M NaOH pH 12.5 
pH 7.2 Sodium 
phosphate buffer 
for 100 mL: 1 M Na2HPO4 (68.4 mL), 1 M NaH2PO4 (31.6 mL) 
 
Protein sample buffer DDH2O 3.6 mL, 0.5 M tris-HCl (pH 6.8) 1.0 mL, glycerol 1.6 mL, 10% SDS 1.6 
mL, 1% (w/v) bromophenol blue (in water) 0.2 mL 
RNA sample Buffer 2.2 (X) formamide, 0.77(X) formaldehyde, 0.44(X) MOPS buffer, 
0.44(X) RNA dye (X is sample volume for RNA) 
TCM buffer 0.3 M CaCl2, 0.3 M MgCl2, 0.1 M tris-HCl, pH 7.5  
TE buffer 10 mM tris-HCl (pH 7.4), 1 mM EDTA (pH 8.0) pH 7.4 
Transfer buffer 30.3 g tris base, 144 g glycine, 500 mL methanol to 10 L with DDH2O 
Tris Borate EDTA  
(TBE)  buffer 
5x stock solution: 54 g tris base, 27.5 g boric acid, 20 mL of 0.5 M  
EDTA (pH 8.0) to1 L with DDH2O 
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Tritration  
buffer 
100 mM CaCl2, 70 mM MgCl2, 40 mM sodium acetate (pH 5.5) 
 
4.1.3 Plasmids 
 
 The rALS /pBSII plasmid construct (Delhanty 1998b) was a generous gift from 
Dr. Patrick Delhanty from the Kollings Institute of Medical Research, Sydney, New 
South Wales, Australia. The plasmid was used in transformation of XL-1 E.coli.. The 
RPPO (ribosomal phosphoprotein PO)/pBR322 plasmid vector (Laborda 1992) was 
generously provided by Dr. W.J. Roesler, Dept. of Biochemistry, University of 
Saskatchewan. Plasmid were isolated and stored in TE buffer at -20o C. Bacterial stocks 
containing vectors were stored at -80o C in cryogenic vials containing bacterial culture 
and 15% glycerol. 
  
4.1.4 [I125] -labelled IGF 
 
 [I125]-labelled IGF (3.0 x 108 cpm/mL) was a generous gift from Dr. van Kessel, 
Dept. of Animal and Poultry Science, University of Saskatchewan. The samples were 
stored at -20o C until required for use in Western ligand blotting. 
  
4.1.5 Chemicals and Enzymes 
 
 Enzymes and chemicals used in these experiments are listed in Table 4.2. 
Addresses of suppliers are given in Table 4.3.  
 
 
Table 4.2 List of materials used for experiments 
 
Chemicals Suppliers 
Acrylamide Pharmacia 
Agarose Gibco BRL 
[α-32P] dCTP Perkin-Elmer 
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Agar Difco 
Ammonium persulfate Sigma 
Antibiotic-antimycotic agent Gibco-BRL 
Bacto-tryptone Difco 
Bacto-yeast extract Difco 
Bis acrylamide Sigma 
BSA (fraction V) Sigma 
BSA (RIA grade) Sigma 
Chloroform BDH 
Dexamethasone Sigma 
D- (+) - glucose Sigma 
Diethyl pyrocarbonate (DEPC) Sigma 
DMSO (Dimethyl Sulfoxide) Gibco BRL 
DNase-free pancreatic RNase A Sigma 
Dulbecco’s modified eagle medium         
(DMEM): Nutrient mixture F12 (Ham)  
(1:1) – with glutamine 
Gibco-BRL 
Ethidium bromide Bio-Rad 
Fetal bovine serum Gibco-BRL 
Ficoll Sigma 
Folin reagent Sigma 
Formaldehyde EM Science 
Formamide Sigma 
Sephadex G-25 and sephadex G-50 Amersham/Pharmacia 
Gene screen plus hybridization transfer   
membrane  
NEN Life Sciences 
Growth hormone Sigma 
Clinistix - Glucose strips Bayer 
Glycine EM Science 
Insulin Sigma 
Kodak X-OMAT 5 X-ray film Kodak 
KpnI New England Biolabs 
Lysozyme Sigma 
MOPS Sigma 
NaH2PO4 BDH 
Na2HPO4 EM Science 
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NaK- tartrate Sigma 
N6,2’-O-dibutyryladenosine 3’,5’-cyclic  
Monophosphate 
Sigma 
PD98059 Calbiochem 
PEG 8000 BDH 
Polyvinyl pyrrolidine reagent (50x) Sigma 
Pork ILETIN II NPH insulin isophane Eli Lilly 
Prime-A-Gene system kit Promega 
protease inhibitor cocktail Sigma 
Pronase Sigma 
PstI New England Biolabs 
RNA Sigma 
SacI New England Biolabs 
Salmon sperm DNA Sigma 
Sodium citrate EM Science 
Sodium dodecyl Sulfate. Schwartz/Mann Biotech (ICN) 
Somnotol MTC pharmaceuticals 
Streptozoticin Sigma 
Tetracycline Sigma 
Tissue culture dish Falcon 
Transblot nitrocellulose transfer membrane Bio-Rad 
TriZol reagent Invitrogen 
Trypsin-EDTA Gibco-BRL 
Wortmannin Sigma 
3M paper Whatman 
Transblot nitrocellulose transfer membrane Bio-Rad 
 
 
 
Table 4.3 Addresses of suppliers 
Supplier Address 
Gibco-BRL Gibco Life Technologies, Inc. Burlington, 
Ontario, Canada 
Fisher Fisher Scientific, Winnipeg, Manitoba,  
MTC pharmaceuticals MTC Pharmaceuticals, Cambridge, 
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Ontario 
Sigma Sigma Chemicals Co., St.Louis, Missouri, 
USA 
BDH British Drug House, Toronto, Ontario,  
EM science Darmstadt, Germany 
Amerisham/Pharmacia Amersham Pharmacia Biotech. Baie 
d’Urfe, Quebec,  
Bio-Rad Bio-Rad Laboratories, Mississauga, 
Ontario, Canada 
NEN life sciences New England Nuclear, Dupont Canada 
Inc., Missisauga, Ontario, Canada 
VWR VWR Scientific Inc. West Chester, P.A. 
USA 
Calbiochem Calbiochem-Novabiochem Corp., La Jolla, 
CA, USA 
Perkin Elmer Perkin Elmer, Wellesley, MA, USA 
Eli Lilly Eli Lilly and Co., Indianapolis, IN, USA 
Invitrogen Invitrogen Canada Inc. Burlington, Ontario 
BRL Gaithersburg, MD, USA 
 
 
4.1.6 Apparatus 
 
Table 4.4 List of apparatus used 
 
Apparatus Manufacturer and Usage   
Laminar flow hoods The Forma Biological safety cabinet was used for all work with mammalian 
cells. 
Spectrophotometer The Bio-Rad  Smart Spec was used for determination of protein, RNA and DNA 
concentrations as well as sample purities 
Centrifuges Centrifugation of large volumes (>10 ml) under 65,000 x g were performed 
using the RC5C (Sorvall) centrifuge with GSA and SS34 rotors. The eppendorf 
5402 centrifuge was used for small volume samples. 
Electrophoresis units For small DNA gels to visualize DNA the Bio- Rad mini-sub cell GT was used. 
For the running of formaldehyde gels the BRL horizontal system for submerged 
electrophoresis was used. For SDS-PAGE the Bio-Rad mini-protean 3 gel 
electrophoresis system was used. 
Transfer 
electrophoresis 
For the transfer of protein from SDS PAGE gels to nitrocellulose the Bio-Rad 
trans-blot system was used. 
Freeze dryer Labonco Freeze dry system and stoppering tray dryer were utilized for 
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lyophilization of protein samples 
-80 oC  Freezer Forma Bio-freezer (Forma scientific) was utilized for storage of protein and 
RNA products 
UV illumination box For visualization of ethidium bromide stained DNA and RNA gels the 
Transilluminator LM-20E (VWR scientific) was used. 
Crosslinker The UV stratalinker 1800 (statagene) was utilized on all Northern blots 
Film developer The KODAK X-OMAT 1000A film processor was used in the developing of 
autradiograph x-ray film 
Gel Doc system Bio-Rad Gel Documentation system was utilized along with Quantity One 
software to observe autoradiogaphs and document them as well as take 
densitometry readings for all western-ligand and Northern blots. 
Microscope Nikon Phase Contrast-2 microscope was used to observe hepatoma cell growth 
and morphology 
pH meter pH of all reagents were measured by Accumet pH meter 915 (Fisher) 
Water purification Preparation of double distilled water was through Mega-PureTM System (MP-
6A, Corning Co.) 
 
 
4.2 Methods 
 
4.2.1 Treatment Conditions for HepG2 and H4IIE Cells 
 
 The experimental conditions for isolation of mRNA, protein and secreted protein 
from HepG2 and H4IIE cell cultures are indicated below. The concentrations of all 
modulators as added to serum free media and the times of incubation are included for  
each experiment and are also found in figure legends for respective experiments.  
 For time course experiments, insulin (10 nM), N 6,2’-O-Dibutyryladenosine 
3’,5’-cyclic monophosphate (db-cAMP) (0.5 mM), dexamethasone (1 µM), growth 
hormone (GH) (100 nM) and glucose (5.5 mM) were added to cell culture media and 
incubated for 24-36 hr. The cells or media were collected at 0, 4, 6, 12, 24 and 36 hr. 
 The concentrations of various modulators used for experiments on the expression 
of ALS mRNA and IGFBP-1 protein were: insulin (0, 0.1, 1.0, 10, 100, 1000 nM); db-
cAMP (ALS) (0, 0.2, 0.5, 2, 4.4, 10 mM); db-cAMP (IGFBP-1) (0, 0.1, 0.25, 0.5, 1.5, 
2.5mM); dexamethasone (0, 0.1, 0.25, 0.5, 1.5, 2.5 µM); GH (0, 50, 100, 250, 500, 1000 
nM); glucose (0, 5, 25, 50, 100, 200 mM) (above the 17.7 mM which is found in cell 
growth media). All mRNA related experiments (ALS) had 12 hr incubations while 
protein experiments (IGFBP-1) had 6 hr incubations. 
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 In the study of IGFBP-1 and ALS expression in relation to modulators and 
inhibitors of PI-3K and MAP kinase pathways concentrations of modulators were as 
shown with time course experiments above. Incubation times were 12 and 6 hr with ALS 
and IGFBP-1 expression, respectively. The pathway inhibitors used were added to culture 
media 30 min prior to addition of modulators. The concentration of wortmannin and 
PD98059 were 0.2 mM and 10 µM, respectively. After the pre-incubation, fresh serum 
free media was added including modulator and pathway inhibitor. 
 For insulin:cAMP factorial study on ALS expression, 0.5 mM cAMP and 10nM 
insulin were used with the following ten groups: 1) no treatment, 6 hr; 2) cAMP, 6 hr; 3) 
insulin, 6 hr; 4) cAMP + insulin, 6 hr; 5) insulin, 12 hr; 6) insulin, 6 hr, then cAMP, 6 hr; 
7) cAMP 30 min then insulin, 6 hr; 8) insulin 6 hr then decant off media and add fresh 
media no modulator, 6 hr; 9) insulin, 6 hr then decant off media and add fresh media with 
insulin, 6 hr; 10) insulin 6 hr then decant off media and add fresh media with cAMP, 6 hr.       
 
4.2.2 Animal Maintenance, Treatments and Tissue Excision 
 
 Male Wistar rats (3 month old, 120-150 g body weight) were used for determining 
ALS gene expression in liver. Rats were grouped as: 1) Control untreated (Citrate buffer), 
2) Streptozotocin (STZ)-induced diabetic and 3) Insulin treated STZ-induced diabetic 
(Roesler et al., 1987). The rats were allowed to adjust to the local environment. The rats 
in groups 2 and 3 were made diabetic with a single i.p. injection of STZ (80 mg/kg BW) 
dissolved in 100 mM citrate (pH 4.5). Control rats (group 1) were injected with the same 
volume of citrate buffer. The animals were monitored for glucose levels in urine using 
Clinistix® glucose detection strips. After a period of 5-7 days, all STZ-treated animals 
were deemed hyperglycemic according to urine glucose levels as indicated on glucose 
detection strips (maroon /purple). Insulin was subcutaneously injected at a dosage of 2 IU 
into diabetic group 3 animals once every day for a seven day period. After this period, all 
animals were killed using Somnotol (1 ml/kg BW rat) and liver tissue removed. Livers 
tissue was immersed in an equal volume of TriZol and homogenated using a Brinkman 
polytron. TriZol suspended primary homogenate samples were left to incubate 10 min at 
RT and mRNA was extracted or frozen for later processing at -80o C. 
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4.2.3 rALS Fragment Preparation from prALS/BSII Plasmid Construct 
 
 The BSII plasmid construct was solubilized in TE buffer, quantified and 
concentrated by adding 3 M sodium acetate (pH 5.5) (1/10 volume) and isopropanol 
(7/10 volume) at -20o C for 2 hr. The mixture was centrifuged at 14000 rpm (14900 x g) 
for 20 min. The pellet was washed with 70% ethanol, dried and reconstituted in TE 
buffer. The isolated prALS/BSII plasmid construct was utilized in transformation of 
competent XL-1 MRF- E.coli cells. 
 In production of competent XL-1 MRF- E.coli cells a single XL-1 MRF- E.coli 
colony was selected from LBA containing tetracycline (12.5 µg/ml). The positive E.coli 
was then re-cultured in 10 mL LB by shaking 37o C incubator with selective pressure and 
re-inoculated into 250 mL LB until the OD600 reached 0.45 to 0.55 A. XL-1 MRF- E.coli 
were chilled on ice water for 2 hr and collected by centrifugation at 6000 rpm (5800 x g 
15 min in GSA rotor). Cells were resuspended in 10 mL tritration buffer and further 
diluted to 250 mL with the same buffer and incubated on ice for 1 hr. Cells were 
centrifuged at 1800 x g for 10 min and then gently resuspended in 25 mL ice cold 
tritration buffer. For long term storage 140 µL DMSO was added per 4 mL cell 
suspension gently swirled and placed on ice for 15 min. An additional 140 µL DMSO 
was then added to 4 mL cell suspension, gently mixed and quickly aliquoted into chilled 
cryotubes. The tubes were quickly frozen in liquid nitrogen and stored at -80o C.    
 For transformation, the XL-1 competent E.coli cells were thawed and the 
rALS/BSII (1 µL = 100 ng) was added to 19 µL TCM buffer (Table 4.3) and left on ice 
for 20 min. The sample mixture was then heat shocked at 42o C for 90 sec and put on ice 
for 5 min. The sample was left at RT for 5 min and 250 mL LB was added. The mixture  
was incubated at 37 o C for 1 hr. The culture was plated on to LBA with ampicillin (50 µg 
/ mL) and incubated overnight at 37o C. Transformed colonies were selected the 
following day.  
Plasmid was isolated using the cleared lysate method of plasmid isolation 
(Clewell et al., 1969). Transformed cells were grown in a 100 ml LB (50 µg/ml 
ampicillin). The medium was inoculated and shaken at 37o C for 14 to 16 hr. The cells 
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were pelleted for 5 min at 5000 rpm (4100 x g) at 4 o C using GSA rotor. The supernatant 
was poured off and the pellet was washed with 50 mL of 50 mM tris-HCl pH 7.5, 2 mM 
EDTA. The cells were re-pelleted and resuspended in 1.4 mL 50 mM tris-HCl pH 8.0 in 
15 mL Oakridge tubes. For cell lysis, 500 µL of lysozyme solution (10 mg/mL) was 
added and the mixture was vortexed and left on ice for 10 min. Six hundred µL of 0.5 M 
EDTA was added to the lysis mixture and again left on ice for 10 min. Finally, 100 µL 
2% Triton X-100 was added and left for 60 min on ice. The cell debris was removed by 
centrifugation (60 min, 8000 rpm, 7600 x g, 4o C, SS34 rotor). The supernatant was then 
extracted with equal volume of phenol and chloroform. At this stage, 25 µL of 5 M NaCl 
was added per mL of the supernatant and precipitation was carried out with 0.8 volume of 
isopropanol at -20o C for 30 min. After 5 min centrifugation (7000 rpm, 5800 x g, at 4o C 
in SS34 rotor), the supernatant was decanted and the pellet was washed with 80% ethanol 
and dissolved in 500 µL of TE buffer. The plasmid mixture was then digested with 2.5 
µL of DNase-free pancreatic RNase A (10 mg/ml) at 37o C for 1 hr. The DNA was 
subsequently precipitated with 150 µL of 5 M NaCl and 200 µL 30% PEG overnight on 
ice. The pellet obtained after centrifugation (20 min, 10,000 rpm, 12000 x g, 4oC, SS34 
rotor) was re-dissolved in 300 µL of TE containing 0.5% SDS and transferred to 1.5 mL 
eppendorf tubes . Proteins were then removed through pronase treatment (3 mL, 20 
mg/mL) at 37 o C for 30 min. Denaturing of the bacterial chromosomal DNA was 
achieved with 10 min incubation at RT with equal volume of freshly prepared pH 12.5 
buffer (Table 4.3). The alkaline reaction mixture was neutralized with 30 µL of 1 M Tris-
HCl (pH 7.5) for 5 min on ice. Sodium acetate 3 M (1/10th volume) was added before the 
DNA was extracted once with equal volume of phenol and chloroform. Ethanol (2.5 
volumes) was added for precipitation (2 hr at -20o C). Finally the DNA was pelleted (15 
min, 11600 x g), washed twice with 70% ethanol, dried, and resuspended in 200 µL TE. 
The OD260 was taken to determine plasmid concentration (for double stranded DNA: 20 
O.D. = 1mg/mL)     
 To obtain the rALS fragment from BSII plasmid construct the plasmid was 
digested as follows: 33.75 µL distilled water, 5 µL 10 x NEB buffer #1, 5 µL BSA (10x), 
2.5 µL DNA sample (30 ug), 2.5 µL KpnI, 1.25 µL SacI. The reaction was left 7 to 9 hr in 
37o C water bath. Agarose gels were poured (0.8% agarose (w/v) in TBE). Digested DNA 
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samples were loaded on to gel and electrophoresis was carried out at 100 V for 
approximately 1 hr. The bands of interest were located using UV lamp and the slice of 
agarose containing the fragment was taken and placed into a 1.5 mL microcentrifuge 
tube. Gel slices were covered with phenol and stored at -80o C. The phenol immersed gel 
was thawed and DNA was purified from gel using the phenol-freeze-fraction method. In 
this method the sample was frozen again at -80 o C and thawed once more at 37 o C. This 
freeze thaw cycle was repeated twice more followed by the addition of 50 µL TE and 
freezing again at -80o C for 15 min. The samples were then centrifuged at 14000 rpm 
(14900 x g) for 20 min and upper aqueous layer was transferred to fresh tubes. The 
aqueous phase was extracted once with chloroform followed by precipitation with 1/10 
volume of sodium acetate (3M, pH 5.2) and 2.5 volume of ethanol for 30 min at -20o C. 
The sample was then centrifuged at 12000 rpm (12600 x g) for 15 min, the pellet was 
washed with 70% ethanol and solubilized in TE. 
 
4.2.4 32P-labelling of rALS and RPPO Probes   
 
 The purification of RPPO fragment was carried out by the same procedure as 
outlined for rALS.  The digestion of the pBR322 plasmid construct was carried out 
overnight at 37o C in a reaction mixture containing: 36 µL distilled water, 5 µL 10 x NEB 
buffer #3, 5 µL BSA (10 x), 2.5 µL DNA sample and 1.5 µL pstI. 
 The RPPO and rALS fragment probes for Northern analysis were labeled using 
random priming with the Prime-A-Gene system kit (Promega). 30 ng of purified rALS 
and RPPO fragment was used to prepare the random labeled probe with denaturing 
through boiling before addition to reaction mixture. The reaction mixture consists of the 
following: 5 µL (30 ng) rALS or RPPO (cDNA), 2.5 µL 10 x labelling buffer, 3.0 µL 
dNTPs (1.0 µL of each of 10 mM stock), 5.0 µL (50 µCi)  [α-32P] dCTP, 2.0 µL (5 units) 
DNA polymerase, Klenow and 32.5 µL of nuclease-free water. The priming reaction was 
allowed to continue for a period of 4-6 hr. The DNA was labeled to an approximate 
specific activity of 1.0 x 108 cpm/µg of DNA. The unincorporated radionucleotide was 
removed using a 1 mL Sephadex G-50 spin column. The purified probe was then boiled 
for 10 min and chilled for 5 min on ice and used directly for Northern hybridization.    
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4.2.5 Total RNA Isolation from Rat Liver Tissue and H4IIE and HepG2 Cell Culture  
 
 The various plastic containers and apparatus used were rinsed with DEPC treated 
water before use in these protocols. In addition, the glassware and metal tools used were 
autoclaved before use.  
 TriZol suspended rat liver tissue primary homogenate samples were thawed at RT 
and 500 µL was transferred to 1.5 mL microcentrifuge tube. To this, 500 µL TriZol was 
added, mixed gently and incubated at RT for 10 min. To this mix, 200 µL of chloroform 
was added and gently mixed and incubated 2-3 min at RT. The mixture was centrifuged 
(14900 x g, 4o C, 15 min) and the aqueous phase was transferred to a 1.5 mL 
microcentrifuge tube containing 500 µL isopropanol. The mixture was then precipitated 
at -20o C for 1-2 hr and centrifuged (14900 x g, 4o C, 30 min). The supernatant was then 
discarded and the pellet was washed with 70% ethanol in DEPC treated water. The pellet 
was allowed to air dry and was resuspended in 40% formamide (DEPC water) and stored 
at -80o C. 
 For total RNA isolation from H4IIE and HepG2 cells, confluent cell monolayer 
plates were placed on ice, conditioned media was removed and cell monolayer was 
washed 2 times with 1 x PBS (5 mL). After complete removal of wash solution, 1 mL 
TriZol reagent was added to the plates and was left for 1-3 min. The cells were pooled 
with the aid of a rubber policeman and then transferred into a 1.5 mL microcentrifuge 
tube. These samples were stored at -80o C. Further processing was as seen above for rat 
liver tissue primary homogenate samples.  
 
 
4.2.6 Protein Isolation from H4IIE, HepG2 and HepG2-PKB-CA Conditioned Media 
 
 Protein isolation in all experiments was performed using an identical protocol. 
Following cell treatments, conditioned media was removed (10 mL) with the addition of 
protease inhibitor cocktail (10 µL, 1:1000) and was immediately frozen at -80o C. The 
media samples were thawed on ice and applied to a Sephadex G-25 (fine) desalting 
column. The protein was eluted with 50 mM Tris-HCl buffer (pH 8.2) and the protein 
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fraction was identified by measuring absorption at OD280. These fractions were pooled 
and lyophilized in a freeze dry system. The lyophilized protein powder was reconstituted 
in water with a concentration factor of 80-100 times and stored at -80o C. 
   
4.2.7 Northern Analysis 
  
Formaldehyde gel electrophoresis was performed using a formaldehyde gel with 
the following components: Agarose (1% in DEPC treated water), 2.0 g; 10 x MOPS 
electrophoresis buffer, 20 mL; formalahyde, 35 mL; water (DEPC treated), 145 mL. The 
gel was poured into a 14 cm x 11cm gel tray and allowed to polymerize.  
30-50 µg of RNA sample was mixed in RNA sample buffer (Table 4.1). This 
RNA denaturing mixture was denatured at 65o C for 10 min and then chilled on ice for 5 
min. The gel was placed in an electrophoresis unit and 10x MOPS electrophoresis buffer 
(Table 4.1) was added to immerse the gel. The sample was then loaded onto the gel based 
on equal RNA concentrations and was electrophoresed at 2 V/cm gel. The gel was run for 
approximately 3 hr and put aside for gel transfer protocol. In all cases, a gel was run for 
assurance of equal loading in each gel and subsequent transfer. These gels were made 
through addition of 1 µL ethidium bromide per denatured RNA sample volume. Gels 
were run as usual and total RNA was visualized using UV illumination.   
The downward capillary blotting method was performed to transfer RNA to nylon 
membrane. In this method, the prepared gel was washed for 45 min in DEPC-treated 
water (repeated 3 times) to remove formaldehyde from the gel. The well portion of the 
gel was cut off to aid in an even transfer to the Gene screen Plus hybridization transfer 
nylon membrane. The nylon membrane and three 3M paper (Whatman) pieces were cut 
with the same dimensions as the gel size and briefly wetted in 10x SSC buffer (Table 
4.1). In the preparation of the transfer apparatus, two pieces of 3M paper were cut as 
wicks long enough to soak in transfer buffer on either side. The wick paper was placed on 
the center of a square glass plate which was placed upon a large glass container 
containing 10 x SSC solution. Each of the wick ends were immersed in 10 x SSC. The 
gel was placed on top of the wick paper followed by the transfer membrane and then the 
3 pieces of 3M paper. A small stack (2-3 inches) of paper towel was stacked on top of 
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3M paper and then a glass plate was stacked on the paper towel and a centered weight 
was placed on top. The entire apparatus was covered in a plastic wrap to avoid 
evaporation and was left to transfer overnight. After completion, the membrane was 
washed in 5 x SSC buffer for 5 min. Transferred RNA was crosslinked on autocrosslink 
mode using Stratalinker and stored between two wet membrane papers at 4o C.  
For the hybridization of probe and the detection of mRNA of interest the 
crosslinked membrane was placed inside a hybridization bottle and was incubated with 
prehybridization solution at 50o C in a hybridization oven for 12 to 16 hr. The 
components of the prehybridization solution for one membrane hybridization are as 
follows: formamide, 1.0 mL; 50 x Denhardts, 2.0 mL; 20 x SSC, 5.0 mL; 20% SDS, 0.5 
mL; 0.5 M EDTA, 0.04 mL; sodium phosphate buffer (1M pH 7.2), 1.0 mL; carrier RNA 
(10 µg/uL), 0.2 mL; salmon sperm DNA (20 µg/uL), 0.4 mL; water (DEPC treated), 11.2 
mL. Following prehybridization the prepared radioactive probe was added to the 
prehybridization solution and hybridization was carried out for 16 hr at 50o C with gentle 
mixing. After the hybridization period was finished the labeled blot was washed 
sequentially as follows with constant readings for background radioactivity and 
discernment for the specific formation of bands of activity representing the desired 
mRNA species: 1) 2 x SSC, 0.1% SDS (3 x 5 min, RT), 2) 0.2 x SSC, 0.1% SDS (2 x 10 
min, RT), 3) 0.2 x SSC, 0.1% SDS (3 x 10 min, 50o C), 4) 0.1 x SSC, 0.1% SDS (2 x 15 
min, 50o C), 5) 0.1 x SSC, 0.1% SDS (1 x 10min, 55o C). After removing background 
signals, the membrane was wrapped in Saran Wrap and exposed to X-ray film at -80o C 
for various amounts of time depending on the strength of radioactive signal. X-ray film 
was developed using a Kodak film processor. The autoradiograms were quantified using 
the Gel Doc System (Bio-Rad) 
 
4.2.8 Western Ligand Analysis 
 
 The Lowry method was chosen for determination of all protein samples due to the 
predicted lower concentrations of protein which would be secreted into the media. An 
alkaline solution (30 g Na2CO3, 6 g NaOH dissolved in 1.5 L distilled water), NaK 
tartrate solution (1 g / 100 mL) and Folin reagent (1:1 with water) were made. To make 
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the alkaline reagent, 0.15 g CuSO4 was added to 10 mL NaK tartrate solution and was 
mixed until dissolved. From the CuSO4  /  NaK tartrate solution 1 mL was transferred to 
50 mL alkaline solution and mixed. The alkaline reagent (1.5 mL) was added to 308 µL 
of the test solution, was gently mixed and allowed to stand at RT for 10 min. 154 µL 
Folin reagent (1:1) was then added and allowed to stand at RT for an additional 10 min. 
The absorption was then read against the appropriate blank at OD600. A protein standard 
curve was done using BSA (0.2 mg/mL) in the range of 0-200 µg BSA and protein was 
determined against this curve.     
 Determined protein samples were added at 30-50 µg and mixed with protein 
sample buffer (5:1 ratio of sample volume to buffer volume), were boiled 3-4 min and 
were added in equivalent concentrations to gel for electrophoresis. The composition of 
separating gel was as follows: DDH2O, 3.35 mL; 1.5 M Tris-HCl, pH 8.8, 2.5 mL; 
acrylamide/Bis, 4.0 mL;10% SDS, 100 µL; 10% ammonium persulfate, 50 µL; TEMED, 
5 µL. The composition of the stacking gel was as follows: DDH2O, 6.1 mL; 0.5 M Tris-
HCl, pH 8.8, 2.5 mL; acrylamide/bis, 1.3 mL; 10% SDS, 100 µL; 10% ammonium 
persulfate, 50 µL; TEMED, 10 µL. The SDS PAGE was run at a constant voltage of 100 
V for 2-3 hr in 1 x running buffer (diluted 5 x running buffer). Upon completion of 
electrophoresis, the gel was removed from glass plates and allowed to soak in transfer 
buffer at 4oC for 20 min.  
For protein transfer to nitrocellulose, 4 equal sized 3MM chromatography papers 
and 2 absorbent pads were soaked in transfer buffer for 10 min and nitrocellulose was 
soaked in transfer buffer for 5 min. The gel was placed between nitrocellulose and 3MM 
papers in a proper orientation (ensuring protein transfer to nitrocellulose membrane) and 
was immersed in transfer buffer. A constant current of 150 mA was applied for 2 hr. The 
transfer was done with gentle stirring at 4o C.  
 Following the transfer, the nitrocellulose membrane was soaked in saline solution 
with 3% Nonidet P-40 at RT for 30 min (buffer was replaced after 15 min). The 
membrane was then blocked in saline with 1% BSA and 0.1% Tween 20 for 2 hr at RT. 
The membrane was incubated with 20 mL 1% BSA in saline + 0.1% Tween 20 
containing 2.0 x 105 cpm/mL [125I] - IGF-I (20,000 cpm/100 µL) overnight at 4o C with 
gentle agitation. The following day, the membrane was washed with saline + 0.1% 
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Tween 20 for 2 x 15 min at 4o C. This wash was followed by 3 x 15 min washes in saline 
at 4o C. The membrane was then dried at 37o C for one hr and the membrane was exposed 
to X-ray film. Autoradiograph was quantified using a Gel Doc system and basic statistics 
(ex. SD and sample mean) were done using Microsoft Excel. Experimental p values were 
calculated using the T test and SISA online statistics 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
. 
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5.0 RESULTS 
 
5.1 ALS Gene Expression in Streptozotocin-Induced Diabetic Rat livers 
 
 Several studies have demonstrated that insulin induces the expression of ALS 
(Dai et al., 1994a). It was of interest to investigate whether an in vivo change in ALS 
mRNA levels occurred in conditions which naturally alter insulin levels such as in the 
case of Type I diabetes. The effect of streptozotocin (STZ)-induced type-I diabetes on 
ALS mRNA levels were analyzed in the liver tissue of male Wistar rats. Three groups of 
animals were used for this purpose. One group received citrate buffer injections and 
served as a negative control. Saline injection was not used a negative control in these 
studies. A second group was given an i.p. injection of STZ and a third group was given 
STZ followed by daily insulin injections. All rats were monitored for glucose in urine 
using Clinistix® (Bayer) glucose strips and were deemed hyperglycemic with an 
indicated high level of glucose (purple colour on strip). Northern analysis of liver total 
RNA was performed and data was analyzed for ALS expression. STZ treated rats showed 
an approximate 50% decrease in ALS gene expression in comparison to the controls 
(Figure 5.1). The supplement of insulin to STZ-induced diabetic rats brought ALS gene 
expression to near control levels. All ALS expression was analyzed in comparison to 
hepatocyte RPPO expression which is used for determination of equal loading amongst 
samples. In these experiments RPPO expression is used as a measure of base expression 
in cell samples and is unresponsive to some hormonal regulation such as seen with 
estradiol (Laborda et al., 1992). The ratio of ALS/RPPO is utilized for the determination 
of modulator effects on ALS expression. 
 
5.1.1 Discussion 
 
 Diabetes has been shown to lead to the development of a number of secondary 
diseases (Regimbeau et al., 2004, Giovannucci 2001). The importance in determining 
biochemical changes caused by diabetes may therefore assist in further research to  
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Figure 5.1 Effect of streptozotocin-induced diabetes on ALS gene expression in rat liver tissue. Rat livers 
were removed following treatments, homogenized in Trizol reagent (Gibco) and stored. RNA was isolated 
and samples were subjected to Northern analysis. ALS expression was visualized using radiolabelled rALS 
probe and RPPO expression was analyzed for equivalency of RNA loading. Autoradiographs were 
produced of x-ray film and blots (A) were analyzed using Gel Documentation system (Bio-Rad) and 
Quantity One software (Bio-Rad) (B). Values represent the ratio of ALS/RPPO density units. Experiments 
were performed in triplicate, and means + SE is given. T test was performed to determine significance using 
SISA online statistics. STZ, streptozotocin.    
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determine how such changes may illicit an effect and cause secondary disease. ALS is 
found in the bloodstream and acts to regulate the bioavailability of IGF. Regulation of 
ALS expression and secretion in the liver during Type I Diabetes may be an important 
factor in downstream effects affecting the availability of IGF-1. Our results indicate that 
during STZ-induced type 1 diabetes the decrease in insulin secretion results in an 
approximate 50% decrease in accumulation of ALS mRNA in the rat liver. This large 
decrease may affect ALS levels in the bloodstream and lead to the possibilities of 
increased degradation of IGF-1 or increases in IGF-1 activity in target tissues. It has been 
postulated that IGF-1 activity may be responsible for growth of tumours (Manousos et 
al., 1999, Khandwala et al., 2000, Macaulay 1991). Diabetes has been correlated with the 
development of a number of cancer types (Regimbeau et al., 2004, Giovannucci 2001). 
Decreased formation of ternary complexes in circulation may lead to a loss in IGF-1 
control and a resulting IGF-1 mediated stimulation of tumour growth.     
 
5.2 IGFBP-1 Protein Secretion and ALS Gene Expression in PKB Over-expressing                         
      HepG2 Cells 
 
5.2.1 ALS Gene Expression 
 
 As shown in Figure 5.1 ALS mRNA levels decrease in STZ-induced Type 1 
diabetic liver and are restored after insulin supplementation. Decreased and increased 
insulin may, therefore, have a role in the regulation of ALS gene expression. Protein 
kinase B (PKB) is an important component of the PI-3 kinase pathway. Insulin is known 
to activate the PI-3 kinase pathway via signal transduction through the insulin receptor 
(IR). It is possible that upregulation of ALS mRNA involves upregulation of PKB. The 
involvement of PKB in the regulation of ALS expression was, therefore, studied through 
comparison of ALS expression in normal HepG2 and HepG2 cells stably transfected with 
a constitutively active PKB construct (HepG2-PKB-CA). This experiment was performed 
in triplicate with and without insulin. Cells were incubated for 12 hr in DMEM (with or 
without insulin), total RNA was isolated and subjected to Northern analysis. The level of  
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Figure 5.2 The levels of ALS gene expression in parental HepG2 and HepG2-PKB-CA cells. Over-night 
serum starved cell cultures were incubated for 12 hr at 37o C with or without 10 nM insulin. Total RNA 
was isolated and changes in ALS mRNA levels were assessed using Northern analysis. ALS expression 
was visualized using radiolabelled rALS probe and RPPO expression was analyzed for equivalency of 
RNA loading. Autoradiographs were produced of x-ray film and blots (A) were analyzed using Gel 
Documentation system (Bio-Rad) and Quantity One software (Bio-Rad). Experiments without insulin were 
performed in triplicate while those with insulin were performed in quadruplicate. Means + S.D. is given 
(B).  T-test was performed separately for those results with insulin and without insulin using SISA online 
statistics. For both sets comparison of PKB-CA and Parental HepG2 cell ALS expression had a value of 
p<0.05. For comparison between PKB-CA (no ins.) and PKB-CA (ins.): p<0.5.   
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ALS mRNA in parental, non-transfected HepG2 cells was 20% lower than transfected 
HepG2 cells overexpressing PKB (Figure 5.2). The addition of insulin slightly increased   
ALS expression in both cell types but increase was insignificant (p<0.5). The difference 
in activation between these two cell types was very similar with and without insulin. 
 
 
5.2.1.1 Discussion 
 
 Our results in HepG2-PKB-CA cells showed a larger ALS expression as 
compared to parental HepG2 cells with and without insulin signal. Endogenous PKB is 
activated through the PI-3 kinase pathway which is dependent on PI-3 kinase activation 
by insulin signal transduction through the IR. The addition of insulin appeared to slightly 
increase ALS expression in both cell types. Insulin is thought to have no effect on ALS 
expression in HepG2-PKB-CA cells due to insulin independent activity of the PKB-CA 
construct. Although statistically there was no change an activity of insulin without the 
involvement of PKB and possibly the PI-3 kinase pathway may be possible. In later 
sections, data will be presented showing the effects of PI-3 kinase pathway inhibition on 
ALS gene expression in H4IIE cells. Nonetheless, increased PKB activity results in larger 
levels of ALS gene expression in HepG2 PKB-CA cells as compared to parental Hep2 
cells. Any difference in ALS gene expression may also be due to clonal effects and 
without clear quantitative data on PKB levels this result does not prove, without doubt, 
the involvement of PKB in ALS gene regulation. 
Past studies have shown that increased ALS expression does not occur at the 
transcriptional level in primary hepatocytes in response to insulin. Increased ALS 
secretion occurs, but occurs without increases in ALS gene expression (Dai et al., 1994a). 
Our studies in HepG2 hepatoma cells and in STZ-treated rats, however, indicate that ALS 
mRNA levels may be also affected with changes in insulin and insulin signaling (PKB 
levels).         
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5.2.2 IGFBP-1 Secretion 
 
 The repressive effect of insulin on IGFBP-1 expression has been well documented 
(Suikkari et al., 1989). Some studies have implicated a role for PKB in this activity (Rena 
et al., 1999, Guo et al., 1999).  IGFBP-1 expression was analyzed through Western-
ligand blotting. For this, cells were incubated in serum-free media for 6 hr and secreted  
total protein was isolated from conditioned media. Protein was electrophoresed by non-
denaturing SDS-PAGE, transferred to nitrocellulose, probed with [125I]-IGF-1, visualized 
and protein bands were quantified. IGFBP-1 expression was not investigated in cell 
lysate due to almost non-existent IGFBP-1. As shown in Figure 5.3, there was 
approximately 30% less IGFBP-1 secretion in HepG2-PKB-CA cells into media as 
compared to parental HepG2 cells. Insulin was not added in these experiments due to the 
supposed lack of importance with an already well characterized regulatory pattern 
through the PI-3 kinase pathway. 
 
5.2.2.1 Discussion 
 
 IGFBP-1 expression and secretion has been shown to be negatively regulated by 
insulin (Suikkari et al., 1989). It has been suggested that PKB may have a role in 
signaling for the suppression of IGFBP-1 expression. This signaling may occur through 
mTOR,  p70s6k, and FKHR related protein which is thought to bind to the IRE on the 
IGFBP-1 gene promoter region and inhibit IGFBP-1 expression. FKHR is activated 
through phosphorylation by PKB (Rena et al., 1999, Patel et al., 2002). With increased 
PKB activity in HepG2-PKB-CA cells, there was an associated IGFBP-1 secretion which 
was 30% lower than Parental HepG2 cells (Figure 5.3). Thus it appears that IGFBP-1 
secretion may be partially regulated by active PKB. This data may agree with qualitative 
observations made by Rena et al. (1999) and Patel et al. (2002), but the involvement of 
FKHR related protein in gene regulation was not investigated. Any difference in IGFBP-
1 secretion may be due to clonal effects and without clear quantitative data on PKB levels 
this result does not prove the involvement of PKB in the negative regulation of IGFBP-1 
by insulin.  
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Figure 5.3 The levels of IGFBP-1 secretion in parental HepG2 and HepG2-PKB-CA cells. Over-night 
serum starved cells were incubated for 6 hr at 37o C. Following incubation, media was stored at -80o C after 
addition of protease inhibitors. The thawed samples were subjected to desalting on a Sephadex G-50 
column, protein fractions were collected and lyophilized. Following lyophilization, samples were 
resuspended in sample buffer and 50 ug was loaded onto a 12 % SDS PAGE gel and then transferred to 
nitrocellulose. Blots were probed with radiolabelled IGF-1 and autoradiographs analyzed. Blots shown 
above represent averages of three independent sets of data analyzed (A). Autoradiographs were analyzed 
using densitometry with the Gel Documentation System (Bio-Rad) and Quantity One software program 
(Bio-Rad) (B). Means + S.D. are given as well as T test values.  
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Regulation of IGFBP-1 levels in circulation through insulin signaling reveals a 
secondary mechanism of hypoglycemic potential in hepatic cells. In states of increased 
insulin levels IGFBP-1 is repressed (Suikkari et al., 1989a and b, Holly et al., 1988). Our 
results qualitatively may indicate that this repression is controlled through insulin 
mediated activation of PKB and the PI-3 kinase pathway. Repression of IGFBP-1 
expression may result in a larger available pool of free IGF-1 acting in an accumulative 
manner with insulin to bring down levels of glucose in circulation. This IGF-I mediated 
event may occur as a long term effect compared to the short term effects of insulin. 
Although this is a possibility it may also be possible that increased free IGF-1 will bind in 
ternary complexes and increase the half life of IGF-I.  
 
5.3 Secretion of IGFBP-1 Protein in H4IIE Cells 
 
5.3.1 Effects of Incubation Time on IGFBP-1 Protein Secretion 
 
 H4IIE hepatoma cells have been shown to express and secrete IGFBP-1 
(Orlowski et al., 1990, Unterman et al., 1991) and therefore provide a suitable model for 
protein expression analysis. The effect of incubation time on IGFBP-1 expression in 
H4IIE cells was first investigated in order to determine optimum time for expressional 
analysis in experiments determining the transcriptional effects of cAMP, glucose, 
dexamethasone, insulin, and GH. As IGFBP-1 is a secreted protein, all proteins were 
analyzed in conditioned media. The effects of various modulators on IGFBP-1 protein 
expression as a function of incubation time are shown in Figure 5.4a (blots), Figure 5.4b 
(quantitation bars) and Figure 5.5. A control H4IIE time course was done for comparison 
to those with metabolic modulators. Blots were analyzed using measurements of optical 
density and a 5.0-fold  increase in protein expression over a 36 hr period was observed in 
control samples (Figure 5.4a, A; Figure 5.4b, A, Figure 5.5). Again, using optical density 
measurement, increases similar to control were measured with cAMP, glucose and 
dexamethasone incubation. These modulators showed relatively no difference in effect as 
compared to control samples (Figure 5.4a and Figure 5.4b; B, C and D). The effect of 
insulin over a 36 hr period showed a steady increase in IGFBP-1 expression. The 
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Figure 5.4a The level of IGFBP-1 secretion in response to modulator time of incubation in H4IIE 
cells. Cell cultures were incubated for 0 to 36 hr with or without modulators. The experiments are 
shown above for treatments with (A) Control, (B) cAMP(0.5 mM), (C) Glucose (5.5 mM), (D) 
Dexamethasone (1 µM), (E) Insulin (10 nM), (F) GH (100 nM). Media was stored at -80o C after 
adding protease inhibitors. The thawed samples were run through Sephadex G-50 column and 
protein fractions collected and lyophilized. The samples were resolubilized in 50 mM Tris-HCl 
(pH 7.4). Western Ligand analysis was performed on these samples and autoradiographs 
produced were analyzed. The quantitative data is shown in Figure 5.4b. GH, Growth Hormone. 
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Figure 5.4b The level of IGFBP-1 secretion in response to modulator time of incubation in H4IIE 
cells. Autoradiographs were analyzed using densitometry with the Gel Documentation System 
(Bio-Rad) and Quantity One software program (Bio-Rad). The experiments are shown above for 
treatments with (A) Control, (B) cAMP(0.5 mM), (C) Glucose (5.5 mM), (D) Dexamethasone (1 
µM), (E) Insulin (10 nM), (F) GH (100 nM). Values presented are the averages of two duplicated 
independent experiments (4 values). S.E. of mean are shown as vertical bars in respective sample 
plots. p<0.5 for all values obtained less than 6 hr and p<0.05 for values between 6 and 12 hr. For 
values obtained at 24 and 36 hr p< 0.005 except for insulin samples where these values are 
p<0.05.   
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Figure 5.5. H4IIE cell IGFBP-1 secretion in response to incubation time with insulin and 
GH effect represented as percentage of control. In this plot the arbitrary density units of 
the control time-dependent expression (Figure 5.4b, A) were given a value of 100% in 
each timed sample. The corresponding values obtained with GH and insulin (Figure 5.4b, 
E and F) were calculated with respect to the control values. The resulting curves 
correspond to the deviation of H4IIE IGFBP-1 expression from control due to the 
presence of metabolic modulator. For the statistics on individual samples (S.E., p-value) 
refer to Figure 5.4b. Trendlines (log derived) of both insulin and GH effects were added.     
 
 
 
 
 
 
  - insulin 
  - GH 
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maximum expression was only 3.0-fold above the insulin zero time control and the 
maximum value for insulin was 40% lower than the maximum value obtained in control 
samples (Figure 5.4a and Figure 5.4b, E; Figure 5.5). In contrast, the IGFBP-1 protein 
secretion in GH treated H4IIE cells was 2-fold greater than the maximal response seen in 
control samples (Figure 5.4a and Figure 5.4b, F, Figure 5.5). A 10-fold increase in H4IIE 
IGFBP-1 levels were observed with GH after 24 hr with comparison to the zero time GH 
control.  
 
5.3.2 The Effects of Varying Concentrations of Modulators on IGFBP-1 Protein   
         Secretion 
 
 Next the effects of varying concentrations of metabolic modulators on IGFBP-1 
secretion were analyzed in H4IIE cells. For this, H4IIE cells were incubated 6 hr (as 
determined in time course) in the absence and presence of modulators added to serum-
free media. Total protein was isolated from conditioned media and subjected to Western 
ligand analysis as described in material and methods section. The results are shown in 
Figure 5.6a (blots) and Figure 5.6b (quantitation bars). cAMP and dexamethasone had no 
effect on expression as compared to controls (Figure 5.6a and Figure 5.6b; A and B). GH 
and glucose treatments increased IGFBP-1 levels 4.0-fold and 2.0 fold, respectively, as 
compared to controls. The effect of GH was seen as a plateau, with little change with 
increasing concentrations, whereas the change with glucose was linear (Figure 5.6a and 
Figure 5.6b; C and D). Insulin treatment of H4IIE cells resulted in a linear decrease in 
IGFBP-1 expression. The largest decrease was observed with 100 nM insulin, decreasing 
IGFBP-1 expression to 50% of the control (Figure 5.6a and Figure 5.6b, E).  
 
5.3.3 The Involvement of PI-3 kinase and MAP Kinase Pathway Inhibitors on the   
         Regulation of IGFBP-1 by Metabolic Modulators 
 
 Wortmannin and PD98059 are inhibitors of the PI-3 kinase and MAP kinase 
pathways, respectively (Lam et al., 1994, Alessi et al., 1995). Experiments were  
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Figure 5.6a Effects of varying modulator concentration on IGFBP-1 secretion in H4IIE cells. 
Cells were treated with varying doses of modulators in serum-free media for 6 hr. The 
experiments are shown above for treatments with (A) cAMP, (B) Dexamethasone, (C) GH , (D) 
Glucose and (E) Insulin. Conditioned media was removed after treatment and protease inhibitor 
cocktail was added (10ul/10mL media) and stored at -80o C. Samples were subjected to desalting 
on a Sephadex G-50 column and protein fractions were collected and lyophilized. Following 
lyophilization, samples were resuspended in 50 mM Tris buffer and concentrated 80 to 100x. 
50ug of the sample was loaded onto a 12 % SDS PAGE gel (low denaturing) and transferred to 
nitrocellulose membrane. Blots were probed with radiolabelled IGF-1 and autoradiographs 
analyzed. Exposure times varied. Each experiment was done in duplicate and repeated 
independantly two times (4 values). 
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Figure 5.6b Effects of varying modulator concentration on IGFBP-1 secretion in H4IIE cells.  
Autoradiographs were analyzed using densitometry with the Gel Documentation System (Bio-Rad) and 
Quantity One software program (Bio-Rad) as well as Scion imaging software. The experiments are shown 
above for treatments with (A) cAMP, (B) Dexamethasone, (C) GH , (D) Glucose and (E) Insulin. Values 
presented are the averages of two independent experiments done in duplicate (4 values). S.E. is given as an 
error bar in respective sample plot. Significant P values are given in x axis title and represent the 
comparison between individual samples and the zero time control.   
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performed to investigate the effects of wortmannin and PD98059 on the ability of insulin, 
GH and glucose to affect IGFBP-1 secretion. Dexamethasone and cAMP previously did 
not show an affect on IGFBP-1 secretion and were therefore excluded. 
 In all experiments, cells were pre-incubated for 30 min with wortmannin or 
PD98059 followed by 6 hr incubations with various modulators and/or inhibitors. It was 
previously determined that 6 hr incubation was adequate in order to see effects of 
metabolic modulators (Figure 5.4b). Conditioned media was collected and protein was 
partially purified as described previously. Protein was subjected to Western ligand 
analysis and blots analyzed for relative IGFBP-1 secretion. The results are shown in 
Figure 5.7 (blots and quantitation bars). 
 The effects of metabolic modulators as well as wortmannin and PD98059 were 
assessed for their effects on IGFBP-1 secretion. GH and glucose caused 3-fold and 2-fold 
increases in IGFBP-1, respectively (Figure 5.7, A and B). Insulin appeared to decrease 
IGFBP-1 secretion by about 25% as compared to control, but this decrease was 
statistically insignificant (Figure 5.7, C). All effects of modulators tested were 
comparable to results obtained in Figures 5.5 and 5.6. The pre-incubation of cells with 
wortmannin alone resulted in an average increase of 2.0-fold as compared to the control 
(Figure 5.7). The pre-incubation of cells with PD98059 alone decreased IGFBP-1 
expression to an average value of 50% of control (Figure 5.7)  
 Examination of the results indicated that wortmannin did not affect the regulation 
of IGFBP-1 secretion by GH (Figure 5.7, A). The effect of wortmannin on glucose 
mediated upregulation of IGFBP-1 appeared to be additive resulting in a 1.5-fold increase 
over glucose and wortmannin controls, but this was not supported by the statistics and 
therefore is not statistically significant (Figure 5.7, B). There was, however, a significant 
50% decrease in IGFBP-1 levels with the addition of insulin to wortmannin as compared 
to the wortmannin control which was also 1.5-fold higher than the insulin control.   
 The effects of PD98059 on all modulator effects showed significant increases as 
compared to the PD98059 control. Increases in insulin, glucose and GH were 2-fold, 4-
fold and 4-fold, respectively. GH and glucose mediated regulation of IGFBP-1 levels, in 
the presence of PD98059, increased to levels comparable with respective modulator 
controls. The effect of PD98059 on insulin mediated effects was additive with a 1.4-fold  
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Figure 5.7 The effects of wortmannin and PD98059 on GH, glucose and insulin regulated IGFBP-1 
secretion. (0.2 uM wortmannin, 10 uM PD98059, 100 nM GH, 22 mM glucose, 10 nM insulin).  H4IIE cell 
cultures were pre-treated with inhibitors for 30 min, followed by the addition of metabolic modulators 
(except for controls) and incubated for 6 hr. Blots were probed with radiolabelled IGF-1 and 
autoradiographs analyzed. The experiments are shown above for treatments with (A) GH, (B) glucose and 
(C) Insulin. Blots shown above represent one of two sets of data analyzed for H4IIE IGFBP-1 expression 
and secretion into conditioned media. Autoradiographs were analyzed using densitometry with the Gel 
Documentation System (Bio-Rad) and Quantity One software program (Bio-Rad). Values presented are the 
averages of two duplicated independent experiments (4 values). Significant P values are indicated below 
Figures according to the pairs of samples tested by the T test. 
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increase in IGFBP-1 levels as compared to the insulin control. However, this assumption 
is not supported by statistics in this case. 
 
5.3.4 Discussion 
  
 GH has previously been shown to either suppress or not effect IGFBP-1 secretion 
in different cell types (Seneviratne et al., 1990; Orlowski et al., 1991). Our results 
indicate that GH did strongly affect IGFBP-1 secretion over time (Figure 5.4b, Figure 
5.5). Also, in dose dependency studies, the results indicated a maximal 4-fold increase in 
IGFBP-1 secretion (Figure 5.6b). There was no change in IGFBP-1 secretion as GH 
concentrations increased. This may indicate that changes in IGFBP-1 secretion due to GH 
concentrations tested were above a threshold to see dose dependent increases in the 
H4IIE cell response. This was also comparable to results where 6 hr incubation with a 
100 nM GH dosage increased IGFBP-1 concentrations 3-fold above untreated samples 
(Figure 5.7). The effect of PI-3 kinase and MAP kinase pathway inhibition through 
wortmannin and PD98059 treatments, respectively, and the positive effect of GH on 
IGFBP-1 protein secretion showed limited involvement of PI-3 and MAP kinase 
pathways in GH mediated effects.  
 PD98059 treatment, alone, brought IGFBP-1 secretion to levels below control 
values. This may indicate a possible importance of the MAP kinase pathway in the 
constitutive secretion of IGFBP-1 and more specifically the possible control of IGFBP-1 
transcription through Erk1 (Band et al., 1997). Wortmannin treatment increased IGFBP-1 
levels 1.25-fold, suggesting a possible inhibitory role for the PI-3 kinase pathway. These 
were common characteristics in all inhibitor studies completed using wortmannin and 
PD98059. 
 Although not much is known about the effects of glucose on IGFBP-1 secretion, 
Snyder et al., (1990) have suggested that glucose uptake may have a role in the regulation 
of IGFBP-1 secretion. A positive glucose regulation of IGFBP-1 would result in 
decreased availability of IGF in circulation, but at the same time, increase IGF half life 
and have possible long-term effects on glucose control in circulation. Our data suggests 
that glucose positively regulates IGFBP-1 secretion (Figure 5.6b, D; Figure 5.4b, C). A 
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similar 5-fold maximal IGFBP-1 secretion is seen in both glucose and control secretion 
profiles (Figure 5.4b). The initial rate of increase was higher with glucose than in control 
samples (e.g. compare 4 hr time points). Similarly, the maximum increase with glucose 
was observed at 24 hr as compared to control secretion that was reached at 36 hr. To 
further support the positive effect of glucose on IGFBP-1 secretion, dose dependency 
also showed a maximum 2-fold increase in IGFBP-1 secretion with increasing glucose 
concentration (Figure 5.6b). There was no effect of PD98059 on glucose-mediated 
secretion of IGFBP-1. However, wortmannin had an additive effect on glucose mediated 
upreglation of IGFBP-1 indicating a potential involvement of the PI-3 kinase pathway. 
Although the exact mechanism by which glucose mediates IGFBP-1 upregulation is 
unknown, it is probable that the observed positive regulation of IGFBP-1 by glucose may 
be the result of increased cell growth due to increased glucose utilization by H4IIE cells.  
 Other studies in H4IIE cells have shown that cAMP inhibits IGFBP-1 secretion 
(Unterman et al., 1991). The completed time course studies show a slight repressive 
effect with IGFBP-1 secretion increasing to 4-fold as compared to the control secretion 
increase to a maximum of 5-fold (Figure 5.4b, B). However, cAMP repression was not 
clearly shown in dose dependent studies (Figure 5.6b, A). According to these results 
repression of IGFBP-1 secretion through cAMP signal is minimal and insignificant 
within H4IIE cells (Figure 5.6b, A). 
 The ability of insulin to repress IGFBP-1 activity has been well documented in 
H4IIE cells (Orlowski et al., 1990) as well as in in vivo studies (Suikkari et al., 1989). 
Our results support these data as both insulin time course and dose dependency 
experiments exhibited a decrease in IGFBP-1 secretion (Figure 5.4b and Figure 5.6b). 
The maximum inhibitory effect was observed with 100nM insulin.  
 Examination of the effects of wortmannin and PD98059 treatment on the 
repressive effect of insulin on IGFBP-1 secretion showed involvement of the PI-3 kinase 
and MAP kinase pathways. In the presence of wortmannin, insulin repression may be 
reversed to values above those of the insulin control. This data is inconclusive as p<0.5, 
representing a statistical insignificance. However, the ability of insulin to repress IGFBP-
1 secretion may be inhibited when the PI-3 kinase pathway is blocked as compared to the 
insulin control. Future tests must be conducted to confirm. This idea may be supported by 
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data obtained with HepG2-PKB-CA that showed increased repression of IGFBP-1 as 
compared to Normal HepG2 with and without insulin treatment. The level of IGFBP-1 
secretion with insulin and wortmannin was significantly lower than wortmannin 
treatment alone. This is suggestive of an activity of the PI-3 kinase pathway regardless of 
the insulin signal or an independent function of the inhibitor. In contrast, when insulin 
was added to PD98059 inhibited H4IIE, the repression of secretion was totally reversed 
resulting in a large increase in IGFBP-1 secretion as compared to PD98059 controls. 
Thus a product of the activated insulin signaling cascade may be interacting with 
components of the inhibited MAP kinase pathway and allowing inhibition to be reversed. 
Interplay between these two pathways has been suggested and may prove to be an 
important property in IGFBP-1 regulation (Band et al., 1997; Patel et al., 2002) (Figure 
5.7b).  
 All of our data indicated no significant effect of dexamethasone on IGFBP-1 
secretion in H4IIE cells (Figure 5.4b and Figure 5.6b) This is in contrast to a previous 
report in which an increase of IGFBP-1 mRNA by 10-fold was reported (Orlowski et al., 
1990). They, however, did not measure secreted IGFBP-1 levels. IGFBP-1 secretion, 
although related to expression, may occur as a result of separate cellular mechanisms.  
 
5.4 ALS Gene Expression in H4IIE Cells 
 
5.4.1 Effect of Incubation Time on ALS Gene Expression 
 
The effect of metabolic modulators on ALS gene expression as a function of 
incubation time was examined in H4IIE cells. In these studies, H4IIE cells were chosen 
due to their known sensitivity to the metabolic modulators and their marked similarity to 
the differentiated hepatocyte. It is known that hepatocytes are the primary site of ALS 
expression and as such H4IIE cells provide a suitable cell model for analysis. In addition, 
the experiments were performed to determine the effectiveness of the rALS and RPPO 
cDNA probes used in Northern analysis. A time course control was not performed in this  
 
 
 
 99
 
 
 
 
 
 
                
                                                   
 
 
               
 
 
Figure 5.8a. The effect of modulators on ALS gene expression in response to H4IIE cell     
incubation time. Changes in ALS gene expression were analyzed by Northern analysis in 
comparison to RPPO expression. RPPO mRNA expression is an accepted measure of equivalency 
amongst loaded RNA samples. Due to apparent unequal loading the data is represented as a ratio 
of ALS:RPPO. All controls (zero time) were arbitrarily set to equal “1” arbitrary density unit 
ratio. Changes in ALS expression were a reflection of changes in this ratio. The concentrations of 
metabolic modulators were: GH (100 nM); cAMP (0.5 mM); glucose (5.5 mM); dexamethasone 
(1 uM); and insulin (10 nM). The cells were harvested at 0, 4, 6, 12 and 24 hr after initiation of 
the experiment and mRNA was isolated and analyzed by Northern analysis.  
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Figure 5.8b. The effect of modulators on ALS gene expression in response to H4IIE cell 
incubation time. Changes in ALS mRNA levels were assessed using Northern analysis and RPPO 
expression was analyzed for equivalency of RNA loading. Autoradiographs (Figure 5.8a) were 
analyzed for band intensity using Gel Doc System and Quantity One software (Bio-Rad). To 
account for differences in loading the arbitrary density units of ALS were divided by those of 
RPPO and represented as a ratio. Expression at time zero was given a value of one arbitrary 
density unit ratio. Experiments were performed using cAMP (A), glucose (B), GH (C), 
dexamethasone (D) and insulin (E). Values presented are the averages of two independent 
experiments +/- S.D. Significant P values are indicated in the Figures compared to control. 
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experiment due to the eventual deterioration of the rALS probe. The metabolic 
modulators chosen for this study were insulin, cAMP, glucose, dexamethasone and GH.  
The effects of various modulators on ALS gene expression as a function of incubation 
time are shown in Figure 5.8a (blots) and Figure 5.8b (quantitation bars). 
Dexamethasone, cAMP, GH and glucose increased ALS gene expression 2-fold, 2-fold, 
2-fold and 3-fold, respectively, over a period of 24 hr with a lag period of 4 to 6 hr 
(Figure 5.8b, D, A, C and B). In the presence of insulin, ALS mRNA accumulated 
immediately and increased to a maximum of 2-fold in 24 hr (Figure 5.8b, E).  
 
5.4.2 Effects of Varying Concentrations of Modulators on ALS Gene Expression 
 
Accumulation of ALS mRNA as a function of modulator concentration was 
determined in H4IIE cells. From the time course experiments, 12 hr incubation time was 
used in these experiments. Metabolic modulators were added to serum-free media and 
incubated for 12 hr in a 37o C CO2 incubator. The effects of various modulators on ALS 
gene expression as a function of varied concentrations of metabolic modulators are 
shown in Figure 5.9a (blots) and Figure 5.9b (quantitation bars). The effect of cAMP on 
ALS mRNA accumulation was negative overall with increases in cAMP concentrations 
(0.5 to 10 mM) resulting in a maximal decrease in ALS mRNA levels to 64% of the 
control value (Figure 5.9b, A). The effect of glucose and dexamethasone on ALS gene 
expression was positive with maximal 3.0 and 2.5-fold increases, respectively (Figure 
5.9b, B and D). The stimulation of ALS expression by dexamethasone plateaued at a 0.5 
uM dexamethasone concentration (Figure 5.9b, E). Effects of increasing GH 
concentrations were not evident at lower concentrations tested (<100nM). At 
concentrations higher than 100 nM, ALS gene expression dramatically increased 4-fold at 
a GH concentration of 500 nM (Figure 5.9b, C). In these studies, with measurement of 
the ALS/RPPO OD ratio, insulin showed a 2-fold increase in ALS mRNA with a 
maximal expression at 10-100 nM (Figure 5.9b; E). It was noted in these experiments that 
12 hr H4IIE incubations with cAMP (0.5 mM), glucose (5.5 mM) and GH (100nM) 
differed somewhat from the expression seen at like concentrations and times of 
incubation in time course studies (Figure 5.8b). In these cases increases seen in time  
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Figure 5.9a Effects of varying modulator concentrations on ALS gene expression in H4IIE cells 
Changes in ALS gene expression were analyzed in comparison to RPPO gene expression for 
assurance of equivalency amongst samples. The metabolic modulators with which the H4IIE cells 
were treated and the concentrations used were as shown above: GH (0-1000nM) (A); glucose (0-
200mM) (B); insulin (0-1000nM) and cAMP (0-10mM) (C); dexamethasone (0-2.5 uM) (D).  
Autoradiographs were produced on X-OMAT 5 Kodak film and/or done on phosphoimager (Bio-
Rad).  
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Figure 5.9b Effects of varying modulator concentrations on ALS gene expression in H4IIE cells 
Changes in ALS mRNA levels were assessed using Northern analysis. Experiments are shown as: 
GH (0-1000nM) (A); glucose (0-200mM) (B); insulin (0-1000nM) and cAMP (0-10mM) (C); 
dexamethasone (0-2.5 uM) (D). RPPO expression was analyzed for equivalency of RNA loading. 
Autoradiographs were analyzed for band intensity using Gel Doc System and Quantity One 
software (Bio-Rad). All expression at time zero was given a value of one arbitrary density unit. 
To account for differences in loading the arbitrary density units of ALS were divided by those of 
RPPO and represented as a ratio above. All ratios of expression at time zero were given a value of 
one arbitrary density unit + S.D.. Values are the averages of two independent experiments.  P 
values are indicated in the figures. 
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course studies were not observed. Small differences should be expected amongst separate 
experiments. However additional error may have resulted due to probes, hormonal or 
mRNA degradation over time. 
 
5.4.3 Effects of cAMP and Insulin Alone or in Combination on ALS Gene   
         Expression in H4IIE Cells 
 
This study was done to investigate the effects of insulin and cAMP, alone or in 
combination, on ALS gene expression in H4IIE cells. The results are shown in Figure 
5.10 (blots and quantitation bars). In this experiment statistical analysis using the T test 
gave p values < 0.5 which deems all this data to be statistically insignificant. It will, 
however, still be presented. A 6 hr cAMP treatment of H4IIE cells showed a 20% 
decrease in ALS mRNA versus control while insulin treatment for the same time period 
showed an insignificant 5% increase in ALS mRNA accumulation. These results, in 
comparison with cAMP and insulin time dependent effects (Figure 5.8b) with like 
concentrations of insulin and cAMP show similar results. However, the insulin effect at 6 
hr incubation was a 1.5- fold increase and cAMP showed a small insignificant change at 
6 hr (Figure 5.8b). With both cAMP and insulin added for six hr ALS gene expression 
decreased 26% compared to non-treated control. This 26% decrease in ALS was similar 
to the effects of cAMP alone. Insulin treatment for 12 hr displayed a 15% increase in 
ALS mRNA which is a small increase compared to that observed in Figure 5.8b. 
However, when insulin containing media was decanted after 6 hr and fresh media 
containing insulin was added for an additional 6 hr there was an average 1.5 fold increase 
in ALS. This is as was expected in terms of an insulin response which indicated a loss of 
insulin activity after a 6 hr period due to possible deterioration of the insulin molecule. 
With a 12 hr insulin treatment and the addition of cAMP for the last 6 hr of this period 
ALS mRNA levels decreased to levels 20% versus the 12 hr insulin treatment (p<0.1). 
With cAMP treatment of H4IIE cell culture for 30 min followed by 6 hr insulin 
incubation the accumulation of ALS mRNA decreased 20% versus the 6 hr insulin 
treatment alone (p<0.05). With insulin treatment for 6 hr, media decanted and fresh 
media without modulator added, ALS mRNA was similar to the values seen for 12 hr  
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Figure 5.10 The effects of varying cAMP and insulin treatments on ALS mRNA 
accumulation in H4IIE cells. Over-night serum starved H4IIE cell cultures were treated 
as seen above and total RNA was isolated and subjected to Northern analysis. The 
concentrations of insulin and cAMP in all incubations were 10 nM and 0.5 mM, 
respectively. The above blot (A) is aligned with the correct bar within the graph (B). 
Densitometry was done using Gel Documentation system and Quantity One software 
(Bio-Rad). The values represent two sets of independent experiments. P-values of 
independent experiments with control are p<0.5 in all cases measured in comparison to 
negative control with no treatment.   
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insulin treatment alone. When the same experiment was done, but cAMP was added in 
fresh media, after decanting, ALS mRNA levels decreased 15% as compared to 
experiment where insulin was added for 6 hr, media was decanted and insulin was added 
for an additional 6 hr. However, there was little difference noted as compared to 
experiment where insulin was added for 6 hr, media was decanted and fresh media was 
added for an additional 6 hr.  
 
5.4.4 Effects of PI-3 Kinase and MAP Kinase Pathway Inhibitors on the Regulation 
of ALS Gene Expression by Metabolic Modulators 
 
It is known that transcriptional effects of insulin are mediated through the PI-3 
kinase and MAP kinase pathways (section 2.5.1.2). It is also known that cAMP indirectly 
interacts with the PI-3 kinase pathway through proteins such as PKC and PP-2A (Begum 
et al., 1996). As shown in Figures 5.8 and 5.9, ALS gene expression is altered by a 
number of the metabolic modulators examined, including insulin and cAMP. 
Wortmannin and PD98059 are inhibitors of the PI-3 kinase and MAP kinase pathways, 
respectively. Experiments were performed to investigate the effects of wortmannin and 
PD98059 on the ability of insulin and cAMP to affect ALS gene expression. In all 
experiments, cells were pre-incubated with wortmannin and PD98059 and this was 
followed by 6 hr incubation with respective modulators in the continued presence of 
inhibitor. 
The deterioration of insulin was suspected due to mentioned effects noted above 
(Section 5.4.3). This led us to use a shorter, 6 hr period instead of the prescribed 12 hr 
period. The results are shown in Figure 5.11a and Figure 5.11b (blots and quantitation 
bars). cAMP caused little decrease in ALS mRNA levels as was expected (Figure 5.11a; 
Figure 5.11b, B). This data was in relative agreement with the cAMP response seen in 
Figure 5.8. H4IIE incubation with insulin also showed little, if any, increase of ALS 
expression while results using similar time interval and dosage, in Figure 5.8, showed a 
1.5-fold increase. These values, again, differ from those determined in Figure 5.8 due to a 
number of possible factors such as the quality of the modulator used, the quality of the 
probes used and perhaps the general viability of the H4IIE cells used. The pre-incubation  
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Figure Legend 
 
Lane/treatment # Cell Treatment and inhibitor 
1 No treatment; no inhibitor 
2 Insulin; no inhibitor 
3 cAMP; no inhibitor 
4 No treatment; wortmannin 
5 Insulin; wortmannin 
6 cAMP; wortmannin 
7 No treatment; PD98059 
8 Insulin; PD98059 
9 cAMP; PD98059 
 
 
 
Figure 5.11a The effects of wortmannin and PD98059 on the ability of insulin and 
cAMP to affect expression. H4IIE cell cultures were pre-treated (treatment 4-9) with 
inhibitors 30 minutes. Following 30 minute pre-treatment metabolic modulators were 
added (except for controls) and in all cases cells were incubated for 6 hr. Following 
treatments media was removed, total RNA was isolated and samples were subjected to 
Northern analysis with radiolabelled rALS probe. Blot was stripped and re-probed with 
radiolabelled RPPO probe. Blots shown above represent one of two sets of data analyzed 
for expression in H4IIE cells. 
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Figure 5.11b The effects of wortmannin and PD98059 on the ability of insulin (A) and 
cAMP (B) to effect ALS gene expression. Auto-radiographs were analyzed through 
densitometric analysis using Scion Imaging system. Negative controls were given a value 
= 1. All ALS mRNA arbitrary density unit ratios were derived using RPPO as a standard 
for cell expression. Values presented are the averages of two independent experiments (4 
values). S.E. is given as an error bar in respective sample plot. P values are indicated 
below Figures according to the pairs of samples tested. P-values calculated using online 
T-test provided by SISA (Simple Interactive Statistical Analysis) program. 
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of wortmannin and PD98059 resulted in a statistically insignificant (p<0.5) 17% decrease 
and a significant 20% increase in ALS gene expression, respectively (Figure 5.11b). 
Wortmannin inhibition of the PI-3 kinase pathway and cAMP treatment resulted 
in statistically insignificant decreases in ALS mRNA to levels 60% of the untreated 
control and 70% of the cAMP control. A decrease, 70% of the wortmannin control, was 
also observed (Figure 5.11a; 5.11b, B). Levels of ALS mRNA increased with insulin with 
levels 10% higher than untreated control,  3% higher than insulin control and 30% higher 
than the wortmannin control, respectively, all statistically insignificant (Figure 5.11a; 
5.11b, A). Inhibition of the MAP kinase pathway in insulin and cAMP signaling caused a 
significant 15% and 20% increase, respectively, in ALS gene expression when compared 
to PD98059 control (Figure 5.11a; Figure 5.11b, A and B). PD98059 inhibitor with 
insulin and cAMP increased ALS gene expression 25% and 20% higher than respective 
modulator controls, respectively. In comparison to the untreated control, insulin and 
cAMP (with inhibitor) increased ALS gene expression 30% and 20% (Figure 5.11a, 
5.11b). Overall the statistics done on this experiment render these results insignificant 
and will be discussed as such. 
 
5.4.5 Discussion 
 
 The effects of glucose, insulin, GH, dexamethasone and cAMP on ALS mRNA 
accumulation in H4IIE cells were analyzed as a function of incubation time and their 
doses. The involvement of the PI-3 kinase and MAP kinase pathways were also 
investigated with the use of pathway specific inhibitors. In addition, various 
combinatorial studies were done with insulin and cAMP. Prior to this work, much of the 
literature on ALS regulation has been derived from in vivo studies and in vitro primary 
hepatocyte studies (Guck et al., 1999). Western analysis of ALS from lysate and 
conditioned media was attempted with a commercially available anti-ALS antibody, but 
the quality of the antibody was poor resulting in no usable data.   
GH has previously been shown to be the most potent hormonal inducer of ALS 
expression. This has been shown in vivo and in primary hepatocyte cultures (Dai et al., 
1997, Labarta et al., 1997). ALS is thought to be inducible through a growth hormone-
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responsive promoter element in the mouse, sheep and human ALS gene, entitled 
ALSGAS1 (Suwanichkul et al., 2000, Rhoads et al., 2000). GH activation of ALS 
expression is through the Jak-Stat pathway (Figure 2.12) which interacts with a diverse 
number of downstream signaling proteins. The incubation of H4IIE cells with GH (100 
nM) for 24 hr showed a 2-fold increase in ALS expression as compared to control. There 
was a 6-12 hr lag in response and increases in mRNA levels were only seen beyond 12 hr 
(Figure 5.8a; Figure 5.8b, B). GH dose dependent expression of ALS mRNA, however, 
showed a 4-fold increase with 500 nM concentration of GH (Figure 5.9a; Figure 5.9b, B). 
Low responses to GH in time dependent ALS gene expression may be remedied through 
a higher 500 nM GH concentration as was seen in dosage experiments. Nonetheless, GH 
has proven to be a relatively strong inducer of ALS mRNA accumulation in the H4IIE 
cell line. 
 Although glucose has been implicated in the regulation of expression of many 
genes (Vaulont et al., 2000), its effects on ALS have not been investigated. As shown in 
Figures 5.8 and 5.9, glucose up-regulates ALS expression in both a time- and dose- 
dependent manner. The incubation of H4IIE with glucose resulted in a 3-fold increase in 
ALS levels as compared to the control. The response was first observed at 6 hr of 
incubation followed by linear increases with time. A maximal 3-fold increase in dose-
dependent ALS expression was observed with glucose (200 mM) as compared to the 
control. The fact that increases in ALS expression are partially caused by increases in 
glucose levels may partially negate the possibility that enhanced cell growth during time 
course experiments were responsible for increased ALS expression. However, further 
work will be required to be conclusive. Nonetheless, our data suggests that glucose levels 
positively regulate ALS gene expression in H4IIE cells.  
 Dexamethasone has been found to be a negative regulator of ALS gene expression 
at the transcriptional level in primary hepatocytes (Werner 1999). Our time course results 
indicated a 1.8 fold increase in ALS mRNA accumulation by 12 hr (Figure 5.8a; Figure 
5.8b, E). With variation of dexamethasone concentrations there was a positive regulation 
of ALS mRNA accumulation. This expression reached a 2.5-fold peak at 0.5 µM 
dexamethasone and then slightly decreased with increased dosages (Figure 5.9a; Figure 
5.9b, E). In H4IIE cells, dexamethasone concentration may determine whether the effect 
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on ALS expression is positive or negative. Further experiments are required to clarify the 
effect of dexamethasone.  
It has been previously observed that cAMP has a negative effect on ALS gene 
expression in primary hepatocytes. cAMP has been thought to regulate at a post-
translational level and has not been shown to regulate at the level of mRNA (Delhanty 
1998b). Results from cAMP treated H4IIE cells as a function of time have shown no 
change in ALS expression in the first 6 hr. Expression increases after 12 hr to a 
maximum 2.0-fold at 24hr. It may be that the negative effects of cAMP are lost with 
increases in time resulting in an ALS mRNA increase as cells resume constitutive ALS 
production. With increases in cAMP concentrations ALS gene expression significantly 
decreases to a minimum, 64% of the negative control, indicating that H4IIE cell ALS 
gene expression may be negatively regulated through cAMP (Figure 5.9a; Figure 5.9b, 
D). Wortmannin had a statistically insignificant negative effect on cAMP negative 
regulation of ALS gene expression with a level of expression 70% of the wortmannin 
control, 67% of the cAMP control and 56% of the untreated control (Figure 5.11a; Figure 
5.11b, B). From this data, cAMP mediated ALS gene expression and repression may be 
enhanced by the inhibition of PI-3 kinase activity but it was likely that there was no 
effect. However, the negative effect of cAMP on ALS gene expression may be dependent 
on the PI-3 kinase pathway and partially be regulated by it. Further experimentation will 
be required. Levels of ALS gene expression do not change with the addition of cAMP to 
PD98059 as compared to PD98059 controls. However, with PD98059 treatment, levels of 
ALS expression increase significantly versus the negative control. The addition of cAMP 
did not reverse this effect which may indicate an involvement of the MAP kinase 
pathway independent of cAMP effects. Further investigation is required to make 
conclusive arguments about the involvement of cAMP in modulation of ALS gene 
expression through the PI-3 kinase and MAP kinase pathways. 
 In primary hepatocytes, insulin induces ALS secretion without any change in ALS 
mRNA levels. This may suggest a post-translational mechanism of ALS regulation (Dai 
et al., 1994a). Database searches for proteins which contain consensus sequences for 
phosphorylation by PKB have shown human ALS to be a likely candidate. A potential 
phosphorylation of ALS may explain why Dai et al., observed increased ALS secretion 
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with no change in the accumulation of mRNA. As seen with IGFBP-1, increased 
phosphorylation may translate to increased secretion. Phosphorylated  IGFBP-1 is the 
predominant form of IGFBP-1 in the bloodstream (Frost et al., 1993). However, our 
results in rat H4IIE cells clearly indicated a very positive regulation of ALS gene 
expression in both time course and dose dependency studies. In time course studies the 
increase was very linear and immediate with a 2-fold increase by 24 hr of H4IIE 
incubation (Figure 5.8a; Figure 5.8b, F). The dose dependent expression of ALS mRNA 
was also positive as a 2-fold increase occurred at 10-100nM insulin (Figure 5.9a; Figure 
5.9b, C). 
The importance of insulin in the regulation of ALS expression was shown in STZ-
induced type I diabetic rats. These rats developed hyperglycemia and hypo-insulinemia 
(not assayed for) which we found was accompanied by a large decrease in ALS gene 
expression in the liver (Figure 5.1). Decreased ALS in circulation in such conditions may 
result in decreased ternary IGF-1 complex formation. This translates to possibilities that 
IGF-1 may be more active in IGF-1 sensitive tissues as well as more transportable across 
epithelial barriers. However, less ALS in circulation may also be indicative of a more 
rapid IGF-1 degradation in the circulatory system. The two possibilities may, however, 
balance each other out resulting in little or no change in IGF-1 activity. Further 
experimentation is required to elucidate the effects of diabetes on IGF complex formation 
and downstream results.   
 Results in HepG2-PKB-CA displayed a 1.2-fold increase in ALS mRNA 
accumulation (Figure 5.2) indicating a possible importance for the PI-3 kinase pathway in 
activation of ALS expression. The inhibition of the PI-3 kinase and MAP kinase 
pathways using wortmannin and PD98059 treatment caused a statistically insignificant 
17% decrease and 20% increase in ALS gene expression compared to the negative 
controls, respectively (Figure 5.11a; Figure 5.11b, A). It was observed that insulin 
mediated positive regulation of ALS gene expression occurred independent of the PI-3 
kinase pathway. Addition of insulin to wortmannin treated cells appeared to reverse the 
negative effect of wortmannin and increased insulin levels to that of the insulin control, 
although statistically insignificant. This was surprising as PKB, a downstream component 
of the wortmannin inhibited PI-3 kinase pathway, was shown to be required for the 
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positive regulatory activity of insulin on ALS gene expression (Figure 5.2). The effects of 
insulin on PD98059 inhibited H4IIE cells appeared to be additive as the resulting ALS 
gene expression was significantly larger than insulin control and PD98059 controls. 
However this was also shown to be statistically insignificant.  It appears, therefore, that in 
H4IIE cells insulin effects on ALS gene expression may act independent of the PI-3 
kinase pathway but may be controlled through the MAP kinase pathway. There may be 
complicated crosstalk between these two pathways whose interactions result in a positive 
regulation of ALS. However, due to the lack of statistical significance this will have to be 
investigated further.    
The results in our investigation of the effects of varying cAMP and insulin 
treatments on the expression of ALS were largely statistically insignificant. However, in 
H4IIE cells a decrease in ALS gene expression with 6 hr cAMP incubation was observed 
and insulin increased expression at 6 hr incubation with further increases seen at 12 hr. 
Interestingly, the H4IIE co-incubation with insulin and cAMP appeared to have no effect 
of insulin but rather an increased negative activity in comparison to the cAMP 6 hr 
samples. The activation of cAMP activities in the cell may have inhibited the activity of 
insulin. This is possibly due to activities of phosphatases such as protein phosphatase 2A 
interaction with PKC and resulting affects on the PI-3 kinase pathway (Begum et al., 
1996, Ugi et al., 2004). As little as 30 min exposure to cAMP may be required for 
inactivation of the insulin cascade responsible for the upregulation of ALS. This will 
need to be further investigated to make valid conclusions.  
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6.0 CONCLUSIONS AND FUTURE STUDIES 
 
 Our interest in ALS and IGFBP-1 expression arose from observations that 
suggested the involvement of metabolic modulators in their regulation. Insulin, for 
example, has been shown to regulate both ALS and IGFBP-1 expression in hepatic cells. 
Therefore, the fundamental reason for performing the work described in this thesis was to 
elucidate the regulation of ALS and IGFBP-1 by metabolic modulators and further the 
understanding of the role of nutritional/hormonal status on the regulation of IGF-1 
bioactivity and address the hypotheses made in the introduction  section of this thesis 
(Section 1.0). 
The expression and secretion of IGFBP-1 in H4IIE cells is positively regulated by 
glucose and GH and negatively regulated by insulin. HepG2-PKB-CA cells showed a 
significant decrease in IGFBP-1 expression as compared to parental HepG2 cells 
implicating PKB in repression of IGFBP-1. PKB is activated through the PI-3 kinase 
pathway and may also interact with the MAP kinase pathway. Inhibition of these 
pathways and addition of GH, glucose or insulin showed GH to act independent of these 
pathways while glucose and insulin may be partially dependent. With the inhibition of the 
PI-3 kinase pathway the normally negative effects of insulin were reversed with an 
increased IGFBP-1 expression. However, comparison to the wortmannin control shows 
IGFBP-1 levels to be much smaller with the addition of insulin and experiments using 
PD98059, a MAP kinase inhibitor, indicated insulin activity to increase in strength with 
inhibited MAP kinase pathway activity. Therefore, IGFBP-1 regulation may be 
negatively regulated by insulin through the PI-3 kinase pathway but this does not appear 
to be likely as the statistics are not in support of this idea. There does however seem to be 
interaction between these two pathways in IGFBP-1 secretion. In the future I would like 
to also look at IGFBP-1 phosphorylation and determine what roles, if any, the PI-3 kinase 
and MAP kinase pathways have in this capacity. Inhibition of PI-3 kinase pathway 
resulted in an additive glucose effect. Inhibition allowed a large glucose mediated 
increase in IGFBP-1 expression. Future studies will be required to better characterize the 
regulation of IGFBP-1 by GH, glucose and insulin. Some research has suggested mTOR 
involvement in insulin regulation of IGFBP-1 regulation. Inhibitor studies utilizing 
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rapamycin could be utilized for investigation of mTOR involvement in IGFBP-1 
regulation. Important future research would also include the analysis of serum IGFBP-1 
isolated from STZ-treated diabetes-induced rats with the hypothesis that serum IGFBP-1 
will increase due to increased glucose and decreased insulin in circulation. Analysis may 
also be completed for the complexation of IGFBP-1 with IGF-1 within serum fractions of 
STZ-induced diabetic rats. 
The expression of ALS mRNA in H4IIE cells is positively regulated by GH, 
glucose, dexamethasone and insulin and negatively regulated by cAMP. HepG2-PKB-CA 
cells showed a significant increase in ALS gene expression as compared to parental 
HepG2 cells. The addition of insulin to these cell types increased expression of ALS 
equally. This may indicate an activity independent of PKB and the PI-3 kinase pathway. 
As mentioned previously, PKB is activated through the PI-3 kinase pathway, but may 
interact with the MAP kinase pathway. Inhibition of the PI-3 kinase and MAP kinase 
pathways and addition of insulin was performed. These results were insignificant and 
may need to be repeated to increase the sample size and obtain meaningful data on which 
to base a conclusion. The effect of insulin on ALS expression may act entirely or partially 
through the MAP kinase pathway and not the PI-3 kinase pathway as thought. Further 
studies will be required to provide the appropriate data. 
 cAMP activity was also assessed in relation to pathway inhibition. Although 
investigated the data gathered was insignificant. The interactions between cAMP and 
insulin in terms of their separate effects on ALS gene expression were also investigated 
in combination studies. These results were also shown to be statistically insignificant. 
The interactions between these two hormones are important as they serve to represent the 
metabolic status of an individual and determine the expression levels of ALS mRNA 
which in turn determines the amount of stable IGF available in serum. These experiments 
should be repeated a number of times to increase the sample size and provide more 
reliable and statistically conclusive data. Future experimentation should include factorial 
studies which will give further information on the combined activities of cAMP and 
insulin. 
The results from rat studies have clearly shown a decreased ALS gene expression 
in STZ-induced diabetic rats with decreased insulin release. The addition of insulin to 
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these STZ treated rats returned ALS levels to those of untreated controls. Further research 
could utilize this in vivo STZ-induced diabetic rat model to investigate primary 
hepatocytes for ALS mRNA levels and serum samples for measure of glucagon and 
insulin levels. An overall view of the expression of ALS in relation to hormonal levels 
can be done through experiments designed to look at complex formation using serum 
samples and methods to isolate the IGF-1 complex and respective components (ALS, 
IGF-1 and IGFBP-3 or -5). This could be done in isolation with normal conditions and 
abnormal conditions such as those associated with disease. Of personal interest is the 
relationship between disease conditions such as diabetes and cancer (Regimbeau et al., 
2004, Giovannucci 2001). A relationship between IGF and tumour formation has been 
shown in literature (Manousos et al., 1999, Khandwala et al., 2000, Macaulay 1991). The 
availability of IGF is dependent on ALS and complex formation which stabilizes IGF in 
circulation, allowing an available supply of IGF. The effects of STZ-induced diabetes 
include a significant decrease in ALS in rats. This could translate to less IGF 
complexation in circulation and either more available free IGF to interact with IGF 
receptive tissues or a large decrease in available IGF-1 due to degradation. It must be 
determined which occurs, as transformed cells may be especially sensitive to such rises in 
IGF-1 levels. Another issue is Type 2 diabetes which is accompanied by 
hyperinsulinemia. Increased levels of insulin may cause large increases in ALS which 
may exist in circulation uncomplexed due to limited availability of IGF-1-IGFBP-3 
complexes. However, increased levels of insulin would mean a large decrease in IGFBP-
1 which could also translate to increased free IGF-1 expression. This also will need to be 
investigated to clarify the roles of the IGF system in disease.  
In our preliminary investigations of potentially PKB phosphorylated proteins we 
noted a PKB consensus sequence for phosphorylation within ALS. Although our data 
exists based on ALS gene expression and not ALS protein it is very desirable to 
investigate the possibility of ALS phosphorylation by PKB and the function of this 
phosphorylation. This could initially be investigated through in vitro studies to see 
whether it occurs at all and later, in cell culture studies, to investigate whether this occurs 
in cells. However, available anti-ALS antibody did not work well against H4IIE 
conditioned media and lysate samples.   
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In conclusion, both IGFBP-1 and ALS are significantly regulated in cells of 
hepatic origin through a number of metabolic hormones. There is strong correlation 
between metabolic status and the levels of ALS and IGFBP-1 expression. The use of the 
newly available rALS probes made visualization of ALS gene expression possible, 
although very difficult, within H4IIE and HepG2 cells. It was also shown that PKB levels 
are involved in both IGFBP-1 secretion and ALS gene expression but the involvement is 
unclear at this point as inhibitor studies did not give any clear and undeniable evidence as 
to the involvements of the PI-3 kinase and MAP kinase pathways in PKB effects. In STZ-
induced diabetic rats the expression of ALS is decreased. This may indicate the 
possibility of downstream physiological effects involving altered IGF system functions.  
The potential of this research area is very promising and exciting in terms of research into 
disease etiology and prevention as well as continuing the endeavor to increase our 
understanding of animal biology and biochemistry.        
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